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 The Human Immunodeficiency Virus (HIV) epidemic still poses a problem with 
approximately 2 million new infections reported worldwide in 2014. New strategies are 
required to alleviate this burden. Our laboratory has previously shown that crude saliva and 
purified mucins from cervical plug mucin, saliva and breast milk inhibit HIV-1 infection in 
vitro. This project investigates purified mucins sourced from pig and horse mucus, as an 
alternative and abundant source of material for anti-HIV-1 research.  
Pig gastric and cervico-vaginal mucus was collected and stirred overnight in 6M guanidine 
hydrochloride with 10mM Na2HPO4, 10mM EDTA, 1mM PMSF and 5mM NEM. Gastric and 
cervicovaginal mucus was purified by density gradient ultracentrifugations in CsCl at 105 000g 
for 48 hours, twice, and mucin rich fractions were separated by size exclusion column 
chromatography. Mucin-rich materials eluting in the void volume (V0) were reduced with 
10mM dithithreitol (DTT) or subjected to proteolysis with trypsin. Pig saliva was collected in 
0.2M NaCl:0.02% sodium azide and horse saliva (due to its viscous nature) was collected and 
stirred overnight in 6M guanidine hydrochloride with 10mM Na2HPO4, 10mM EDTA, 1mM 
PMSF and 5mM NEM. Pig and horse saliva samples underwent size exclusion column 
chromatography, where the V0 fractions of both were purified with one density gradient 
ultracentrifugation and then dialysed and freeze dried, after which aliquots were treated with 
either DTT or trypsin. At every stage of purification, lyophilized aliquots of all mucin sources 
were tested on a luciferase based replication defective HIV neutralization assay on a CD4 
expressing HeLa cell line. Luciferase expression quantified as relative light units by a 
luminometer was used to calculate percentage neutralization. Log dose response curves were 
constructed to extrapolate the half maximal inhibitory concentrations (IC50) on GraphPad 
Prism. Samples were tested on an MTT cell toxicity assay. Pig gastric and cervicovaginal 
mucins were added to a simulated vaginal fluid to make gels (at a concentration of 30mg of 
mucin per ml of buffer). These gels were tested on the neutralization, MTT assays and the pig 
gastric mucin gel then underwent particle tracking and nanoparticle diffusion assays at varying 
pH.  
Pig gastric and cervicovaginal mucin showed good inhibition and low toxicity, with pig gastric 
mucin V0 having the best IC50 (1.668μg/ml). Pig and horse saliva showed inhibition but low 
cell viability. Pig gastric and cervicovaginal mucin gels exhibited good IC50’s but pig gastric 
xviii 
 
mucin had the best neutralization and lowest toxicity (PGM in Gel Solution 4 IC50: 
20.23μg/ml). HIV particle tracking and nanoparticle diffusion assays showed that the pig 
gastric mucin gel inhibited HIV-1 at low pH and existed as a soft gel. This project shows the 




CHAPTER 1: LITERATURE REVIEW 
 
1.1 The Human Immunodeficiency Virus Epidemic 
In 2015, the United Nations Joint Programme on Human Immunodeficiency Virus/Acquired 
Immune Deficiency Syndrome (UNAIDS) released a global report detailing Human 
Immunodeficiency Virus (HIV) statistics for 2014 (UNAIDS, 2015). This report indicated that 
~36.9 million people were living with HIV worldwide and that approximately 2 million people 
acquired new infections. In 2014, there were 1.2 million deaths resulting from AIDS-related 
diseases, globally (UNAIDS, 2015). 
Sub-Saharan Africa was the most affected region that year, accounting for 25.8 million persons 
living with HIV. Over half of the 25.8 million were women. Sub-Saharan Africa accounted for 
1.4 million new infections and ~790 000 people died of AIDS-related illnesses (UNAIDS, 
2015).  In 2014, South Africa had ~6.8 million people living with HIV and deaths due to AIDS 
were approximately 140 000. In 2012, the UNAIDS report highlighted an increase in unsafe 
sexual practices in South Africa (e.g. no condom use, multiple partners etc.) (UNAIDS, 2013). 
In 2015, the South African National Department of Health released HIV provincial data for the 
year end 2013 (National Department of Health, 2015). This report indicated that the province 
with the highest prevalence was KwaZulu-Natal (KZN), with an increase of 37.4% in 2012 to 
40.1% in 2013 (National Department of Health, 2015). 
1.2 Characterization of HIV-1 
There are 2 types of Human Immunodeficiency Virus namely HIV-1 and HIV-2. Both HIV-1 
and HIV-2 infection lead to disease, but type 1 has higher transmission rates and faster clinical 
progression (Nyamweya et al., 2013). HIV-1 represents most of the AIDS burden and is 
thought to have originated from the simian virus, SIVcpz (Nyamweya et al., 2013; Taylor et al., 
2008). This virus infected several chimpanzee communities in southern Cameroon (Nyamweya 
et al., 2013; Taylor et al., 2008). This progenitor most likely passed from chimpanzees to 
human hunters through blood borne transmission. Phylogenetic analysis performed on HIV-1 
and its related progenitor viruses show that there have been three transmission events in the 
early parts of the 20th century. These three transmission events gave rise to three HIV-1 groups, 
viz. Major (M), Outlier (O) and non-major and non-outlier (N) (Keele et al., 2006; Korber et 
al., 2000). The predominant circulating HIV-1 group is group M, and can be further divided 
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into phylogenetically linked subtypes (or clades) A1, A2, A3, A4, B, C, D, F1, F2, G, H, J and 
K. Researchers suggests that the infecting subtype can influence Cluster of Differentiation 4 
(CD4) thymus cell (T cell) decline (Novitsky et al., 2010; Touloumi et al., 2013). Studies in 
East Africa showed that there is a shorter median time of progression to AIDS in people 
infected with subtype D than subtype A (Baeten et al., 2007; Kaleebu et al., 2002; Kiwanuka 
et al., 2008). Research in Sub Saharan Africa suggest that despite subtype C having a less 
efficient replication process than subtype B (Ball et al., 2003), individuals with subtype C 
infection have a faster disease progression (Amornkul et al., 2013; Neilson et al., 1999). 
Subtype C is the predominant clade in countries with over 80% of HIV-1 infections worldwide 
such as southern Africa and India (Buonaguro et al., 2007; Hemelaar et al., 2006). The most 
predominant subtype in South Africa (as well as countries with the largest epidemics like 
Zimbabwe and Zambia) is subtype C which accounts for 48% of infections, worldwide (Lihana 
et al., 2012). A study carried out in 2003 showed that 95% of HIV-1 samples from the province 
of KwaZulu-Natal were subtype C (Gordon et al., 2003). 
1.3 Sexual Transmission of HIV 
The HI virus infects any cells bearing CD4 glycoprotein receptor and co-receptors CCR5 or 
CXCR4 (both are members of a seven-transmembrane chemokine-receptor family) (Levy, 
2007). HIV can also attach to miscellaneous cell surface receptors like dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and lectins on dendritic 
cells, heparan-sulphate moieties (these interact with positively charged side chains present on 
the viral Env) or natural receptors for cellular host proteins present in its viral envelope (Klasse, 
2012). Susceptible cells residing in the genital and colorectal mucosae include CD4 T cells, 
macrophages and dendritic cells (DCs) (Haase, 2011). Typically, HIV infection involves 
binding of the viral envelope glycoprotein 120 (gp120) to the host cell CD4 receptor (Klasse, 
2012). This results in a conformational change that exposes co-receptors CXCR4 or CCR5 that 
interacts with the viral gp120 (Klasse, 2012). This interaction of gp120 with a co-receptor 
exposes another viral envelope protein, gp41, which fuses the viral envelope with the cell 
membrane. After viral entry, the viral core is released into the cytoplasm and disassembled. 
Viral RNA is then converted into viral DNA, via viral reverse transcriptase, and transported to 
the cell nucleus, where it integrates into the host genome, by means of viral integrase.  At this 
stage, the infection is irreversible and the cell can release progeny virions (Klasse, 2012). 
Sexual transmission of HIV usually occurs when semen infected with HIV encounters the 
cervico-vaginal or colorectal mucous membranes. At this stage the virus may be transmissible 
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in a free form or cell associated form (e.g. infected macrophages). The latter seems to act as 
the viral reservoir at mucosal surfaces (Collins et al., 2000).  Before breaching the epithelium, 
the virus must overcome the non-specific mucus defence layer, the cervico-vaginal mucus. 
Vaginal fluids also have natural defences (for example lactic acid, antibodies, cytokines, 
chemokines, secretory leukocyte protease inhibitor, defensins) to protect from HIV infection. 
These are produced either by the host or microbiota (Cole et al., 2008; Hirbod et al., 2007). 
Even the physiochemical properties of the mucus fluids (e.g. pH, content, external fluids 
present) covering the sites of infection can effect HIV/leukocyte infection (Cone, 2009; 
Olmsted et al., 2005). For example, lactic acid produced by lactobacilli, lowers the pH of the 
vagina in healthy women (of reproductive age) to 3.5 – 4.5  (Owen et al., 1999) and this low 
pH can strongly inhibit HIV (Aldunate et al., 2013). Conversely an increase in pH of vaginal 
fluid has been shown to increase the ability of HIV to cross this barrier (Erickson et al., 2015; 
Lai et al., 2009). 
There are less recognized roles in rectal fluids to HIV infection, and the mucin network present 
may slightly decrease viral transmission but its neutral pH is thought to offer no protection 
against HIV (Alexander et al., 2007; Evans et al., 1988; Mestecky et al., 2005).  
There have been many mechanisms proposed as to how HIV sexual transmission can occur via 
the cervico-vaginal route, for example the role semen plays. Semen induces naturally formed 
amyloid fibrils that enhances HIV from infected semen to target cells and epithelial cells 
(Church, 2008). Semen also causes an upregulation in pro-inflammatory chemokines and 
cytokines that recruit HIV target cells (Doncel et al., 2014). Infected leukocytes can cross 
disrupted stratified squamous epithelium or through the simple columnar epithelia of the 
endocervix and colorectum (Anderson et al., 2010) via intercellular gaps or transcytosis to 
establish an infection in the lamina propria (Hladik et al., 2009; Meng et al., 2002). 
The colorectal epithelium is easily damaged during sexual intercourse, facilitating viral 
transmission as well as uptake of microfold cells and infected dendritic cells (Fotopoulos et al., 
2002; Gurney et al., 2005) which may also be a pathway to HIV infection. The presence of 
multiple lymphoid nodules in the rectum aids viral replication in the rectum (Cameron et al., 
2006). These criteria may in part explain the higher transmission rates of anal intercourse 
(0.65% to 1.7% higher during anal intercourse) when compared to the vaginal route (Baggaley 
et al., 2010; Boily et al., 2009; Jin et al., 2010). 
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Once HIV has reached the vaginal lamina propria, the initial infection can occur within an hour 
in either “resting” or activated CD4+ T cells, due to their sheer abundance (Haase, 2005; Keele 
et al., 2006; Zhang et al., 1999). After amplification, free or cell associated virus can be 
transported to nearby lymphoid tissue where extensive replication takes place leading to 
systemic distribution (Haase, 2005). 
In the colorectal mucous membrane CD4+ T cells play the same role as the vaginal 
counterparts, with one marked difference, namely the colorectal lymphocytes are constitutively 
activated (Lapenta et al., 1999). HIV transmission at the colorectal mucosal membrane is 
further exacerbated by the presence of lymphoid cells and follicles in the lamina propria as well 
as direct access to blood circulation (Brenchley et al., 2008). 
1.4 Anti-HIV Vaginal Microbicides 
Topically applied vaginal microbicide gels are products first thought of in the early 1990s to 
provide women with protection against sexual transmission of HIV-1 (Stein, 1990; Voelker, 
2006). The goal was to create an HIV prevention landscape (along with oral pre-exposure 
prophylaxis(PrEP)) that allowed women to have different antiretroviral (ARV) drug-based 
formulations for HIV prevention with or without their partners’ agreement (Doggett et al., 
2015). The 2013 statistics showed ~16 million women (aged 15 and above) living with HIV 
worldwide and 80% of which reside in sub-Saharan African (UNAIDS, 2014). In this region 
the primary contributor to the HIV epidemic is heterosexual transmission among female 
adolescents and young women (UNAIDS, 2014). This emphasizes the need for an effective 
non-toxic microbicide. 
The first generation of vaginal microbicide gels were not effective at preventing HIV infection 
but actually induced genital inflammation and subsequent cytokine responses that enhanced 
HIV-1 infection in the women that used them (Fichorova et al., 2001; Mesquita et al., 2009). 
These early microbicides were surfactants that either non-specifically disrupted cellular and 
microbial membranes or altered the pore size of the mucus coating the genital mucosal surfaces 
(Lai et al., 2010a). Banerjee and Puniyani showed that different formulations of surfactants 
altered mucus gel simulants by lowering its viscosity (Banerjee et al., 2000; Banerjee, 1999). 
In the past 20 years, no candidate microbicides (viz. N-9, C31G [Savvy®], sodium laurel 
sulphate, cellulose sulphate, Carraguard® containing carrageenan and PRO-2000® showed 
significant protection against HIV in clinical trials (Ariën et al., 2011; Doncel et al., 2010; 
Karim et al., 2010). 
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Unlike the previous non-specific inhibitors of HIV-1, Karim et al (2010, 2012) developed an 
antiretroviral microbicide, Tenofovir (TFV) gel providing proof of concept that such 
formulations are possible in the fight against the AIDS pandemic and the empowerment of 
women whose vulnerability to infection in this situation is obvious. This gel consisted of a 1% 
TFV (a nucleotide reverse transcriptase inhibitor (NTRI)) and showed 39% protection against 
male-to-female sexual transmission of HIV (Karim et al., 2010; Karim et al., 2012). Despite 
this data, the ongoing Vaginal and Oral Interventions to Control the Epidemic (VOICE) clinical 
trial showed poor efficacy of the 1% TFV vaginal gel. This gel as well as an oral TFV tablet 
(Viread) were halted as they showed poor efficacy compared to placebo products (Cost et al., 
2012; Microbicide Trials Network, 2011).  
1.5 Mucus and Mucins 
There has been recent interest in mucins with respect to detection and treatment of carcinomas 
(Devine et al., 1992; Mall, 2008) and also in particular in their role as diagnostic and therapeutic 
agents (Graham et al., 1996). Crude mucus secretions form gels on the epithelial surfaces of 
the auditory, gastrointestinal, respiratory, urogenital systems, lacrimal gland, apical cells of the 
cornea and the conjunctiva of the eyes (Hodges et al., 2013; Perez-Vilar et al., 2007). These 
gels hydrate and protect the epithelial surfaces from physical or chemical injury, dehydration 
and infection as well as help the movement of materials through internal tracts. (Allen, 1981b; 
Perez-Vilar et al., 1999). 
Mucins are large molecular weight glycoproteins and are the major component of the mucus 
gels coating the epithelial tracts of the body, and are secreted by the epithelial cells lining these 
tracts (Perez-Vilar & Hill, 1999). Members of the mucin family can differ in their size spans 
from a few hundred to several thousand amino acid residues and are some of the largest known 
proteins (Perez-Vilar & Hill, 1999). Mucins are heavily O-glycosylated glycoproteins that fall 
into three broad categories: i) gel forming, that coat and protect the epithelial surfaces of the 
internal tracts of the body (Allen, 1981b), ii) secreted and non-gel forming (Bobek et al., 1996) 
and iii) membrane-bound (Pratt et al., 2000). All mucin peptide chains contain tandem repeats 
of serine and/or threonine rich domains, whose hydroxyl groups form O-glycosidic linkages 
with oligosaccharides. Carbohydrates make up to 90% of mucins. The physiochemical and 
biological properties of mucus are due to mucins. Mucins are large glycoproteins responsible 
for the viscoelastic properties of normal mucus gels (Allen, 1981b). Figure 1.1 shows the 




Figure 1.1 Illustration of the general structure of mucins. This diagram shows the structure of MUC2, 
but the general arrangement is displayed by all mucins. The top most panel highlights the glycosylated 
(gly) and non- (or weakly) N-glycosylated (non-gly) domains of mucin represented by symbols as 
shown in the picture. The second panel shows the gly and non-gly domains associated to form the mucin 
monomer, with von Willebrand Factor (vWF) domains at the N terminal, cysteine rich and cysteine 
knot domains at the C terminal, intermingled with the O-glycosylated Serine-Threonine-Proline (STP) 
repeats creating the gly domain. The third panel shows how mucin dimers are formed by disulphide (S–
S) linking of two monomers via a bond linking the C-terminal cysteine knot domains. The bottom panel 
shows the branched structure of a mucin multimer with alternating gly (black with red brush) and non-
gly (blue) domains. The N-terminal branch can be seen. The right panel shows how a mucin gel is 
formed by hydrophobic grouping of unfolded non-gly domains of the multimer. The crosslinking of 
non-gly domains is represented by the colour green instead of blue (Bansil et al., 2013).
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Thus far, five secreted polymeric gel-forming (MUC2, MUC5AC, MUC5B, MUC6 and 
MUC19), three secreted non-polymeric non gel-forming (MUC7, MUC8 and MUC9), fourteen 
membrane bound (MUC1, MUC3A, MUC3B, MUC4, MUC9, MUC12, MUC13, MUC15, 
MUC16, MUC17, MUC18, MUC20, MUC21 and MUC22) and one unclassified mucin 
(MUC14) have been identified (Baños-Lara et al., 2015; Rose et al., 2006; Thornton et al., 
2008). Every human mucin has a homologous mucin in other animals, for example, pig 
submaxillary mucin has similar tissue distribution and structure to MUC5B (Eckhardt et al., 
1997; Perez-Vilar & Hill, 1999). Human mucins are represented as capital letters (e.g. 
MUC5B) whereas animal homologues start with a capital letter (e.g. Muc5b). Another 
similarity between human and pig mucin is the size of native and reduced MUC6 subunits 
being larger than MUC5AC (Nordman et al., 1997; Nordman et al., 1998). The conformation 
of gel forming mucins has been disputed as the conformational changes with the purification 
methods used to investigate mucins. Researchers who extracted mucins in 0.2M NaCl: 0.02% 
NaN3 in the absence of proteolytic inhibitors proposed a “windmill” model that described gel-
forming mucins as four high molecular weight subunits (2 x 106 Daltons (Da)) being linked by 
the naked, non-glycosylated regions to a low molecular weight linker protein (70 000 – 
90 000Da) via disulphide bonds (Pearson et al., 1981). Researchers extracting gel-forming 
mucins in 6 Molar (M) guanidine hydrochloride (GuHCl) and protease inhibitors proposed a 
different model as their buffer was not subjected to endogenous proteolysis (Carlstedt et al., 
1983c; Carlstedt et al., 1984). They suggested a linear, flexible, random coil model that linked 
subunits by disulphide bridges (Carlstedt & Sheehan, 1983c; Carlstedt & Sheehan, 1984). 
1.5.1 Secreted gel forming mucins 
The genes coding for MUC2, MUC5AC, MUC5B, and MUC6 have been mapped to 
chromosome 11p15.5, localized in a 400kb cluster that is rich on CpG islands (Pigny et al., 
1996). These genes are located between HRAS and IGF2, and share the common ancestor gene 
comparable to the human von Willebrand factor (vWF) gene  (Desseyn et al., 2000; Desseyn 
et al., 1998a). The last gel forming mucin MUC19 has its genes localized to chromosome 
12q12. Secreted gel forming mucins are created by the oligomerization of the mucus 
backbone’s tri-dimensional network, giving mucus its viscoelastic properties. All gel forming 
mucins share some structural characteristics, like a large central tandem repeat region flanked 
by a non-repeating region. These tandem repeats vary in length from 24 nucleotides (nt) for 
MUC5AC (Duperat et al., 1995) to 507nt for MUC6 (Toribara et al., 1993). These tandem 
repeat domains encompass several sub-domains that are rich in cysteine residues. The number 
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of sub-domains varies between mucin, which allows dimerization of mucins (Ambort et al., 
2011). The amino and carboxy regions share structural similarities with the B, C, D and CK 
domains of the pro-von Willebrand factor (pro-vWF). The N and C- regions also allow for 
mucin polymers to form (Desseyn et al., 1997a; Desseyn et al., 1998b; Desseyn et al., 1997b; 
Duperat et al., 1995; Gum et al., 1992; Gum et al., 1994; Toribara et al., 1997). 
1.5.1.1 MUC2 
This mucin was first characterized by Gum et al in 1989, when its cDNA was identified from 
the cDNA library of human small intestine (Gum et al., 1994; Williams et al., 1999b). MUC2 
is mostly expressed in the goblet cells of the intestine, colon and rectum (Escande et al., 2004; 
Gum et al., 1989; Toribara et al., 1991; Tytgat et al., 1994) and mature MUC2 has a molecular 
mass of 550 kiloDaltons (kDa) (Tytgat et al., 1996). MUC2 expression is associated with the 
pathogenesis of colorectal neoplasia and furthermore, downregulation of MUC2 is detected in 
colorectal cancer, gastric cancer as well as ovarian tumours (Blank et al., 1994; Dong et al., 
1997; Reis et al., 2000; Utsunomiya et al., 1998). Adenomas and mucinous carcinomas also 
express MUC2 (Blank et al., 1994).  
1.5.1.2 MUC5AC 
MUC5AC is primarily secreted from tracheobronchial goblet cells of gastric epithelia (Audie 
et al., 1993; Vandenhaute et al., 1997), conjunctiva and lacrimal gland tissues (Yu et al., 2008). 
DTT reduction of glycosylated MUC5AC produced subunits with a molecular mass of 2.2 
megaDaltons (MDa) (Sheehan et al., 2004). Aberrant expression of MUC5AC can be seen in 
colorectal adenomas (Bartman et al., 1999; Buisine et al., 1996) and pancreatic cancers (Aubert 
et al., 1994; Kim et al., 2002). MUC5AC expression levels are associated with the stage of 
cellular dysplasia.  
Patients suffering with cystic fibrosis, asthma, bronchitis, Sjögren syndrome and advanced 
cholangiocarcinoma express higher levels of MUC5AC (Hughes et al., 2001; Mall et al., 2010; 
Park et al., 2009; Temann et al., 1997). Contrary to the previous examples, a reduction in 
MUC5AC expression is an indicator of declining survival in colorectal carcinoma patients 
(Kocer et al., 2006; Kocer et al., 2002). 
1.5.1.3 MUC5B 
MUC5B is composed of 5 000 amino acids and is the second largest gel-forming mucin 
(Desseyn et al., 1997a; Desseyn et al., 1997b). It’s glycosylated structure has a high molecular 
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mass of 14 – 40MDa (Piras et al., 2011). MUC5B is found in human saliva, salivary glands, 
tracheobronchial and oesophageal epithelia, endocervical and pancreatobiliary epithelial cells 
(Audie et al., 1993; Thornton et al., 1999; Vandenhaute et al., 1997). MUC5B isolated from 
human saliva has been shown to have anti-HIV-1 activity (Habte et al., 2006; Peacocke et al., 
2012). MUC5AC and MUC5B mucin proteins are present in healthy and diseased human 
airway secretions (Sheehan et al., 2000; Sheehan et al., 1999; Thornton et al., 1996; Thornton 
et al., 1997; Thornton et al., 2008).  
1.5.1.4 MUC6 
MUC6 proteins are expressed in the gastric mucosa as well as the mucopeptic cells of the neck 
region in the body (Bartman et al., 1998; Byrd et al., 1997; De Bolós et al., 1995; Ho et al., 
1995; Reis et al., 1999). MUC6 is also produced by gastric and duodenal mucous glands, 
endocervical and pancreatobiliary epithelial cells (Bartman et al., 1998). Abnormal expression 
of MUC6 can be seen in gastric carcinomas and significant levels are detected in well-
differentiated cholangiocarcinomas (Park et al., 2009), breast cancer (De Bolós et al., 1995), 
and colonic sessile serrated adenoma (Owens et al., 2008).  
1.5.1.5 MUC19 
The human MUC19 gene has a size of 180kb, making it the largest gel-forming mucin. It’s 
peptide sequence consists of over 7 000 amino acids and is located at chromosome 12q12 
(Chen et al., 2004). The MUC19 apoprotein has a molecular mass of 693.4kDa (Culp et al., 
2004). It is expressed in the middle ear, mucous cells of sublingual and submandibular glands, 
corneal and conjunctival epithelial cells, submucosal gland of tracheal tissue as well as the 
lacrimal gland tissues (Chen et al., 2004; Kerschner et al., 2009; Yu et al., 2008). MUC19 is 
not present in human salivary glands and there is a decreased expression in the conjunctiva of 
patients with Sjögren syndrome (Rousseau et al., 2008).  
1.5.2 Soluble mucins 
1.5.2.1 MUC7 
The MUC7 gene is 10kb long and is situated on chromosome 4q13.3 (Bobek et al., 1993a). 
gene has a low molecular mass of 150 – 200kDa and encodes a 39kDa protein. MUC7 is 
secreted by the sublingual and submandibular salivary glands (Gururaja et al., 1998). It acts as 
an antimicrobial agent in the oral cavity, and has been shown to agglutinate HIV-1 thus 
inhibiting infection (Bergey et al., 1994; Bergey et al., 1993b; Habte et al., 2006; 
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Nagashunmugam et al., 1998; Peacocke et al., 2012). This may be a result of the MUC7 
structure, namely the two cysteine residues located in the N-terminal region (Liu et al., 1999). 
MUC7 also has anti-candidal activity via the histatin-like domain it possesses (Bing et al., 
2000). MUC7 is expressed in the oral cavity, minor salivary gland, respiratory tract, healthy 
conjunctiva, pancreas, submucosal glands of the bronchus and in cholangiocarcinomas 
(Jumblatt et al., 2003; Li et al., 2006; Sasaki et al., 1998; Sharma et al., 1998; Zhang et al., 
1998). In diseased states, the MUC7 gene is expressed in bladder cancer specifically during 
malignant transformation of the bladder urothelium in pre-invasive carcinoma in situ but is not 
expressed in superficial non-invasive bladder tumours (Retz et al., 1998). 
1.5.2.2 MUC8 
The MUC8 gene is located on chromosome 12 at position q24.3. This mucin is expressed in 
the nasal epithelial cells, the epithelium of the middle ear as well as middle ear effusions 
(Kerschner, 2007; Kim et al., 2005; Takeuchi et al., 2003). MUC8 expression is upregulated in 
nasal polyp epithelium and is thought to play a role in pathogenesis of chronic sinusitis with 
polyps (Seong et al., 2002). 
1.5.2.3 MUC9 
MUC9 is expressed from late follicular development through to the early cleavage stage in 
embryonic development, middle ear epithelia, and middle ear effusions (Kerschner, 2007; 
Takeuchi et al., 2003). MUC9 exists as incompletely glycosylated non-sulphated molecules 
with a molecular mass of 90 – 120kDa (Zaretsky et al., 2013). MUC9 may also be membrane-
bound in the fallopian tubes (Parham, 2014). 
1.5.3 Transmembrane mucins 
Membrane bound mucins are linked to cells via a unique transmembrane domain. It is the 
cytoplasmic tail of these mucins that facilitates their association with cytosolic adaptor proteins 
and cytoskeletal elements (Carraway et al., 2003). In this way transmembrane mucins play an 
important role in signal transduction (Carraway et al., 2003).  
1.5.3.1 MUC1 
MUC1 spans about 4-7kb of genomic DNA (depending on the size of the central domain) and 
is located on chromosome 1q21-24 (Gendler et al., 1990; Lan et al., 1990; Lancaster et al., 
1990; Ligtenberg et al., 1990; Peat et al., 1992; Siddiqui et al., 1988; Swallow et al., 1987a; 
Wreschner et al., 1990). Mature glycosylated MUC1 has a molecular mass of 250 – 500kDa 
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(Brayman et al., 2004). MUC1 is expressed by nearly all glandular epithelial surfaces of the 
female reproductive, respiratory and gastrointestinal tracts, middle ear; salivary and mammary 
glands and healthy pancreatic intralobular ducts (Brayman et al., 2004; Buisine et al., 2000; 
Gendler, 2001; Lee et al., 2003; Masaki et al., 1998; Ringel et al., 2003; Terada et al., 1996). 
MUC1 expression is highly upregulated in breast, colorectal, lung, ovarian, pancreatic and 
prostate cancers (Ajioka et al., 1996; Burdick et al., 1997; Girling et al., 1989; Zhang et al., 
1998; Zotter et al., 1987). One function of MUC1 proteins is to maintain luminal integrity of 
the lining epithelium by acting as an anti-adhesive protein, thereby aiding in the metastasis of 
tumour cells (Kim et al., 1996; Taylor-Papadimitriou et al., 2002). 
1.5.3.2 MUC3A and MUC3B 
The MUC3 gene is large and located on chromosome 7 in the q22 region (Fox et al., 1992; 
Gum et al., 1990). MUC3A and MUC3B are expressed by gastrointestinal epithelia. The 
alternative splicing of the central domain results in four variants that may be membrane bound 
or secretory (Crawley et al., 1999; Hattrup et al., 2008; Williams et al., 1999b).  
1.5.3.3 MUC4 
The MUC4 gene was first isolated from tracheobronchial cDNA and then from colon mucosa 
and pancreatic tumour cell lines (Khorrami et al., 2002; Moniaux et al., 1999; Porchet et al., 
1991). The gene has been mapped to chromosome 3q29 (Gross et al., 1991). MUC4 proteins 
are expressed in various healthy tissues like the respiratory tract, colon, eye, lung, salivary 
glands, stomach, vagina, ectocervix, uterus, and the prostate (Audie et al., 1993; Gendler et al., 
1995; Gipson, 2001; Gipson et al., 2004; Juusola et al., 2005; Liu et al., 1998; Reid et al., 1997). 
MUC4 has a molecular mass of 550 – 930kDa (Moniaux et al., 2007). Aberrant MUC4 
expression can be seen in inflammatory conditions and cancers like Crohn's disease, dysplasia 
and adenocarcinoma of the oesophagus, gall bladder carcinomas, lung adenocarcinoma, 
salivary gland mucoepidermoid carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, 
epithelial ovarian carcinomas, breast cancer, cystic fibrosis and chronic obstructive pulmonary 
disease (Andrianifahanana et al., 2001; Arul et al., 2000; Balagué et al., 1995; Buisine et al., 
2000; Buisine et al., 2001; Buisine et al., 1999; Chauhan et al., 2006; Copin et al., 2001; 
Handra-Luca et al., 2005; Lamblin et al., 2001; Leikauf et al., 2002; Llinares et al., 2004; 





The MUC12 gene has been mapped to chromosome 7q22 (Williams et al., 1999a). MUC12 
(also known as MUC11) is expressed mostly in healthy colons and stomachs, and to a lesser 
extent in the pancreas, prostate and uterus ([Internet], 2017; Hattrup & Gendler, 2008; Packer 
et al., 2004; Williams et al., 1999a). 
1.5.3.5 MUC13 
The MUC13 gene is located on chromosome 3q13.3 and encodes a cell surface membrane-
anchored mucin that is expressed in healthy gastrointestinal tracts, respiratory tracts, tracheas, 
middle ears and kidneys (Hattrup & Gendler, 2008; Kerschner, 2007; Walsh et al., 2007; 
Williams et al., 2001). Glycosylated MUC13 has a molecular mass between 54.7 – 175kDa 
(Milman, 2006). In diseased states it is abnormally expressed in gastric, colorectal, 
oesophageal, lung and pancreatic cancers (Packer et al., 2004; Walsh et al., 2007). 
1.5.3.6 MUC15 
The MUC15 gene has been mapped to chromosome 11p14.3. MUC15 expression is abundant 
in placenta, kidney, testis, oesophagus, salivary glands, thyroid glands and trachea. It is 
moderately expressed in the pancreas, foetal kidney, foetal lung, lymph nodes, foetal and adult 
thymus (Pallesen et al., 2002; Pallesen et al., 2008). Glycosylated MUC15 has a molecular 
mass between 33.3 – 110kDa (Milman, 2006). Aberrant MUC15 expression can be seen in 
colorectal tumours and its expression may enhance the invasive potential of colorectal cells 
(Huang et al., 2009).  
1.5.3.7 MUC16 
The MUC16 gene is located on chromosome 19p13.2. MUC16 is a transmembrane-bound 
molecule that is also known as CA125 and was cloned from an ovarian cancer cell line 
OVCAR-3 (Gipson et al., 2004). Glycosylated MUC16 has a molecular mass of 1 519.2kDa 
(www.proteinatlas.org). It is mainly expressed in the female reproductive tract, the middle ear, 
the ocular surface and the respiratory tract (Bast et al., 2005; Blalock et al., 2007; Kerschner, 
2007). 
1.5.3.8 MUC17 
The MUC17 gene is mapped to the same chromosomal locus as MUC3A/B, MUC11 and 
MUC12, viz. 7q22 (Gum et al., 2002; Williams et al., 1999a). The MUC17 apoprotein has a 
molecular mass of 36kDa (Moniaux et al., 2006). MUC17 is expressed in the gastrointestinal 
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tract, stomach, foetal kidney and conjunctival epithelium (Corrales et al., 2003; Gum et al., 
2002; Malmberg et al., 2008). The overexpression of MUC17 can be seen in pancreatic cancer 
cells (Moniaux et al., 2004). 
1.5.3.9 MUC18 
MUC18 is a membrane bound glycoprotein, and in its mature form is 113kDa. The gene 
encoding MUC18 resides on chromosome 4. It is expressed in lung and breast tissue. MUC18 
is expressed on primary melanomas and is found on 80% of advanced metastases ad primary 
tumours (Lehmann et al., 1989; Parham, 2014). 
1.5.3.10 MUC20 
MUC20 has been mapped to chromosome 3q29 and is expressed mostly in the kidney, but is 
moderately expressed in the placenta, prostate, lung, liver, colon, oesophagus, middle ear and 
rectum (Higuchi et al., 2004; Kerschner, 2007). Glycosylated MUC20 has a molecular mass 
between 76 – 78kDa (Higuchi et al., 2004). There is an up-regulation of MUC20 in 
immunoglobulin A neuropathy (Higuchi et al., 2004; Li et al., 2005). 
1.5.3.11 MUC21 
The MUC21 gene is an epiglycanin and is located on chromosome 6, neighbouring the MHC 
class I, and is within the vulnerability domain for panbronchiolitis (DPB) (Keicho et al., 2000). 
MUC21 expression is abundant in the colon, lung, normal bronchi, bronchioles, bronchial 
glands, thymus, large intestine and testis (Itoh et al., 2008).  
1.5.3.12 MUC22 
The MUC22 gene, much like MUC21, resides on chromosome 6 (6p21.3) (Azuma et al., 
2017). MUC22 mucin is also known as Panbronchiolitis-related mucin-like protein 1 
(PBMUCL1). MUC22 is expressed in lung tissue and is the mature protein is 173.478kDa 
(GeneCards; Matsuzaka et al., 2002). 
The summarized distribution of various mucins can be seen below in Table 1.
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Table 1. The distribution of mucins in human tissue 
Mucin Type of Mucin Expression site Reference 




colon, kidney, eye, B 
cells, T cells, 
dendritic cells, middle 
ear epithelium 
(Gipson et al., 
1997b; Ho et al., 
1995; Kerschner, 
2007; Linden et al., 
2008; Pinkus et al., 
1985; Swallow et al., 
1987b; Wreschner et 
al., 1990; Wykes et 
al., 2002) 
MUC2 Secreted and Gel 
forming 
Small intestine, colon, 
respiratory tract, eye, 
middle ear epithelium 
(Berry et al., 2004; 
Dohrman et al., 
1994; Gum et al., 
1989; Kerschner, 
2007; Linden et al., 
2008; Ogata et al., 
1992) 
MUC3A/B Transmembrane Small intestine, colon, 
gall bladder, 
duodenum, middle ear 
epithelium 
(Ho et al., 1993; 
Kerschner, 2007; 
Linden et al., 2008; 
Pratt et al., 2000; 
Vandenhaute et al., 
1997) 
MUC4 Transmembrane Respiratory tract, 
colon, stomach, 
cervix, eye, middle 
ear epithelium 
(Gipson & Inatomi, 
1997b; Gipson et al., 
1999; Kerschner, 
2007; Linden et al., 
2008; Moniaux et 




MUC5AC Secreted and Gel 
forming 
Respiratory tract, 
stomach, cervix, eye, 
middle ear epithelium 
(Gipson et al., 
1997a; Inatomi et 
al., 1996; Kerschner, 
2007; Linden et al., 
2008; Porchet et al., 
1995; Spurr-
Michaud et al., 
2007) 





seminal fluid, middle 
ear epithelium 
(Davies et al., 2002; 
Escande et al., 2002; 
Gipson et al., 2001; 
Kerschner, 2007; 
Linden et al., 2008; 
Porchet et al., 1995; 
Russo et al., 2006; 
Vandenhaute et al., 
1997) 




seminal fluid, cervix, 
middle ear epithelium 
(Bartman et al., 
1998; De Bolós et 
al., 1995; Kerschner, 
2007; Linden et al., 
2008; Toribara et al., 
1993; Vandenhaute 
et al., 1997) 




middle ear epithelium 
(Bobek et al., 1993b; 
Kerschner, 2007; 
Linden et al., 2008; 
Sharma et al., 1998) 
MUC8 Not known if it is 
secreted and/or gel 
forming 
Respiratory tract (Rose et al., 1997) 
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MUC9 Secreted and Gel 
forming 
Fallopian tube (Levanon et al., 
2010) 
MUC12 (also known 
as MUC11) 





(Linden et al., 2008; 
Packer et al., 2004; 
Williams et al., 
1999a) 




middle ear epithelium 
(Kerschner, 2007; 
Linden et al., 2008; 
Packer et al., 2004; 
Williams et al., 
2001) 
MUC15 Transmembrane spleen, thymus, 
prostate, testis, ovary, 
small intestine, colon, 
peripheral blood 
leukocyte, bone 
marrow, lymph node, 
tonsil, breast, foetal 
liver, lungs, middle 
ear epithelium 
(Kerschner, 2007; 
Linden et al., 2008; 
Pallesen et al., 2002) 
MUC16 Transmembrane Peritoneal 
mesothelium, 
reproductive tract, 
respiratory tract, eye, 
middle ear epithelium 
(Andersch-
Björkman et al., 
2007; Gipson et al., 
2008; Hori et al., 
2004; Kerschner, 
2007; Linden et al., 




MUC17 Transmembrane Small intestine, colon, 
duodenum, stomach, 
middle ear epithelium 
(Gum et al., 2002; 
Kerschner, 2007; 
Linden et al., 2008) 
MUC18 Transmembrane Lung and breast (Lehmann et al., 
1989; Parham, 2014) 





tract, eye, middle ear 
epithelium 
(Chen et al., 2004; 
Kerschner, 2007; 
Linden et al., 2008; 
Yu et al., 2008) 
MUC20 Secreted and Gel 
forming 
Kidney, placenta, 
colon, lung, prostate, 
liver, middle ear 
epithelium 
(Higuchi et al., 
2004; Kerschner, 
2007; Linden et al., 
2008) 




intestine and testis 
(Itoh et al., 2008) 
MUC22 Transmembrane Lung (Matsuzaka et al., 
2002) 
 
1.5.4 Difficulties when working with mucin glycoproteins 
There are many problems when working with native gel-forming mucins, the first issue being 
the size of mucins. For example, human MUC5B is composed of 5000 – 6000 amino acid 
residues of which ~3000 are in the highly glycosylated mucin domains (i.e. serine and threonine 
rich sequences) (Perez-Vilar & Mabolo, 2007). O-glycosylated mucins can reach an average 
molecular weight of over 1 MegaDalton (MDa) and this is further increased when disulphide-
linked species are assembled. This varied range of molecular weights, renders resolution via 
classical techniques inadequate (Perez-Vilar & Mabolo, 2007). The copious amount of O-
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linked oligosaccharide chains causes mucins to have aberrant results in common size exclusion 
techniques like size-exclusion chromatography or sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) (Tytgat et al., 1995). Another problem is the molecular 
polydispersity that is brought on by genetic polymorphism, proteolysis and/or the level of 
glycosylation, all of which are characteristic of gel-forming mucins (Veerman et al., 2003; 
Vinall et al., 2000; Wickstrom et al., 2001). 
The next problem is the viscosity of gel forming mucins as they can range from a viscous fluid 
(e.g. saliva) to a strongly viscoelastic gel (e.g. gastric mucins). These viscous gels are not 
readily dispersible in non-denaturing buffers (Bansil et al., 1995; Bansil et al., 2006). 
One method to overcome these issues is to extract the mucins in a solution containing 
chaotropic agents (e.g. guanidine hydrochloride) to reduce the stability of the native proteins 
by reducing the hydrophobic effect (Perez-Vilar & Mabolo, 2007; Salvi et al., 2005) or the 
reduction of disulphide bonds. Guanidine hydrochloride has been shown to cause proteins to 
adopt a randomly coiled structure, unfold proteins, break non-covalent bonds and the 
disassembly of gels (Georgiades et al., 2014). The drawback to using these chemicals is the 
disappearance of structural information and may hamper functional studies (Bansil et al., 1995; 
Raynal et al., 2003). It is possible to extract mucins in non-denaturing conditions but there is 
the risk of contamination from cellular and bacterial proteins which may alter properties of 
mucin (Perez-Vilar and Mabolo, 2007). An example of a non-denaturing compound that retards 
bacterial growth and preserves human salivary markers is sodium azide (NaN3) (Whembolua 
et al., 2006).  
1.5.5 Mucin Research 
Mucins are an integral part of innate immunity and with the advancement of new research 
technologies; there are many novel directions that mucin research can take. As mentioned in 
section 1.5.3, the correlation between inflamed or diseased states and dysregulation of mucin 
expression has been well documented (Blank et al., 1994; Dong et al., 1997; Reis et al., 2000; 
Utsunomiya et al., 1998; Yu et al., 2008; Bartman et al., 1999; Buisine et al., 1996; Aubert et 
al., 1994; Kim et al., 2002; Hughes et al., 2001; Park et al., 2009; Temann et al., 1997; Kocer 
et al., 2006; Kocer et al., 2002; Henke et al., 2004; De Bolós et al., 1995; Owens et al., 2008; 
Rousseau et al., 2008; Retz et al., 1998; Seong et al., 2002; Ajioka et al., 1996; Burdick et al., 
1997; Girling et al., 1989; Zhang et al., 1998; Zotter et al., 1987; Andrianifahanana et al., 2001; 
Arul et al., 2000; Balagué et al., 1995; Buisine et al., 2000; Buisine et al., 2001; Buisine et al., 
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1999; Chauhan et al., 2006; Copin et al., 2001; Handra-Luca et al., 2005; Lamblin et al., 2001; 
Leikauf et al., 2002; Llinares et al., 2004; Moniaux et al., 2004; Rakha et al., 2005; Singh et 
al., 2007; Swartz et al., 2002; Tsutsumida et al., 2007; Williams, et al., 1999a; Hattrup & 
Gendler, 2008; Packer et al., 2004; Packer et al., 2004; Walsh et al., 2007; Huang et al., 2009; 
Higuchi et al., 2004; Li et al., 2005; Keicho et al., 2000). Mucin expression is a valuable marker 
to determine normal versus diseased conditions. Prognoses can be made on the development 
and progression of malignant diseases based on mucin expression and alterations in 
glycosylation (Rachagani et al., 2009). The changes in glycosylation give rise to several 
epitopes in oligosaccharide side chains which can be exploited as diagnostic or prognostic 
markers. These carcinoma markers are also used therapeutically in cancer immunotherapy  
(Devine & McKenzie, 1992; Hollingsworth et al., 2004). An example of this immunotherapy 
was published in 2006, where stage II breast cancer patients were vaccinated with an oxidized 
mannan-MUC1 (Apostolopoulos et al., 2006). Immunized patients showed T cell populations 
directed towards MUC1 variable number of tandem repeats (VNTR) and there was no 
recurrence of the disease over a 5 year period after immunization (Apostolopoulos et al., 2006).  
A Korean research group recently reported that inflammatory airway disease in a patient with 
diabetes, high glucose concentrations increased MUC5B expression and pro-inflammatory 
factors in human airway epithelial cells (Ye et al., 2016). Previous research has shown that 
changes in the amount, glycoform and structure of MUC5B are associated with airway 
obstruction (Kirkham et al., 2008; Kirkham et al., 2002; Sheehan et al., 1999; Sheehan et al., 
1995). These alterations in MUC5B assembly and processing may play a role in the abnormal 
properties of mucins in disease. Ye et al (2016) found that the addition of pro-inflammatory 
factor inhibitors (p38 inhibitor or epidermal growth factor receptor inhibitor) reduced 
inflammation and high glucose induced MUC5B expression. 
In 2009, Sandberg et al proposed that partially fractionated mucins sourced from bovine 
submaxillary gland (BSM), pig gastric mucin (PGM) and human saliva (MG1) could be used 
as biomaterial coatings (Sandberg et al., 2009).  They suggested that an ideal implanted 
biomaterial would perform its intended function over a long period with minimal repercussions. 
They further stated that such an implant would control non-specific adsorption of human host 
proteins to the material surface while at the same time allowing necessary integration for 
extensive contact with the implant. To maintain this balance, they decided to look at mucins as 
they are the central components of epithelial mucosa forming an anti-adhesive barrier 
preventing interactions with the epithelium while acting as a selective mediator between the 
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external environment and the host (Van Klinken et al., 1995). Their previous work showed how 
commercially available mucin from the bovine submaxillary gland adsorbed to polymeric 
materials, PMMA, silicone, Tecoflex® polyurethane and polystyrene; and reduced the risk of 
infection from Staphylococcus aureus and CNS S. epidermis (Shi, 2000; Shi et al., 2000a; Shi 
et al., 2000b). Their 2009 study showed that stable mucin coatings were formed on polymers 
of different wettability. They noted that there was batch-to-batch variability in commercially 
bought BSM, and that using mucins from animal sources was better with rigorous purification 
procedures. This may indicate valuable non-mucin components being lost during commercial 
purification. This study outlined two important areas, viz. the ability of animal sourced mucins 
in microbial protection and the importance of using non-commercially sourced animal mucins. 
In 2012 Lieleg et al, published a paper in which they incorporated animal sourced mucins into 
a broad-spectrum antiviral agent. They suggested that because of the increased mutation rates 
and high level of variation between viruses, that there is a need for a broad-spectrum antiviral 
agent (Lieleg et al., 2012). An antiviral agent is crucial when the immune system cannot repel 
infection, or when vaccinations are not available or inadequate. They then decided to look at 
the innate immune system’s anti-microbial biopolymer-based hydrogel also known as mucus 
(Linden et al., 2008; Thornton et al., 2004). Previous studies on native human cervical mucus 
(CVM) have shown that even though the average pore size of CVM matrix is 340 ± 70nm, viral 
particles smaller than that can be trapped at low pH, most notably herpes simplex virus-1 
(HSV-1: ∼180 nm) and human immunodeficiency virus-1 (HIV-1: ∼120 nm) via 
mucoadhesion (Cu et al., 2008; Lai et al., 2009; Lai et al., 2007; Lai et al., 2010b). Human 
salivary mucins have also been suggested to reduce HSV-1 infectivity (Bergey et al., 1993a), 
and isolated gastrointestinal mucins have shown to inhibit rotaviruses and noroviruses (Tian et 
al., 2005; Yolken et al., 1992). Lieleg et al (2012) hypothesized that with the range of microbes 
that mucins already inhibit, it would be an effective supplement for hygiene and health 
products, or lubricants to enhance the natural immune system (Lieleg et al., 2012). They also 
addressed a key problem in human mucin research, in that, the quantity of human mucins 
obtained for investigation is very small, relative to the purified yield required for 
experimentation. Their study looked at pig gastric mucin, as these have been previously used 
as a component for artificial saliva in the treatment for patients salivary deficiency (xerostomia) 
(Blixt-Johansen et al., 1992; Duxbury et al., 1989).  Lieleg et al (2012) used partially purified 
pig gastric mucins reconstituted in a buffered solution which was then layered onto human 
cervical cells. Thereafter they added fluorescently labelled Human Papilloma Virus-16 (HPV-
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16) and Merkel cell polyoma-virus (MCV) reporter vectors. Infection was determined by green 
fluorescent protein (GFP) expression under flow cytometry. They also looked at the effect their 
mucin in buffered solution would have against Influenza A virus on a modified canine kidney 
cell line. Their results showed efficient infection prevention from the small diameter viruses 
HPV-16, MCV and Influenza A. 
In the past our laboratory has worked on human mucins and HIV-1 in vitro, specifically crude 
and purified saliva, breast-milk and cervical plug mucins (Habte et al., 2010; Habte et al., 2008; 
Habte et al., 2007; Habte et al., 2006; Mthembu et al., 2014; Peacocke et al., 2012). In 2008, 
our laboratory showed that purified pregnancy plug mucins (consisting of MUC1, MUC2, 
MUC5AC and MUC5B), incubated on human T lymphoblastoid cell line (CEM SS cells), 
inhibited HIV-1 activity by ~97.5%, whereas crude cervical plug mucus did not (Habte et al., 
2008). The results were based on a p24 ELISA assay. In 2012, the same assay was utilized to 
illustrate the effect of crude and purified salivary mucins (consisting of MUC5B and MUC7) 
on HIV-1 from patients with and without HIV. Our results showed that crude and purified 
human saliva, independent of status, inhibited HIV-1 in vitro (Peacocke et al., 2012). Mthembu 
et al (2014) tested crude and purified breast milk mucins from HIV positive and negative 
patients, on an in vitro HIV-1 p24 assay. She showed that crude breast milk did not inhibit 
HIV-1 in vitro but purified breast milk mucins did inhibit HIV-1 (Mthembu et al., 2014). These 
studies are ongoing and to be able to further develop our ideas we require large volumes of 
crude mucus to perform detailed studies on purified mucins and other components of mucus 
and their effect on the HI virus. One possible solution to this problem, as outlined by Lieleg et 
al (2012), is to work with an animal model for mucin research, primarily the pig model for 
antiviral research.  
1.5.6 Rationale for using pig and horse mucins as an alternative for human mucin research 
An animal model, in general is established to appropriately replicate the condition under 
investigation. This is based on the evidence and inferred similarities between the animal model 
and humans (Meurens et al., 2012). In terms of anatomy, genetics and physiology, pigs are 
very like humans (Mall et al., 1997b; Meurens et al., 2012; Nordman et al., 1998). Several 
surgical procedures in human medicine are typically practiced on pigs, including 
catheterization, heart surgery, endoscopy, valve manipulation and broncho-alveolar lavages. 
Furthermore, the size and composition of the pig genome are comparable to that of humans 
(Hart et al., 2007). There are also high protein and genome sequence homologies in pigs and 
humans. Researchers have shown that the domestic pig (Sus scrofa) is 84.1% homologous to 
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the human genome (Fang et al., 2012). It is thought that the pig and human genomes diverged 
97 million years ago, but the pig genome still has many similarities to the human genome (e.g. 
genes related to cardiovascular function), making the pig model an intriguing disease model 
for researchers (Groenen et al., 2012). 
The effect of animal and human saliva on HIV was previously investigated by Fultz (1986). 
Fultz (1986) mixed 0.2ml of HIV-1 subtype B virus (then termed HIV, LAV strain) with 0.2ml 
of human saliva and chimpanzee saliva (1:1 dilution) (Folks et al., 1986). Samples were then 
either passed through a filter undiluted or diluted with phosphate buffered saline (1:2) and then 
filtered (Fultz, 1986). The virus and saliva mixtures were incubated for either 1 minute, 1 hour, 
5 hours, and 24 hours at 37 degrees Celsius (oC). Virus and saliva mixtures were then added to 
phytohaemagglutinin-stimulated human adult white blood cells for 18 hours. Supernatant was 
collected every 3 – 4 days. The cells were then washed and tested for HIV reverse transcriptase 
activity. This assay was then repeated on HIV infected phytohaemagglutinin-stimulated human 
adult white blood cells. This study showed that whole saliva and filtered saliva from a 
chimpanzee and a human inhibited HIV-1 subtype B virus in vitro (Fultz, 1986). Fultz (1986) 
hypothesised that saliva inactivates the virus but inhibition was not due to saliva constituents 
like lysozymes, lactoferrin, lactoperoxidase or low pH.  
In 2008, Rousseau et al published proteomic data on human saliva in comparison to horse, pig, 
cow and rat saliva (Rousseau et al., 2008). They collected saliva in a denaturing buffer and 
after purification, analysed the resulting products. They found that in human saliva the 
predominant polymeric mucin is MUC5B and while humans have the MUC19 gene (the largest 
gel-forming mucin), MUC19 is not expressed by the salivary glands in humans (Chen et al., 
2004; Rousseau et al., 2008; Thornton et al., 1999). In contrast, they found that gel-forming 
mucins in horse, pig, cow and rat saliva existed as a heterogeneous mixture Muc5b and Muc19, 
of which, Muc19 has similar structures to other human gel-forming mucins  (Chen et al., 2004). 
In 1997, Nordman et al, purified mucins from pig gastric mucosa. They trypsin digested the 
reduced subunits of glycoproteins, and they found two populations of high molecular mass 
mucins, the fragmentation pattern of which, were like those of human cervical and 
tracheobronchial mucins (Carlstedt et al., 1983a; Carlstedt & Sheehan, 1984; Davies et al., 
1996; Nordman et al., 1997; Thornton et al., 1990). In 1998, the same research group used 
antibodies to show that the pig gastric mucosa had the same tissue distribution as the human 
stomach (Bara et al., 1991; Nordman et al., 1998; Turner et al., 1995). They also noted the 
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work of Turner and colleagues who constructed a cDNA library from the pig stomach and 
found that mucin expression was similar to that of human gastric mucosa, where MUC5AC 
was secreted by the surface epithelium and MUC6 by the glands (Carlstedt et al., 1995; De 
Bolós et al., 1995; Ho et al., 1995). Nordman et al (1998) also highlighted that gland mucins 
were less sensitive to proteolytic degradation in comparison to those from the surface, and 
hence play a vital role in protecting the cell surface epithelia from stomach acid (Nordman et 
al., 1998). 
It has been well documented how cow, sheep and sow arborisation peaks correspond to those 
of humans, but the duration of ovulation is greater in animals (Alliston et al., 1958; Betteridge 
et al., 1962; Polge, 1965; Raeside, 1963; Ullery et al., 1959). The longer period of mucus 
production coupled with the ease of sample collection highlights the benefits of using the pig 
model (Haynes, 1971).   
It is our firm belief that our future work will benefit in many ways from sourcing and working 
with animal mucins. 
1.6 Aims and Objectives 
1.6.1 To find an abundant and effective animal sourced alternative for human mucin 
research. Animal mucus sources are from pig saliva, gastric, cervico-vaginal mucus 
and horse saliva. 
  1.6.2 To investigate the animal model mucins effect on cell free HIV infectivity on an in 
vitro pseudo-viral assay and determine which is the most effective for further studies. 




CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Ethics Approval 
This project was granted ethical approval by the University of Cape Town, Faculty of Health 
Sciences Animal Ethics Committee, FHS AEC REF No: 013/027. 
 
2.2 Materials 
Disodium hydrogen orthophosphate (Na2HPO4), guanidine hydrochloride (GuHCl), 
phenylmethanesulfonyl fluoride (PMSF), N-ethylmaleimide (NEM), solid caesium chloride 
(CsCl), Sepharose 2B beads, Sepharose 4B beads, pararosaniline hydrochloride, pararosaniline 
chloride, potassium metabisulphite, Periodic acid, acetic acid, 3-(4,5-dimethylthiazol-2-yl)2,5-
diphenyl tetrazolium bromide (MTT), sodium chloride (NaCl), dithiothreitol (DTT), 
iodoacetamide (IAA), glycerol, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-
hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), sodium azide (NaN3), 
ethylenediaminetetra-acetic acid disodium salt (Na2-EDTA), N,N′-Methylenebisacrylamide 
(Bis/Acrylamide), trypsin-EDTA and diethylaminoethyl (DEAE) dextran were purchased from 
Sigma-Aldrich® Co, St Louis, MO, USA. The Bradford assay reagent was obtained from 
Quickstart, BioRad (Bio-Rad Laboratories Inc., Hercules, California, United States of 
America). Nitrocellulose membranes, dialysis tubing, sodium metabisulphite (Na2S2O5), 
Tris(Hydroxymethyl)aminomethane (Tris) were supplied by Kimix (South Africa). The ECL™ 
Western Blotting Detection Kit was bought from Amersham Biosciences (Amersham, United 
Kingdom). Luciferase substrate was purchased from Promega (Anatech Analytical 
Technology, Bellville, South Africa). Polyclonal rabbit anti-human MUC5AC (1 in 5000 
dilution) and rabbit anti-human MUC5B (1 in 2000 dilution) antibodies were provided by the 
Thornton Lab from the University of Manchester, United Kingdom. Monoclonal mouse anti-
human MUC6 (CLH5) (1 in 100 dilution) was from Novocastra Laboratories Ltd (Newcastle, 
United Kingdom). Monoclonal mouse anti human MUC7 (1 in 1500 dilution) antibody was 
from Santa Cruz Biotechnology, Inc (Santa Cruz, California, United States of America). 
Polyclonal goat anti-rabbit (1 in 5000 dilution) and polyclonal rabbit anti-mouse horse radish 
peroxidise (HRP) linked secondary antibodies were from Dako, Denmark. Foetal bovine serum 
(FBS), Pen-Strep, L-Glutamine, non-essential amino acids (NEAA), Dulbecco modified Eagle 
medium (DMEM) with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were 
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from Gibco (Massachusetts, United States of America). Trypan blue solution, glycine, sodium 
dodecyl sulfate (SDS), bromophenol blue, hydrochloride chloride (HCl), ammonium 
persulphate (AMPS) and tetramethylethylenediamine (TEMED) were obtained from Merck 
(Germany). TZM-bl/JC53 cells (a HeLa cell line engineered with CCR5, CXCR4 co-receptors 
and CD4 receptors) were provided by the International Centre for Genetic Engineering and 
Biotechnology (ICGEB), University of Cape Town (UCT), South Africa. Thermo Scientific 
PageRuler Prestained Protein Ladder was purchased from Thermo Scientific, Lithuania. 
Vacutec Acqua Stain was purchased from Vacutec, Johannesburg, South Africa. 
 
2.3 Sample Collection 
2.3.1 Pig gastric mucus collection 
Twenty-one pig stomachs were collected from Winelands Pork Abattoir, La Belle Rd, Stikland, 
Cape Town, 7530. The stomachs were transported in a closed bucket to our laboratory at the 
University of Cape Town (UCT), Faculty of Health Sciences (FHS), Groote Schuur Hospital, 
Old Main Building, J-Floor, J50 room 30, Main Road, Observatory, 7925, Cape Town, R.S.A. 
On average, transportation of stomachs took 30 minutes. Pig stomachs were opened with a pair 
of scissors along the greater curvature and gently washed with water. Ulcerated stomachs were 
excluded. Mucus was lightly scraped from the pars oesophagea, body, cardiac gland and 
pyloric antrum regions using 2 sterile glass slides. At least 50ml of mucus was collected form 
pig stomachs. The scraped mucus was placed into pre-weighed specimen jars kept on ice. The 
jars contained 10 milliMolar (mM) Na2HPO4, 6 Molar (M) GuHCl, 10mM EDTA, 1mM PMSF 
and 5mM NEM (see Collection Buffer 1, Appendix section 1.1) in a ratio of 3 millilitres (ml) 
10mM Na2HPO4, 6M GuHCl, 10mM EDTA, 1mM PMSF and 5mM NEM at pH6.5 to every 
1ml of gastric mucus. Pig gastric mucus was then pooled and stirred slowly overnight at 4 
degrees Celsius (oC). Thereafter, the sample was homogenized to separate any mucus coupled 
with insoluble contaminants with an ultra-turrax T25 (IKA Laboratory, Staufen, Germany) at 
24 000 revolutions per minute (rpm) for 60 seconds (s). Homogenized samples were then 
centrifuged at 3000rpm for 60 minutes (mins) and the supernatant was stored in a -20oC freezer. 
 
2.3.2 Pig saliva collection 
Pig saliva was collected from 20 pigs by the UCT Animal Unit (AU), Faculty of Health 
Sciences, Chris Barnard Building, Falmouth Road, Observatory, Cape Town, 7935. The saliva 
was collected on site by staff from local pig farms. Approximately 100ml of saliva was 
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collected for each pig. Samples were collected in 0.2M NaCl:0.02% sodium azide (see Sample 
Collection Buffer 2, Appendix section 1.2) in a ratio of, 4ml buffer 0.2M NaCl:0.02% sodium 
azide to every 1ml of pig saliva. Pig saliva was not collected in guanidine hydrochloride as a 
cost saving measure. Saliva samples were brought to our laboratory where the saliva was 
pooled and stirred slowly overnight at 4oC. Samples had low viscosity and solubilized easily 
in the overnight stir. Thereafter, the sample was centrifuged at 3000rpm for 60 mins and the 
supernatant was stored in a -20oC freezer.  
2.3.3 Pig cervical mucus collection 
Pig cervical mucus was collected from 10 pigs by Sister M. Botes, UCT Animal Unit (AU), 
Faculty of Health Sciences, Chris Barnard Building, Falmouth Rd, Observatory, Cape Town, 
7935. The cervical mucus was collected on site by their staff from local pig farms. Pigs were 
in the oestrus cycle of ovulation. Approximately 5ml of cervical mucus was collected from 
each pig. Pig cervical mucus samples were collected in 10mM Na2HPO4, 6M GuHCl, 10mM 
EDTA, 1mM PMSF and 5mM NEM at pH6.5 (see Collection Buffer 1, Appendix section 1.1) 
in a ratio of 9ml buffer for every 1ml of pig cervical mucus. Samples were collected from the 
UCT AU and brought to our lab. Pig cervical mucus was pooled and stirred slowly overnight 
at 4oC. No homogenization was required as there were no insoluble contaminants in the sample 
that could not be removed by centrifugation. Thereafter, samples were centrifuged at 3000rpm 
for 60 mins and supernatant was stored in a -20oC freezer. 
2.3.4 Horse saliva collection 
Horse saliva was collected from 1 horse by Ms Heather Epstein who runs a farm and is an 
acquaintance of Professor A. S. Mall. Approximately 50ml of saliva was collected. The sample 
was collected in 10mM Na2HPO4, 6M GuHCl, 10mM EDTA, 1mM PMSF and 5mM NEM at 
pH6.5 (see Collection Buffer 1, Appendix section 1.1) in a ratio of 4ml buffer for every 1ml of 
horse saliva. This buffer was selected as the sample had to be stored for a long period (at 4oC) 
as Ms. Epstein lived far away. Samples were collected from the UCT AU and brought to our 
lab. The mucus in buffer was slow stirred for overnight at 4oC. Thereafter, the sample was 
centrifuged at 3000rpm for 60 mins and the supernatant was dialysed against distilled water 




2.4 First Ultracentrifugation of samples 
Supernatant collected from sections 2.3.1 and 2.3.3 after the initial 3 000rpm centrifugation 
were subjected to a density gradient ultracentrifugation. Supernatant from sections 2.3.2 and 
2.3.4 underwent a density gradient ultracentrifugation after Sepharose 4B gel filtration. Density 
gradient ultracentrifugation is a separation technique that works on the Archimedes’ principle 
which states that a particle settling in a simple fluid is subjected to its own weight and an 
upward density force that is based on the weight of the displaced fluid (Piazza et al., 2012). 
Supernatant was prepared for caesium chloride (CsCl) density gradient ultracentrifugation to 
separate mucins and proteins in a solution of 4M GuHCl (see Ultracentrifugation Buffer, 
Appendix, section 1.3). During density gradient ultracentrifugation, CsCl molecules dissociate 
and Caesium ions (Cs+) downward movement opposed by a diffusion force results in a density 
gradient from CsCl molecules within the tube. The lower density fractions migrate to the top 
of the tube, with the density gradient moving down the tube. Mucins and proteins in the tube 
move to a fraction corresponding to their density (Creeth et al., 1970). 
The density of supernatants was adjusted to 1.39 grams per millilitre (g/ml), by adding CsCl 
and 4M GuHCl (see Ultracentrifugation Buffer, Appendix, section 1.3). These were injected 
with disposable syringes into ultracentrifuge tubes and heat sealed with a tube topper. Tubes 
were placed in a Ti70 rotor and then into a Beckman L45 ultra-centrifuge for 48 hours at 40 
000rpm at a temperature of 4oC. 
Tubes were divided into 9 fractions spaced 1 centimetre (cm) apart. Fractions were pipetted 
into 10ml glass tubes using sterile disposable syringes. The densities of each fraction were 
recorded by weighing a volume of 1ml on an analytical balance. 
2.4.1 Glycoprotein and Protein detection of ultracentrifugation samples 
2.4.2 Periodic Acid Schiff (PAS) assay for glycoprotein detection 
This assay detects glycoproteins once their hydroxyl groups (-OH) are oxidized to aldehyde 
groups (-CHO) in the presence of periodic acid. Decolourised Schiff’s reagent reacts with the 
aldehyde group to give a pink/purple colour (Thornton et al., 1996). 
Ten microlitres (µl) of each sample from each fraction was plated into a 96-well microtiter 
plate. One hundred microlitres of periodic solution (7% acetic acid with 50% periodic acid) 
was added to 20µl of sample and incubated at 37oC for 1 hour. After incubation, 100µl of 
decolourised Schiff’s reagent (see Appendix, section 5.1) was added to each well and incubated 
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at room temperature for 30 mins. Thereafter, the absorbance was read on an Anthos HTII Plate 
Reader (GoIndustry DoveBid, Lancashire, United Kingdom) at 585nm. While the optimum 
wavelength for this assay is 555nm, our plate reader had 585nm filter which was close enough 
to read the relevant absorbance.  
2.4.3 BIO-RAD Quick StartTM Bradford assay for protein detection 
The Bradford assay utilises a protein-binding dye that exists in 3 forms: cationic, neutral and 
anionic (Compton et al., 1985). The anionic form is not present at the dye reagent pH, but this 
forms complexes primarily with arginine via Van der Waals forces and hydrophobic 
interactions. It also binds slightly to basic amino acids Histidine and Lysine as well as aromatic 
residues Tryptophan, Tyrosine and Phenylalanine (Compton & Jones, 1985). 
Twenty microlitres from each fraction was plated into a 96-well microtiter plate. Two hundred 
microlitres of diluted BIO-RAD Quick StartTM Bradford dye (see Appendix section 6) were 
added to the samples and incubated at room temperature for 5 mins. Thereafter the plate was 
read on an Anthos HTII Plate Reader (GoIndustry DoveBid, Lancashire, United Kingdom) at 
585nm. 
2.4.4 Second Ultracentrifugation of samples 
Fractions containing glycoproteins were pooled and had their densities adjusted to 1.41 g/ml, 
by adding CsCl and 4M GuHCl (see Ultracentrifugation Buffer, Appendix, section 1.3). These 
were injected with disposable syringes into ultracentrifuge tubes and heat sealed. Tubes were 
placed in a Ti70 rotor and then into a Beckman L45 ultra-centrifuge for 48 hours at 40 000rpm 
at a temperature of 4°C. 
Tubes were divided into 9 fractions spaced 1 centimetre (cm) apart. Fractions were collected 
into centrifuge tubes using sterile disposable syringes. The densities of each fraction were 
recorded by weighing a volume of 1ml on an analytical balance. 
Fractions then underwent PAS and Bradford Assays to determine the glycoprotein and protein 
rich fractions, respectively. Thereafter, samples underwent dialysis. 
2.5 Dialysis of samples 
To remove salts and small soluble molecular weight impurities, samples were dialysed against 
distilled water. Dialysis tubing (nitrocellulose membrane, average flat width 25 millimetres 
(mm)) was boiled in a beaker of water (at 100oC) in the presence of 2% weight per volume 
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(w/v) sodium bicarbonate solution in 1mM EDTA solution until the membranes opened and 
floated to the top. Pooled fractions and/or supernatant of each sample were pipetted into the 
opened dialysis tubing. Thereafter, the tubing was placed into a 12 Litre (L) bucket and dialysed 
against at least three changes of distilled water (at 6 hour intervals) with continuous stirring on 
a Fried Electric Magnetic Stirrer (Haifa, Israel), at 4°C.  
2.6 Freeze drying 
Empty centrifuge tubes had holes made in their lids, using a heated needle (using the flame of 
a Bunsen burner). They were weighed and had the dialysed contents, emptied into them (15ml 
or 50ml, depending on the volume of dialysed sample). Tubes were left overnight in a -80°C 
freezer. Samples were then placed in the vacuum chamber of a Freeze Zone 6 Freeze Dry 
System (Labconco, Kansas City, United States) and freeze dried at -50°C under a vacuum of 
0.021 millibars (mBar). Samples were left in the freeze dryer until all the ice in the sample had 
undergone sublimation leaving behind lyophilized protein and/or glycoprotein. 
2.7 Column Chromatography 
2.7.1 Sepharose 2B Column Chromatography 
Sepharose 2B beads were degassed to remove bubbles and then packed into a glass column 
(100cm x 2cm, volume of 300ml). Zero point two Molar NaCl:0.02% sodium azide was eluted 
through the column via a Peristaltic Pump (MINIPULS® 3, Gilson, Inc. USA). The column 
was connected to a chromatography fraction collector (FC 204 Fraction Collector, Gilson, Inc. 
USA) that eluted each fraction at 1ml per minute. Fractions were tested for glycoproteins and 
proteins using the PAS Assay (see Appendix section 5) and BIO-RAD Assay (see section 2.4.3. 
and Appendix section 6). Data was graphically viewed on Microsoft Excel, the resulting peaks 
that were of interest were pooled and dialysed (see Section 2.5. above) and freeze dried (see 
Section 2.6. above). 
2.7.2 Sepharose 4B Column Chromatography 
Sepharose 4B beads were degassed to remove bubbles and then packed into a glass column 
(30cm x 2.5cm, volume of 140ml). Zero point two Molar NaCl:0.02% sodium azide was eluted 
through the column via a Peristaltic Pump (MINIPULS® 3, Gilson, Inc. USA). The column 
was connected to a chromatography fraction collector (FC 204 Fraction Collector, Gilson, Inc. 
USA) that eluted each fraction at 1ml per tube. Every second fraction was tested for 
glycoproteins and proteins using the PAS Assay (see Appendix section 5) and BIO-RAD Assay 
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(see section 2.4.3 and Appendix section 6). Data was graphically viewed on Microsoft Excel, 
the resulting peaks that were of interest were pooled and dialysed (see Section 2.5 above) and 
freeze dried (see Section 2.6 above). 
2.7.2.1 Sepharose 4B Column Chromatography Separation of Pig Salivary Muc19 
Zero point two Molar NaCl:0.02% sodium azide was eluted through the previously prepared 
Sepharose 4B column (see section 2.7.2) via a Peristaltic Pump (MINIPULS® 3, Gilson, Inc. 
USA) at a volume that was three times the bed volume of the column to ensure it was cleared 
of any previously run samples. While Sepharose 4B separation may not have the optimal 
resolution to separate the two similarly sized mucins Muc5b and Muc19, it was the best 
exclusion chromatography that was available to us and it was decided to change the flow rate 
to see if this could help separate the mucins. The column was connected to a chromatography 
fraction collector (FC 204 Fraction Collector, Gilson, Inc. USA). Aliquots of pig saliva 
collected in 0.2M NaCl:0.02% sodium azide were eluted through the Sepharose 4B column at 
0.5ml per tube rather than the 1ml per tube seen in section 2.7.2. This was to ensure broader 
peaks for the void volume (V0). Fractions were tested for glycoproteins and proteins using the 
PAS Assay (see Appendix section 5) and BIO-RAD Assay (see section 2.4.3 and Appendix 
section 6). Data was graphically viewed on Microsoft Excel. The fractions making up the V0 
(i.e. the large molecular weight fraction) were individually investigated under Slot Blot for 
Muc5b and Muc19. It is important to note that there still may be Muc5b present in the Muc19 
sample as antibodies raised to human mucins were used and Muc5b may also be present at 
lower than detectable limits. Fractions that were Muc19 positive and Muc5b negative were 
pooled and dialysed (see Section 2.5 above) against 4M GuHCl over three changes for a 
minimum of 6 hours each at 4oC. The volume of 4M GuHCl was at least 20 times the volume 
of pooled Muc19 fractions. 
2.7.2.2 Sepharose 4B Column Chromatography Separation of Horse Salivary Muc19 
Zero point two Molar NaCl:0.02% sodium azide was eluted through the previously prepared 
Sepharose 4B column (see section 2.7.2) via a Peristaltic Pump (MINIPULS® 3, Gilson, Inc. 
USA) at a volume that was three times the bed volume of the column to ensure it was cleared 
of any previously run samples. While Sepharose 4B separation may not have the optimal 
resolution to separate the two similarly sized mucins Muc5b and Muc19, it was the best 
exclusion chromatography that was available to us and it was decided to change the flow rate 
to see if this could help separate the mucins. The column was connected to a chromatography 
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fraction collector (FC 204 Fraction Collector, Gilson, Inc. USA). Lyophilized crude horse 
saliva was dissolved in 0.2M NaCl:0.02% sodium azide and eluted on a Sepharose 4B column 
(eluting buffer was also 0.2M NaCl:0.02% sodium azide). Fractions were collected at 0.5ml 
per tube. This was to ensure broader peaks for the V0. Fractions were tested for glycoproteins 
and proteins using the PAS Assay (see Appendix section 5) and BIO-RAD Assay (see section 
2.4.3. and Appendix section 6). Data was graphically viewed on Microsoft Excel. Aliquots of 
fractions making up the V0 (i.e. the large molecular weight fraction) were individually 
investigated under Slot Blot for Muc5b and Muc19. It is important to note that there still may 
be Muc5b present in the Muc19 sample as antibodies raised to human mucins were used and 
Muc5b may also be present at lower than detectable limits. Aliquots that were Muc19 positive 
and Muc5b negative were pooled and dialysed (see Section 2.5 above) against 4M GuHCl over 
three changes for a minimum of 6 hours each at 4oC. The volume of 4M GuHCl was at least 
20 times the volume of pooled Muc19 fractions. 
2.8 Chemical Treatments 
2.8.1 DTT Treatment 
DTT (10mM) was added to Sepharose (2B or 4B) eluted V0 samples (pig saliva, gastric and 
cervico-vaginal mucin) in 0.2M NaCl:0.02% sodium azide. The sample was then incubated in 
a water bath at 37oC for 5 hours. To ensure there was no re-association of disulphide bonds, 
25mM IAA was added. The sample tube was covered in foil and incubated in the dark 
overnight. Samples were then dialysed (see Section 2.5. above) and freeze dried (see Section 
2.6. above). 
2.8.2 Trypsin Treatment 
Trypsin from pig pancreas was added to Sepharose (2B or 4B) eluted V0 samples (pig saliva, 
gastric and cervico-vaginal mucin) in 0.2M NaCl:0.02% sodium azide at a dilution of 1:100. 
This was incubated at 37oC for 5 hours. Samples undergoing trypsin treatment were not pH 
controlled so the optimal trypsin treatment may not have occurred. Samples were then dialysed 
(see Section 2.5. above) and freeze dried (see Section 2.6. above). 
2.9 Gel electrophoresis 
2.9.1 Gradient (4 – 20%) Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was used to detect mucins and proteins in all samples as well as to estimate their 
molecular weights. Due to the large sizes of mucins a gradient SDS-PAGE gel was preferred 
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for this analysis, to ensure maximum movement into the gel. The gels were prepared as per 
Laemmli et al (1970). The components of the gels are outlined in Appendix sections 1.6 to 3.3 
(Laemmli, 1970). 
The structure of mucins poses a problem for SDS-PAGE gel analysis. Dense O-linked glycans 
and multimerization (due to intra- and inter-molecular disulphide bonds) results in mucins 
having a range of molecular weights. The high molecular weight mucins (e.g. MUC16 has a 
molecular weight of 1 519.2kDa) are prevented from electrophoretic migration in standard 
SDS-PAGE gels. The inability of these high molecular weight mucins to penetrate the gels 
result in the mucins remaining on the gel surface (Paszkiewiczgadek et al., 1995; Ramsey et 
al., 2016; www.proteinatlas.org). 
Freeze-dried pellets (1mg) were brought up in 100µl SDS sample application buffer (see 
Appendix section 1.6.5), and heated for 1 min in boiling water at 100°C. Fifteen microlitre 
aliquots of each sample and protein ladder were added to the appropriate wells. The BIO-RAD 
Mini-PROTEAN® Tetra Cell, 4-Gel system electrophoresis tank was filled with tank buffer 
and attached to a Consort E844 400 Volts (V) – 400 milliAmperes (mA) Electrophoresis Power 
Supply. The gels were run at the manufacturers recommended Volts, Amperes and time 
depending on the number of gels in the tank.  
2.9.2 Protein Staining of SDS-PAGE gel 
SDS-PAGE gel was placed in a glass container and stained with Vacutec Acqua Stain Protein 
Gel Stain for 10 mins at room temperature (per manufacturer’s instruction). The gel was 
scanned on a Hewlett Packard desktop scanner and saved to a computer. 
2.9.3 PAS staining of SDS-PAGE gel 
Glycoproteins were visualized using the PAS staining method as used by Dubray and Bezard 
(1982) (see Appendix section 4). Briefly, the gel was immersed in 50% ethanol for 30 mins at 
room temperature. After washing the gel with distilled water for 10 mins, the gel was incubated 
in 3% acetic acid with 1% periodic acid for 30 mins. Thereafter, the gel was washed and left 
in distilled water overnight at 4°C. The gel was then washed in a solution of 0.1% sodium 
metabisulphite in 10mM HCl twice for 10 mins. The gel was then incubated with decolourised 
Schiff’s reagent in the dark for 1 hour, followed by 1 hour in 0.1% sodium metabisulphite in 
10mM hydrochloric acid (Dubray et al., 1982). The resulting glycoprotein stained gel was 
scanned and saved on a computer. 
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2.10 Slot Blot Analysis 
Mucins were identified via Slot blotting. One Nitrocellulose membrane and three pieces of 
blotting paper were cut to the appropriate size and immersed in 4x saline-sodium citrate (SSC) 
buffer (see Appendix section 7) for 10 mins. The wet nitrocellulose membrane was placed on 
three pieces of blotting paper and sandwiched in a Minifold® II, Schleicher & Schuell, Inc. 72-
well Slot Blot Manifold (New Hampshire, United States). Samples (50µl for each) were 
pipetted into wells and transferred under vacuum to a nitrocellulose membrane (BioTraceTM 
NT membrane, Pall Corporation, New York, United States) treated with poly-L-lysine (1:50 
dilution with SSC buffer). The bands were vacuum-transferred for 1 hour at 40mBar using a 
Pharmacia LKB Vacugene XL vacuum blotter (Kalamazoo, United States). Membranes were 
incubated with 5% (w/v) low-fat milk powder in 1x TBST (Tris saline buffer with 0.05% 
Tween-20) for 30 mins at room temperature to block non-specific binding sites. The primary 
antibody was diluted accordingly (see Appendix Table 1) in 5% (w/v) low-fat milk powder in 
1x TBST and incubated for 3 hours on a shaker or overnight at 4°C. Membranes were then 
washed with 1x TBST, 4 times for 3 mins each. Secondary antibodies (see Appendix Table 1) 
were appropriately diluted in 5% (w/v) low-fat milk powder in 1x TBST and incubated for 30 
mins at room temperature. Membranes were washed thrice with 1x TBST, for 10 mins, 
followed by a quick rinse with distilled water. To view the mucins, the membranes were 
developed using ChemiFast Chemiluminescent Substrate kit (Vacutec). Briefly, equal parts of 
reagent A and reagent B were mixed and an appropriate amount was added to cover the 
membrane before being dried by blotting with filter paper. The membrane was then viewed in 
a Syngene G-box (Syngene, Haryana, India). 
2.11 Pig Mucin Derived Anti-HIV-1 Gels for in vitro Analysis 
Buffers were constructed from previous work done by Allen et al (1976) and Owen et al (1999). 
Four buffers were constructed using the components seen in Appendix Table 2. Per Allen et al 
(1976) for an effective mucin gel there should be 30mg of mucin for 1ml of buffer. Gels were 
constructed by adding 30mg of either purified pig gastric mucin or purified pig cervical mucin 
to each buffer (Allen et al., 1976; Owen & Katz, 1999). The buffers were adjusted to neutral 
pH (~7.0 – 7.2) to successfully run on pseudoviral and MTT assays. 
2.12 Pseudoviral Assay 
Antiviral properties of mucins were tested on a modified HIV neutralization luciferase-based 
reporter gene assay (Montefiori, 2009). This assay originally assessed neutralizing antibodies 
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for HIV, to study the immune response in infected individuals (Montefiori, 2009). The 
Montefiori (2009) assay was modified by the Dorfman laboratory (from the International 
Centre for Genetic Engineering and Biotechnology (ICGEB)) to test mucins instead of 
antibodies against HIV infection. This pseudoviral assay, uses TZM-bl/JC53 cells (a Hela cell 
line with CCR5, CXCR4 coreceptors and CD4 receptors). This assay was carried out in a P2 
facility at the Dorfman laboratory situated in ICGEB, Faculty of Health Sciences, UCT. These 
cell lines were engineered, frozen, thawed and cultured by the Dorfman laboratory. The cells 
have been transfected with an LTR (long translational repeat) promoted luciferase and ß-
galactosidase gene sequence. The virus is made from plasmid SG3*env transcribing all viral 
genes except for a dysfunctional env and a plasmid containing env. The functional env can be 
varied to represent different viral strains. The viral tat gene initiates the LTR promoter and thus 
luciferase and ß-galactosidase production (see Figure 2.1 and Figure 2.2). This study used a 
moderately infective virus derived from a Durban (KwaZulu-Natal, South Africa) strain, viz. 
Du422.1. This too, was cultured, titrated and supplied by the Dorfman laboratory. 
 
Figure 2.1 Engineering of HIV pseudovirus. Packaging cells are transfected with an LTR (long 
translational repeat) promoted luciferase and ß-galactosidase gene sequence. The HI virus is made from 
plasmid SG3*env transcribing all viral genes except for a dysfunctional env and a plasmid containing 
env. The functional env and/or pseudoviral RNA can be varied to represent different viral strains. This 





Figure 2.2 The HIV pseudoviral assay. Previously engineered HIV pseudovirus is incubated with mucin 
for an hour at room temperature. Thereafter, the HIV pseudoviral and mucin mixture is added to TZM-
bl/JC53 cells (a Hela cell line with CCR5, CXCR4 coreceptors and CD4 receptors). If the mucins fail 
to block HIV pseudoviral infection, the viral tat gene initiates the LTR promoter and thus luciferase and 
ß-galactosidase production. If mucin blocks viral entry, there is no luciferase and ß-galactosidase 
production. 
Pig and horse mucin derivatives were tested on the pseudoviral assay to assess how different 
treatments enhanced or retarded HIV-1 infection in vitro. Samples were prepared in growth 
media (at 500 – 1000 micrograms (µg) per 1ml of buffer) 10% Dulbecco’s Modified Eagle’s 
Medium (DMEM) (see Appendix section 1.5), (a 5% DMEM solution is used for normal cell 
maintenance (see Appendix section 1.4)). Confluent cells on day 1 of the assay were trypsin 
treated (0.8ml trypsin EDTA added to cell culture petri dish) for 4 mins. Thereafter, the cells 
were transferred in 6ml 10% DMEM to a centrifuge tube and centrifuged in an Eppendorf 5810 
R Centrifuge (USA Scientific, Inc, USA) at 1000rpm for 5min at 21oC. Cells were then 
dissolved in an appropriate amount of 10% DMEM and counted on a haemocytometer (30μl 
Trypan Blue and 10μl cells in media). DEAE Dextran (7.5mg/ml) was added to the cells to 
remove any natural charge repulsion between virus and cells. Cell concentration was adjusted 
to give 1 million cells per plate (approximately 10 416 cells per well) and plated on 96 well 
flat-bottomed plates. Plates were placed in a 37oC incubator (5% carbon dioxide (CO2)) 
overnight. On day 2, a separate plate was used to serially dilute the samples by half the volume 
(done 7 times from the starting concentration of 500 – 1000µg/ml), and in duplicate, but leaving 
wells for negative (cells in media only) and positive controls (cells in media plus virus) media. 
The starting volumes for dilution were either 300μl or 350μl. To a new tube, replication 
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defective pseudovirus HIV-1 subtype C Du422.1 virus was diluted in 10% DMEM (the dilution 
was dependant on the virus concentration which was determined by the Dorfman laboratory). 
Briefly, the starting concentration of the virus was mathematically divided by four (as the virus 
would make a quarter of the components of the well i.e. 1 part cells, 2 parts mucin and 1 part 
virus) the total volume of virus required (i.e. number of wells multiplied by the volume of virus 
per well) was divided by the previous quotient to give the volume of pure virus that must be 
diluted up to the total volume needed. Seventy-five microliters or 82.5μl (depending on 
whether the dilutions started at 300μl or 350μl respectively) of virus was added to the 
appropriate wells and incubated for an hour at room temperature, after which, 150μl of well 
contents from the dilution plate was added to the corresponding well of the cell culture plate. 
The previous steps highlight another deviation from the Montefiore (2009) neutralization 
assay. In the Montefiore (2009) based neutralization assay, antibodies under investigation were 
incubated with a replication defective virus for 1 hour, to which TZM-bl/JC53 cells were added 
for 48 hours (Montefiori, 2009). During the optimization of the pseudovirus assay, it was 
shown that adding the cells last to a virus and mucin mixture stopped cells from adhering to 
the bottom of microtitre wells (data not shown) impairing TZM-bl/JC53 cell growth and the 
success of the assay. 
In the virus control, virus was added to wells in the absence of mucin, where luciferase activity 
was detected as 50 000 Relative Light Units (RLU). Plates were then incubated in a 37oC 
incubator (5% CO2) for 48 hours. Thereafter, 100μl of media was removed from each well and 
replaced with an equal amount of Luciferase and incubated in the dark for 2 mins. Results were 
measured and recorded using a GloMax®-96 Luminometer (Promega, France). Data was 
extracted to Microsoft Excel to calculate the percentage Neutralization of each sample at every 
dilution, using the following equation: 
 
(AverageRLUVC - AverageRLU[Sample]) / (AverageRLUVC-AverageRLUCC) x 100% 
Where 
AverageRLUVC = Average Relative Light Units of the Virus Controls 
AverageRLU[Sample] = Average Relative Light Units of the Sample 
AverageRLUCC = Average Relative Light Units of the Cell Controls 
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The readout with no mucin was assigned the output value of 0% neutralization and the sample 
readout with no virus was assigned the output value of 100% neutralization. The percentage 
neutralization and corresponding concentration of samples was exported to GraphPad Prism 
Version 6 to calculate the half maximal Inhibitory Concentration (IC50). The IC50 was 
calculated from a nonlinear regression (curve fit) Dose-response - Inhibition curve, using a 
Log[inhibitor] vs normalized response-variable slope graph, where 
 Y = 100/(1+10^((LogIC50-X)*Hillslope))  
The percentage neutralization previously calculated on Microsoft Excel was imported as the 
inhibitor in the above equation. The solid lines seen in the dose response curves correspond to 
the best model of an inhibition curve. Ninety-five percent confidence intervals were based upon 
curve fit of inhibition curves. A 95% confidence interval is a range where there is a 95% 
probability that the true effect lies within it. Tighter or narrower confidence intervals indicate 
more reliable data (Higgins et al., 2011). In this study that would translate to the effect of mucin 
specific HIV-1 inhibition. The log dose response curves were reported in this assay with the 
X-axis showing the non-logged concentration to better visualize the relationship between 
concentration and HIV-1 neutralization. Data was expressed in 4 significant figures. 
2.13 Toxicity Assay 
An MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) assay (Śliwka et al., 
2016) was used to assess the toxicity of our purified mucin products, including any associated 
proteins, on the same cell line as the pseudoviral assay. The pseudoviral assay method was 
mimicked here but with no HIV addition. This assay relies on the ability of mitochondrial 
enzymes of viable cells to change the MTT tetrazolium salt into its purple formazan derivative 
(Ferrari et al., 1990). This colour change is measured on a microplate reader at 585nm to 
determine the percentage of viable cells relative to the control cells that have no sample just 
media. 
Samples were prepared in growth media 10% DMEM (see Appendix section 1.5), (a 5% 
DMEM solution is used for normal cell maintenance (see Appendix section 1.4). Confluent 
cells on day 1 of the assay were treated with trypsin (0.8ml trypsin-EDTA solution added to 
cell culture petri dish) for 4 mins. Thereafter, the cells were transferred in 6ml 10% DMEM to 
a centrifuge tube and centrifuged at 1000rpm for 5 mins at 21oC. Cells were then resuspended 
in an appropriate amount of 10% DMEM and counted on a haemocytometer (30μl Trypan Blue 
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and 10μl cells in media). DEAE Dextran (7.5mg/ml) was added to the cells to remove any 
natural charge repulsion between virus and cells. Cell concentration was adjusted to give 1 
million cells per plate (approximately 10 416 cells per well) and plated on 96-well flat-
bottomed plates. Plates were placed in a 37oC incubator (5% CO2) overnight. On day 2, a 
separate plate was used to serially dilute the samples by half the volume (done 7 times from 
the starting concentration of 1mg/ml), and in duplicate, but leaving wells for negative (cells in 
media only) and positive controls (cells in media plus virus) media. The contents of wells 
(150μl) from the dilution plate were added to the corresponding wells of the cell culture plate. 
Plates were then incubated in a 37oC incubator (5% CO2) for 44 hours. Thereafter, 20μl MTT 
(5mg/ml in 10% DMEM) was added to all the wells and incubated for 4 hours at 37oC. 
Following incubation, 100μl of wells contents were removed and replaced with 0.1 Normal (N) 
HCl in isopropanol and incubated at room temperature for 5 mins on a shaker, then read on a 
microplate reader at 585nm. Data was extrapolated to Microsoft Excel to determine percentage 
viability using the following formula: 
 
Percentage Viability =   (Absorbance Value of Sample – Absorbance of Media)        x 100% 
                           (Average of Cell Control Absorbance values – Absorbance of Media) 
The percentage viability and corresponding concentration of samples were exported to 
GraphPad Prism V6 to calculate the medium lethal dose (LD50) (Manage et al., 2013; Trevan, 
1927). The LD50 was calculated from a nonlinear regression (curve fit) Dose-response - 
Inhibition curve, using a Log[inhibitor] vs normalized response- variable slope graph, where 
 Y = 100/(1+10^((LogIC50-X)*Hillslope))  
Here, the percentage viability previously calculated on Microsoft Excel was imported as the 
inhibitor in the above equation. In cases where an LD50 could not be calculated for a sample 
(due to non-convergence of dose response curve), the percentage viability closest to that 
sample’s corresponding IC50 was quoted. Ninety-five percent confidence intervals were based 
upon curve fit of cell viability curves (curves not shown). A 95% confidence interval is a range 
where there is a 95% probability that the true effect lies within it. Tighter or narrower 
confidence intervals indicate more reliable data (Higgins & Green, 2011). In this part of the 
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study that would translate to the effect of mucin toxicity on TZM-bl cells (Higgins & Green, 
2011). 
2.14 Nanoparticle and Pseudoviral Analysis of Mucin-Derived Gel 
To assess the thermal motions of particles in our gels, we collaborated with Associate Professor 
Sam Lai, University of North Carolina Eshelman School of Pharmacy, Division of Molecular 
Pharmaceutics. His research centres on particle diffusion analysis of native mucus gels with 
minimal perturbation of the sample. 
2.14.1 Non Muco-adhesive Particles 
Associate Professor Lai’s laboratory uses fluorescent carboxyl-modified polystyrene particles 
sized at 100 nanometres (nm), 200nm, 500nm and 1000nm (purchased from Molecular Probes, 
Eugene, OR, USA). These particles were covalently modified with 2 – 3.4kDa amine-modified 
polyethylene glycol (PEG) (purchased from Nektar Therapeutics, San Carlos, CA, USA). The 
particles were coated with PEG to ensure a reduction in intrinsic forces play a role in the motion 
of the particles. In this way, only steric hindrance would play a role in the retardation of particle 
movement. 
To record the trajectories of the particles, they used a silicon-intensified target camera (VE-
100, Dage-MTI, Michigan, IN, USA) mounted on an inverted epifluorescence microscope with 
a 100x oil-immersion objective (numerical aperture 1.3). In 8-well glass chambers (Labtek, 
Campbell, CA, USA) ~1010 particles/ml were added to 250 – 500µl of our mucin gel mixture, 
to a final concentration of <2% volume per volume (v/v). This mixture was incubated for 2 
hours and then viewed under a microscope. Thereafter, 10% (w/v) 
(nonylphenoxy)polyethylene oxide (Igepal CO-630, Rhône-Poulenc, Courbevoie, France) was 
added to a final concentration of 1% (v/v), gently stirred, incubated for 2 hours and viewed 
under a microscope. Movies of the trajectories were captured with Metamorph software 
(Universal Imaging Corp., Downingtown, PA) at a temporal resolution of 66.7 milliseconds 
(ms) for 20s. With the tracking resolution set at 10nm (Apgar et al., 2000), the coordinates of 
nanoparticles were transformed into time-averaged mean squared displacements (MSDs) and 
were calculated as 
 




τ represents time scale or time lag, from which the distributions of MSDs and effective 
diffusivities (Deff) were calculated (Dawson et al., 2003; Lai et al., 2007; Suh et al., 2005). The 
resulting MSD of nanoparticles vs τ also fit the equation MSD = 4D0τ
α where α is the slope of 
the curve on a log-log scale. This is a measure of the extent of obstruction to particle diffusion 
(Suh, Dawson et al. 2005). 
2.14.2 Probing of the Mucus Gel Mesh to Determine Structural Arrangement 
To calculate the pore sizes of our mucin derived gel, the Lai group used an obstruction-scaling 
model for covalently cross-linked hydrogels, developed by Amsden et al (Amsden, 1998, 1999; 
Olmsted et al., 2001; Shen et al., 2006). The rationale behind using this method is that 
Amsden’s equation is applicable to the physical entanglement cross-links found in mucus as 
long there is no chemical interaction between the solute particles, the gel mesh and that the 
particles traveling through the pores of the gel undergo the viscous drag of water. This model 
describes the ratio of particle diffusion in a gel mesh and its diffusion in water as 
Dg/D0 = exp((-π/4)((rs+rf)/(rg+rf))
2) 
Where Dg = the diffusion coefficient of a particle in a polymer gel; 
D0 = the diffusion coefficient of the same particle in water; 
rs = the particle radius; 
rf = the gel fibre radius (this was set at 3.5nm) (Olmsted et al., 2001; Shen et al., 2006) 
rg = the effective radius of the pore 
 
The average effective pore size (2rg) was calculated by entering measured transport data via 
the maximum likelihood method. 
2.14.3 Preparation of Fluorescent Labelled HIV-1 Pseudovirus  
Replication-defective HIV-1, labelled internally with an mCherry-Gag construct to ensure 
minimal alteration of the viral surface, was prepared by transfecting 293T cells with plasmids 
encoded with NL4-3Luc+Vpr-Env-, Gag-mCherry, and YU2 Env in a 4:1:1 ratio. The cell 
supernatant was collected 48 hours later, and fluorescently tagged virions from the cell 
supernatant was purified by centrifugation through 25% sucrose at 160,000g for 2.5 hours. The 
virions were washed, and resuspended in phosphate-buffered saline (PBS). Thereafter it was 
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CHAPTER 3: THE PURIFICATION OF PGM 
 
3.1 Results 
3.1.1 First Ultracentrifugation of Pig Gastric Mucus 
Aliquots taken from pooled pig gastric mucus samples shared similar profiles to each other 
after the first density gradient ultracentrifugation process. Figure 3.1 shows the protein, 




Figure 3.1 First ultracentrifugation profile of pig gastric mucus. Pig gastric mucus was slowly stirred 
overnight in 6M guanidine hydrochloride with 10mM Na2HPO4, 10mM EDTA, 1mM PMSF and 5mM 
NEM. The densities of samples were adjusted to 1.39g/ml with caesium chloride and 4M GuHCl. They 
were then subjected to a 48-hour ultracentrifugation at 105 000g at 4oC. Protein content was determined 
using Bradford Reagent assay ( ); glycoprotein content was identified using a PAS assay ( ) and the 
densities ( ) were recorded on the secondary axis. The box on the X-axis represents the fractions 
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Fractions that had glycoprotein rich densities of 1.39g/ml to 1.41g/ml were pooled. In Figure 
3.1 the glycoprotein rich fraction were 6 – 8. These samples were then prepared for a second 
round of density gradient ultracentrifugation.  
3.1.2 Second Ultracentrifugation of Pig Gastric Mucus 
The pooled fractions from section 3.1.1 had their densities adjusted to 1.41g/ml with caesium 
chloride and 4M GuHCl. They underwent a second ultracentrifugation under the same 
conditions as the first. Protein and glycoprotein content as well as densities were all recorded 
in the same way as the first density gradient ultracentrifugation. The second density gradient 
ultracentrifugation profiles of pig gastric mucus all shared a similar pattern. Figure 3.2 shows 
the pattern of a representative sample. 
 
 
Figure 3.2 Profile of second ultracentrifugation of pig gastric mucus. Glycoprotein rich fractions from 
the first ultracentrifugation were pooled and had their densities adjusted to 1.41g/ml with caesium 
chloride and 4M GuHCl. The fractions then underwent ultracentrifugation for 48 hours at 105 000g at 
4oC. Protein content was determined using Bradford Reagent assay ( ); glycoprotein content was 
identified using a PAS assay ( ) and the densities ( ) were recorded on the secondary axis. The box 
on the X-axis enclosing numbers 5 – 7 represents the fractions collected, pooled, dialysed against 

















































SECOND ULTRACENTRIFUGATION OF PGM
PROTEIN ASSAY GLYCOPROTEIN ASSAY DENSITIES
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Samples that had high glycoprotein content and a density of 1.40 – 1.41g/ml were pooled, 
dialysed against over three changes of distilled water for a minimum of 6 hours each at 4oC 
and then freeze dried. 
 3.1.3 Size Exclusion Sepharose 2B Column Chromatography of PGM 
Aliquots of lyophilized mucin were run on a Sepharose 2B column to separate mucins based 
on size. Protein and glycoprotein profiles stayed consistent throughout the many 
chromatography runs. Figure 3.3 is a representative sample of protein and glycoprotein 
distribution after PGM was run on the Sepharose 2B column. 
 
 
Figure 3.3 Sepharose 2B separation profile of PGM in 0.2M NaCl:0.02% sodium azide. Purified 
lyophilized pig gastric mucin was resuspended in 10ml 0.2M NaCl:0.02% sodium azide and eluted 
through a Sepharose 2B glass column under peristaltic pressure. Every second fraction was tested for 
proteins and glycoproteins. Protein content was determined using Bradford Reagent assay ( ); and 
glycoprotein content was identified using a PAS assay ( ). The box on the X-axis represents fractions 






































































































SEPHAROSE 2B CHROMATOGRAPHY OF PGM
PROTEIN ASSAY GLYCOPROTEIN ASSAY
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A clear PAS positive peak eluted in the V0 of the column (fractions 38 – 56), suggesting the 
presence of polymeric mucin in the purified sample, together with some subunit trailing into 
the included volume (Vi) (Figure 3.3). The protein positive material under this V0 peak denotes 
the protein of the mucin (Mall et al., 1997b; Pearson et al., 1981). Interestingly a fair amount 
of protein eluted as a series of peaks in the Vi of the column suggestive of reactivity to 
glycoprotein (Allen, 1978; Mall et al., 1988) or possibly the removal of contaminating proteins 
from the preparation. Fractions 116 – 152 were pooled and designated Vi. The V0 and Vi 
fractions were then dialysed against distilled water over three changes for a minimum of 6 
hours each at 4oC and freeze dried.  
3.1.4 SDS-PAGE 4 – 20% Gradient Gel Electrophoresis 
Aliquots of samples were run on an SDS-PAGE gradient gel (4 – 20%) following reduction 
with DTT and proteolysis with trypsin treatments of PGM. Figure 3.4 shows the results of the 
samples run on the SDS-PAGE stained for proteins (see section 2.9.2) and Figure 3.5 shows 





Figure 3.4 Protein stained 4 – 20% gradient SDS-PAGE gel of PGM derivatives. At different stages of 
pig gastric mucin purification and treatment, 1mg lyophilized aliquots were dissolved in 100µl 2% SDS, 
1% glycerol and 0.01% bromophenol blue for SDS-PAGE gel investigation. Lane 1, 10µl of Thermo 
Scientific PageRuler Prestained Protein Ladder; Lane 2, crude pig gastric mucus; Lane 3, purified pig 
gastric mucin after purification after two density gradient ultracentrifugations; Lane 4, the Sepharose 
2B V0 fraction (Muc5ac and Muc6); Lane 5, the Sepharose 2B Vi fraction; Lane 6, DTT treatment of 
the Sepharose 2B V0 fraction (Muc5ac and Muc6) and in Lane 7, trypsin treatment of the Sepharose 2B 
V0 fraction (Muc5ac and Muc6). The red circles denote distinct visible bands (in some cases, partially 
visible). 
 
Protein staining revealed a few bands of interest (outlined by red boxes). Upon gel 
electrophoresis, the crude pig gastric mucus (Figure 3.4, lane 2) showed a strong band that 
could not penetrate the running gel and appeared on the top of the well (first red box). This 
represents the high molecular weight mucin that cannot get into the gel (first red box from the 
top in Figure 3.4, lane 2). There is also a second band of protein (possibly mucin) that lies 
between the stacking and running gel (second red box from the top). Figure 3.4 lane 3 shows 
the effect of purification by two rounds of density gradient ultracentrifugation in CsCl, there 
being less mucin or possible in vivo degradation of mucin in the same position as the previous 
band in Figure 3.4, lane 2 (second red box). It is important to note that this is a protein stain 
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and protein makes up a very small amount of the mucin.  There may have been mucin loss 
during the density gradient ultracentrifugation as only 2 – 3 fractions are collected out of a total 
of 9. Previous work in our laboratory had shown all 9 ultracentrifugation fractions contained 
mucin (data not shown). The 2 – 3 fractions chosen had the least protein contamination. Figure 
3.4, lane 4 shows the eluted V0 fraction from a Sepharose 2B column after two density gradient 
ultracentrifugations. This was the purest of all the samples and was highlighted by the faint 
protein banding pattern in lane 4. Figure 3.4, lane 5 shows the eluted Vi fraction from a 
Sepharose 2B column after two density gradient ultracentrifugations containing most of the 
smaller mucins and impurities. Figure 3.4, lane 5 shows the subunit at the beginning of the 
stacking gel and an intense protein smear in the top of the running gel (see red box). The same 
subunit material appears at the same spot when purified mucin is treated with DTT (Figure 3.4, 
lane 6), again suggesting that the reduction of disulphide bonds produces a subunit in pig 
gastric mucin (Mall et al., 1999; Pearson et al., 1981). DTT treatment of the V0 fraction (Figure 
3.4, lane 6) showed mucin bands in red boxes, these were smaller than the corresponding bands 
in Figure 3.4, lane 2 (red boxes). This suggests that with disulphide bond breakage the large 
mucins could move further down the gel as is evident by the mucin smear. Figure 3.4, lane 7 
shows the effect of trypsin on the non-glycosylated sections of the mucin. There is an increase 
in the mucin smear effect but also the appearance of more bands all the way down the gel, 
together with a stronger background. Identification of bands lay outside the scope of this study 
and may be looked at in future studies with the aid of proteomics.
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 3.1.5 PAS Stained Gradient Gel Electrophoresis 
 
Figure 3.5 Glycoprotein stained 4 – 20% gradient SDS-PAGE gel of PGM derivatives. At different 
stages of pig gastric mucin purification and treatment, 1mg lyophilized aliquots were dissolved in 100µl 
of 2% SDS, 1% glycerol and 0.01% bromophenol blue for SDS-PAGE gel investigation. Lane 1, crude 
pig gastric mucus; Lane 2, purified pig gastric mucin after purification after the second density gradient 
ultracentrifugation; Lane 3, the Sepharose 2B V0 fraction (Muc5ac and Muc6); Lane 4, the Sepharose 
2B Vi fraction; Lane 5, DTT treatment of the Sepharose 2B V0 fraction (Muc5ac and Muc6) and Lane 
6, trypsin treatment of the Sepharose 2B V0 fraction (Muc5ac and Muc6). 
 
Figure 3.5 illustrates the PAS stained distribution of PGM and its derivatives through an SDS-
PAGE (for method see Section 2.9.2). The result of the staining showed a similar pattern to the 
protein staining (Figure 3.4). Figure 3.5, lane 1 shows crude pig gastric mucus appearing as a 
dark band at the top of the gel (see red box). A large amount of mucin did not enter the stacking 
gel for the crude mucus material (Figure 3.5, lane 1), and stained as a ‘blob’ with PAS, 
indicating the presence of mucin in the crude material. As the purification steps continued, 
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there was some loss of mucin (Figure 3.5, lanes 2 – 3). The bigger mucins stayed in the stacking 
gel or stayed in the top of the well (see red boxes) unless treated with DTT or trypsin. After 
two density gradient ultracentrifugations, the mucin had moved further into the stacking gel 
(Figure 3.5, lane 2) (see second red box) more than the crude mucus (Figure 3.5, lane 1). There 
was less of this ‘blob’ after mucin purification (Figure 3.5, lane 2) and some mucin positive 
material is shown to have migrated into the stacking gel. In fact there is some staining at the 
beginning of the running gel (Figure 3.5, lane 2), suggesting the presence of subunit in the 
original crude material (see second red box), as described previously for pig gastric mucin 
(Mall et al., 1999; Pearson et al., 1981). Figure 3.5, lane 3 shows the PGM V0 fraction eluted 
through a Sepharose 2B column after two density gradient ultracentrifugations. The V0 shows 
the larger mucins did not readily move into the gel (see red boxes). Figure 3.5, lane 4 (PGM 
Vi) contrasted with Figure 3.5, lane 3 which showed smaller mucins that moved further down 
the gel (see red box). DTT treatment (Figure 3.5, lane 5) allowed more mucin subunits to enter 
the well and increased migration down the gel (see red box). Trypsin treatment (Figure 3.5, 
lane 6) allowed more subunit material into the stacking gel and into the top of the running gel 
(see red boxes). It is possible that bands seen at the interface of the stacking gel and running 
gel may be due to the presence of cell surface mucins. 
3.1.6 Slot Blot Analysis of PGM     
Antibodies used for this study (see Appendix A, Table 1 for antibody type and dilutions) were 
mostly raised against human gastric proteins. The antibody supplier’s website confirmed 
sequence similarity and binding would occur between antibodies raised against human gastric 
mucins and pig gastric mucins. At the time of the study the availability of antibodies to South 
Africa, raised to pig gastric mucins were limited and extremely expensive. Figure 3.6 shows 
the slot blot detection of Muc5ac and Muc6 performed on PGM extracted from this study.  
 
 
Figure 3.6 Slot Blot analysis of PGM. The left panel shows pig gastric mucins (having undergone 2 
density gradient ultracentrifugations, dialysis against distilled water and freeze drying) dissolved in 
100ml 2% SDS, 1% glycerol and 0.01% bromophenol blue. Samples were then transferred under 
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vacuum to a nitrocellulose membrane and split. The membrane in the left block was probed first with 
rabbit anti-human Muc5ac antibody (1in 5000 dilution) then goat anti-rabbit secondary antibody 
conjugated to horse radish peroxidase (HRP) (1in 5000 dilution). The membrane in the right block was 
probed first with rabbit anti-human Muc6 antibody (1in 1000 dilution) then goat anti-rabbit secondary 
antibody conjugated to HRP (1in 5000 dilution).  
 
PGMs tested positive for both Muc5ac and Muc6. To assess the regional expression of Muc5ac 
and Muc6 in pig stomach, mucus from four histologically different sections (see Figure 3.7) 
were collected and separately underwent purification with two rounds of density gradient 
ultracentrifugation (Chapter 2, sections 2.4 to 2.6).  
 
 
Figure 3.7 Diagram of the pig stomach opened along the greater curvature stomach (Mall, 1984). P, 
pars oesophagea; C, the cardiac gland; B, body and A, pyloric antrum. 
 
Pigs and humans both have a monogastric or simple single-chambered stomach. Figure 3.7 
illustrates the general regions shared by all monogastric stomachs (Colville et al., 2008). The 
regions under investigation are the pars oesophagea, the cardiac gland area, the body area, the 




Figure 3.8 Regional expression of Muc5ac and Muc6 in pig stomach 
 
Muc5ac is present throughout the regions but is present at high concentrations in the pyloric 
antrum, whereas Muc6 is present mostly in the body and antrum regions. It is partially 
expressed in the cardiac and absent in the pars oesophagea. 
3.2 Discussion 
In the past, our laboratory has done significant work on the effect of human mucins on HIV-1 
in vitro (Habte et al., 2010; Habte et al., 2008; Habte et al., 2007; Habte et al., 2006; Mthembu 
et al., 2014; Peacocke et al., 2012). This included saliva, breast-milk and cervico-vaginal 
material. From that preliminary data, the importance of mucins and their inhibitory effects on 
HIV-1 could be seen. However, sourcing human material has its limitations, partly because 
human material is difficult to obtain and the amount of mucin retrieved after purification was 
minute (depending on the source and time of day) (Dawes, 1972; Hardt et al., 2005; Koh et al., 
2007). Our research into the effects of mucin on HIV-1 began with human salivary studies. 
Collecting saliva was difficult partly because many individuals were uncomfortable about 
donating saliva. There was huge variability in the amount of sample from different individuals 
due to diurnal variations in secretions and the difficulty of collection from all volunteers at a 
specific time. The mucin yield could be negligible after purification if the original volume of 
saliva was low. However, the importance of a study such as this was noted from the preliminary 
data. To further our research, we required an abundant source of mucins that were like human 
mucins and would have a similar inhibitory effect on HIV-1. This study bridged that gap by 
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investigating the effect animal sourced mucins and its derivatives had on pseudo-HIV-1 
subtype C in vitro. The chosen animal sources were pig (gastric, salivary, cervico-vaginal 
mucus) and horse (salivary) mucus. The rationale for our pig model was derived from previous 
experiments performed by our laboratory and other groups (Carlstedt et al., 1995; De Bolós et 
al., 1995; Ho et al., 1995; Mall et al., 1997b; Meurens et al., 2012; Nordman et al., 1998). Horse 
saliva was sought after the study by Rousseau et al (2008). 
The derivatives of pig gastric mucin tested in this experiment were commercially bought pig 
gastric mucin Type II from Sigma-Aldrich® Co (St Louis, MO, USA), and mucin derived from 
crude mucus scrapings of pig stomachs obtained from the local abattoir. Stomachs were opened 
along the greater curvature, gently rinsed with running water, and the mucus scraped off the 
mucosal surface with a glass slide (Figure 3.7). This crude PGM was purified by density 
gradient ultracentrifugation in CsCl and called purified PGM. It was further eluted through 
column chromatography and the V0 collected as purified PGM V0 (Muc5ac and Muc6) 
(Nordman et al., 2002; Nordman et al., 1998); the same went for the Vi  material, also eluted 
from a Sepharose 2B column. Finally, we had untreated mucin, DTT treated and trypsin treated 
aliquots of purified PGM V0. 
After the two density gradient ultracentrifugations, aliquots of pig gastric mucin were eluted 
through a Sepharose 2B column. Our laboratory has previously used Sepharose 2B gel filtration 
to separate human gastric mucin so we theorized Sepharose 2B to be the best gel filtration for 
PGM (Mall et al., 1992).  The glycoprotein and protein profile of the Sepharose 2B 
chromatography is shown in Figure 3.3. The protein content of mucins is approximately 13 – 
20% (Allen, 1981b). This low protein content can be seen in Figure 3.3 peak 1 fractions 38 – 
56 but the Vi fraction (second peak of Figure 3.3: fractions 116 – 152) appears to have a high 
protein content. The high protein staining may be due to smaller glycoproteins that have been 
fractionated with the mucins during density gradient ultracentrifugation in CsCl. These smaller 
glycoproteins might have a lower carbohydrate to protein ratio than in the larger mucins. 
Protein peaks are sensitive to the higher protein ratio and show an interference pattern rather 
than the presence of lingering protein contamination in the sample (Mall et al., 1988). Mucin 
purification by CsCl density gradient ultracentrifugation is an established method (Creeth & 
Denborough, 1970) and in this study an additional step of gel filtration was used to ensure that 
all possible contaminants were separated from the sample (Figure 3.7).  
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In Figure 3.4, the “smeared” effect across the lanes is attributed to the heterogeneity and 
polydispersity of glycoproteins (Harding, 1984). Briefly, heterogeneity describes several 
distinct species in which there is no single molecular weight for the solute species due to (in 
this case) polydispersity which is defined by the presence of non-interacting constituents of a 
macromolecular system of different densities or molecular weights (Harding, 1984). Figure 
3.5, lane 2 shows a subunit that has moved down form the top of the well (see second red box) 
after 2 density gradient ultracentrifugations. The relative sizes of mucins that are immobilized 
at the top of the wells and running gels are in line with the predicted size of subunits (2 – 
3MDa) conforming to the linear model of mucin (Carlstedt & Sheehan, 1984). Carlstedt and 
Sheehan (1984) researched the polymeric structures of mucins from cervical, gastric and 
respiratory mucus. Carlstedt and Sheehan (1984) extracted mucins in the same buffer that we 
used for pig gastric mucus (i.e. 6M GuHCl at pH6.5). Pearson et al (1981) also found mucin 
subunits of 2MDa which may suggest windmill conformation, but they also found a 70 – 72kDa 
linker subunit which is not present in our samples. The key difference of the Pearson et al 
(1981) findings and our study is the extraction buffer. Pearson et al (1981) extracted gastric 
mucins in 0.2M NaCl:0.02% sodium azide whereas we used 6M GuHCl with protease 
inhibitors (10mM Na2HPO4, 10mM EDTA, 1mM PMSF and 5mM NEM) at pH6.5. Removing 
mucins from 6M GuHCl with the above protease inhibitors causes aggregation resulting in the 
appearance of larger mucin subunits (Mall et al., 1988).  
The slot blot analysis of our mucins was carried out with antibodies raised against human 
mucins MUC5AC and MUC6 (Appendix, Table 1). This was primarily due to the suppliers 
lacking antibodies raised to pig mucins of interest (i.e. Muc5ac, Muc5b, Muc6, Muc7 and 
Muc19). There were also logistic issues as suppliers who did have pig mucin antibodies did 
not ship to South Africa. Muc5ac is present throughout the regions whereas Muc6 is present 
mostly in the body and antrum regions. It has partial expression in the cardiac and not (or 
possibly at lower than the detectable limit) in the pars oesophagea. Our results confirm the 
immunohistological findings of Nordman et al (2002). They showed that MUC5AC was 
present in surface epithelia of the stomach regions (cardiac, body and antrum regions) and 
Muc6 was present in the glands of those regions (Nordman et al., 2002). Glandular restricted 
expression of MUC6 explains why we did not find any Muc6 in the pars oesophagus as this 




CHAPTER 4: THE EFFECT OF PGM DERIVATIVES ON HIV-1 IN VITRO 
 
4.1 Results 
4.1.1 PGM derivatives Inhibit HIV-1 on the Pseudoviral Assay 
To assess the value of pig gastric mucin derivatives as a potential component of an anti-HIV-
1 gel, samples were tested on a pseudoviral assay. Pseudoviral data (see section 2.12 for 
method) was put into Graphpad Prism Version 6 to construct Log Dose Response Curves (see 
Figure 4.1). From these curves the half maximal inhibitory concentration was calculated. 
 
        
 
Figure 4.1 Dose response curves of PGM derivatives. A, commercially bought pig gastric mucin from 
Sigma Aldrich; B, crude pig gastric mucin; C, purified PGM after two density gradient 
ultracentrifugations; D, PGM V0 (Muc5ac and Muc6) eluted from Sepharose 2B column 
chromatography after two density gradient ultracentrifugations; E, PGM Vi eluted from Sepharose 2B 
column chromatography density gradient ultracentrifugations; F, DTT treatment of PGM V0 (Muc5ac 
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Reliability of the log dose response curves can be assessed visually by how close the points of 
the curve lie to the solid trend line. Commercial pig gastric mucin (Figure 4.1 A), PGM Vi 
(Figure 4.1 E) and DTT treated PGM V0 (Figure 4.1 F) had the least reliable curves. From the 
curves in Figure 4.1, an IC50 was calculated for each sample. The IC50 for this study is defined 
as the concentration of mucin required to inhibit HIV infection by 50% (Montefiori, 2009). 
Table 4.1 show the summary of Graphpad Prism calculations and the effectiveness of the 
treatments on PGM in retarding HIV-1 infection.     
 
Table 4.1 The calculated PGM IC50’s and 95% Confidence Intervals 
Pig Gastric Mucin Derivative IC50 (µg/ml) 95% Confidence Intervals 
(µg/ml) 
Commercial Pig Gastric Mucin 276.1 35.16 to 2168 
Crude PGM 124.2 75.83 to 203.5 
Purified PGM 10.50 7.065 to 15.60 
PGM post-CsCl V0 (Muc5ac and Muc6) 1.668 0.4136 to 6.725 
PGM Vi  No Inhibition  
DTT treated PGM V0 (Muc5ac and Muc6) 110.1 46.52 to 260.6 
Trypsin treated PGM V0 (Muc5ac and Muc6) 66.95 37.72 to 118.8 
 
Results were deemed reliable if the IC50 was within 3 orders of the 95% Confidence Intervals’ 
lower and upper limits. From that calculation, the above data suggests non-gel forming 
commercially bought PGM (Schömig et al., 2016) was not as reliable as our other data. PGM 
Vi did not inhibit HIV-1 as the graph did not converge in Graphpad Prism. Crude pig mucus 
did inhibit the pseudovirus (IC50: 124.2µg/ml) and inhibition was increased over ten-fold after 
purification (IC50: 10.50µg/ml). Once the PGM components were separated on size the best 
inhibition was seen in the PGM V0 fraction (gel filtration after purification) (IC50: 1.668µg/ml). 
From this V0 fraction, disulphide bonds were cleaved with DTT and this drastically reduced 
inhibition to almost the IC50 of crude mucus (IC50: 110.1µg/ml). When the V0 fraction had the 
naked protein removed, there was also a reduction in HIV inhibition (IC50: 66.95µg/ml) but not 
as extensive as the DTT treatment. 
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4.1.2 Gastric Region-Specific PGM Inhibition of HIV-1 on Pseudoviral Assay 
Crude and purified PGM from different regions of the pig stomach were also tested on the 
pseudoviral assay. Figure 4.2 shows the log dose response curves of the assay. 
         
 
Figure 4.2 Dose response curves of PGM from different regions of the pig stomach. Scraping from 
different regions of pig stomachs were kept separate, purified and run on the HIV-1 pseudoviral assay. 
A, crude pars oesophagea mucus; B, purified pars oesophagea mucin; C, crude cardiac gland mucus; 
D, pure cardiac gland mucin; E, crude body mucus; F, purified body mucin; G, crude pyloric antrum 
mucus and H, purified pyloric antrum mucin. 
 
All points in the curves adhered to the trend line and were reliable. Table 4.2 shows the 
summary of Graphpad Prism calculations and the effectiveness of PGM from different regions 
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Table 4.2 Showing the calculated regional PGM IC50’s and 95% Confidence Intervals 
Mucins from Gastric Regions IC50 (µg/ml) 95% Confidence 
Intervals (µg/ml) 
Crude Pars Oesophagea Mucus (Muc5ac) 37.12 25.18 to 54.74 
Purified Pars Oesophagea Mucin (Muc5ac) 24.09 10.31 to 56.29 
Crude Cardiac Gland Mucus (Muc5ac and Muc6) 36.14 21.51 to 60.73 
Purified Cardiac Gland Mucin (Muc5ac and Muc6) 9.392 3.772 to 23.38 
Crude Body Mucus (Muc5ac and Muc6) 49.24 25.68 to 94.44 
Purified Body Mucin (Muc5ac and Muc6) 14.89 7.065 to 31.38 
Crude Pyloric Antrum Mucus (Muc5ac and Muc6) 63.67 42.83 to 94.65 
Purified Pyloric Antrum Mucin (Muc5ac and Muc6) 43.60 20.34 to 93.46 
 
Both the crude and purified regions of PGMs inhibited HIV-1 in vitro suggesting that all 
regions have anti-HIV-1 potential. The lowest mucin IC50’s and hence best HIV-1 inhibition 
came from purified mucins of the cardiac gland and body area. 
4.1.3 Toxicity Assay for Pig Gastric Mucin 
Toxicity was assessed by running the samples on the same cell line as the pseudoviral assay 
(TZM-bl/JC53, Hela cell line). Use of the same cell line assured that any cytotoxic effects of 
mucin did not interfere with inhibition data. LD50 values were calculated from percentage cell 
viability data. LD50 in this study is defined as the lethal dose of mucin derivative that results in 
50% cell death. Commercial PGM, crude PGM, purified PGM, PGM V0 (Muc5ac and Muc6), 
DTT treated PGM V0 (Muc5ac and Muc6), trypsin treated PGM V0 (Muc5ac and Muc6) 
samples were tested for cell toxicity using an MTT assay (see section 2.13). Table 4.3 shows 
the results of the MTT assay. 
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Table 4.3 The Results of PGM derivatives on an MTT Assay 




Commercially bought PGM Curve did not 
converge 196.25 100 
Crude PGM (Muc5ac and Muc6) 2 428   
Purified PGM (Muc5ac and Muc6) 29 727   
PGM post-CsCl V0 (Muc5ac and Muc6) 363   
PGM Vi  Curve did not 
converge 153.75 60.64 
DTT treated PGM V0 (Muc5ac and Muc6) ~8.351   
Trypsin treated PGM V0 (Muc5ac and Muc6) 293.6   
 
There were high LD50s for crude PGM, Purified PGM, PGM V0 and trypsin treated PGM V0 
indicating that higher doses of these mucins are required to be lethal. DTT treated PGM V0 had 
a low LD50 calling into question the validity of the DTT treated PGM V0 IC50 data. Further 
analysis is required to determine the reason for this. Commercially bought PGM and PGM Vi 
did not produce curves from which LD50 values could be calculated. The percentage cell 
viabilities quoted for these samples were at a concentration closely related to their 
corresponding IC50 (from section 4.1.2). Commercially bought PGM showed good percentage 
cell viability (100%) at 196.25µg/ml which is close to its IC50 (IC50: 276.1µg/ml). This suggests 
that commercially bought PGM IC50 data is trustworthy. In contrast, PGM Vi had low 
percentage cell viability (60.64%) at 153.75µg/ml, suggesting that the toxicity of PGM Vi may 
have contributed to PGM Vi having no HIV inhibitive properties. Therefore, it appears that 
toxicity of PGM derivatives (excluding PGM Vi and DTT treated PGM V0) does not 
substantially interfere with measurement of HIV-1 inhibitory activity. 
4.2 Discussion 
4.2.1 PGM inhibits HIV-1 in vitro 
In 2012, Lieleg et al (2012) investigated pig gastric mucin as an anti-viral agent but unlike our 
study which looked at HIV-1, they tested pig gastric mucin against HPV-16, MCV and H1N1 
Influenza Virus. They purchased non-gel forming commercial pig gastric mucins from Sigma-
Aldrich® Co, St Louis, MO, USA. They combined this mucin with HEPES buffer and 
commercial Matrigel to form a biolpolymer on the surface of human cervical cell lines (for 
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fluorescently labelled HPV-16) and kidney cell lines (for fluorescently labelled MCV and 
H1N1 influenza virus) to test viral inhibition. They found inhibition of MCV, H1N1 and HPV-
16 using 0.25 – 1% mucin gels (Lieleg et al., 2012). This result showed the ability of PGM to 
act as an antiviral agent. Lieleg et al (2012) did not look at HIV as their laboratory was not 
certified to work with HIV (personal communication with Dr. Katharina Ribbeck). We 
hypothesized that the inhibitory potential may be higher in gel forming pig gastric mucin 
purified from pig stomachs rather than the use of commercial non-gel forming PGM in the 
Lieleg et al (2012) study. Since studies in our laboratory have shown that human salivary, 
breast milk and cervical plug mucins have inhibitory activity against HIV-1, we proposed pig 
gastric mucins would have similar effects because of suggested biological similarities between 
pig and human (Mall et al., 1997b; Nordman et al., 1997; Nordman et al., 1998) against HIV-
1. This was worth testing and the study of Lieleg et al (2012) was encouraging in this regard. 
PGM derivatives in our study were tested on a pseudoviral assay at neutral pH (~6.5 – 7.2). At 
this pH PGM Hong et al (2005) predicted PGM to exist as an extended fibre-like conformation 
(400nm) in a dilute solution. This was proven by utilizing atomic force microscopy (Hong et 
al., 2005). Our study measured inhibition by calculating the IC50 from log dose response curves. 
Inhibition of HIV-1 was seen in all derivatives but one, the PGM Vi fraction. The commercial 
mucin (like the commercial mucin used by Lieleg et al (2012)) had the highest IC50 
(276.1µg/ml, see Table 4.1) from the inhibiting mucins and the widest range of 95% 
Confidence Intervals. Wider confidence intervals of mucin derivatives indicate there is little 
knowledge of the true inhibitory effect of commercial pig gastric mucin on HIV-1 (Higgins & 
Green, 2011). After performing two density gradient ultracentrifugations and dialysing against 
three changes of distilled water, native pig gastric mucus yielded the second lowest IC50 
(10.50µg/ml, see Table 4.1) which was over 20 times more effective than commercial PGM. 
After eluting this purified PGM through a Sepharose 2B column, the larger fraction containing 
Muc5ac and Muc6, the PGM V0 had an IC50 of 1.668µg/ml (see Table 4.1). When this 
experiment with the same material was repeated a year later it gave an IC50 of 4.35µg/ml (data 
not shown) indicating the low IC50 is reproducible. Once the PGM V0 underwent disulphide 
bond cleavage (DTT treated PGM V0) or proteolysis (trypsin treated PGM V0) the inhibitory 
potential dropped (110.1 and 66.95µg/ml respectively, see Table 4.1). Reduction of disulphide 
bridges of mucin polymer results in the production of ~500kDa subunits (Allen, 1981a; Mall 
et al., 1988; Pearson et al., 1981) or ~2MDa (Carlstedt et al., 1983a; Mall et al., 1988; Mall et 
al., 1987), suggesting that polymer is required for effective inhibition of HIV-1. The differences 
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in size between mucins extracted in non-denaturing versus denaturing medium (Carlstedt et al., 
1983a; Mall et al., 1988) are significant. Mucins in this study were prepared in 6M GuHCl with 
protease inhibitors 10mM Na2HPO4, 10mM EDTA, 1mM PMSF and 5mM NEM, perhaps 
resulting in a more effective inhibition of HIV-1, if this inhibition is by aggregation due to the 
oligosaccharide components of the mucins.  Georgiades et al (2014) showed that in the 
conditions of denaturation with the use of a chaotrophic agent (GuHCl) and DTT, PGM exists 
as an untangled polyelectrolyte comb (Georgiades et al., 2014). This is indicative of the 
importance size and entanglement plays on the HIV-1 inhibitory activity of PGM V0. 
Entanglement or aggregation of HIV-1 by mucins has been reported to be a possible 
mechanism for inhibition of HIV-1 by mucins (Bergey et al., 1994; Bergey et al., 1993b) A 
cell viability assay was necessary to show the effect of mucins on the cervical cell line and that 
the calculated IC50 values were not due to false inhibition because of mucin induced cell death 
(this would lower the luminescence emission). There were generally good cell viability data 
for PGM derivatives (see Table 4.3) apart from PGM Vi (cell viability at 153.75µg/ml was 
60.64%), DTT treated PGM V0 (LD50: ~8.351µg/ml). Cell viabilities were good for 
commercially bought PGM (at 196.25µg/ml, percentage cell viability: 100%; IC50: 
276.1µg/ml), crude PGM (LD50: 2 428µg/ml; IC50: 124.2µg/ml), purified PGM (LD50: 29 
727µg/ml; IC50: 10.50µg/ml), PGM V0 (LD50: 363µg/ml; IC50:1.668 µg/ml) and trypsin treated 
PGM V0 (LD50: 293.6µg/ml; IC50: 66.95µg/ml) thus their corresponding IC50 values were 
deemed reliable. Trypsin treated PGM V0 (IC50: 66.95µg/ml) showed a lower IC50 than DTT 
treated PGM V0 (IC50: 110.1µg/ml) indicating that the size of the mucin is not the full 
explanation of PGM inhibiting HIV-1 in vitro. Further studies need to be done on this point to 
decipher what other mechanisms may be contributing to inhibition.  
4.2.2 Mucins from four regions of the pig stomach inhibit HIV-1 in vitro 
Our next experiment assessed the effect of mucins from four different regions (namely the pars 
oesophagea, cardiac gland area, body area, pyloric antrum) of the pig stomach on HIV-1 in 
vitro. The results of this investigation would streamline mucus collection for future pig gastric 
research. Mucins from all regions of pig stomach showed inhibition with narrow 95% 
confidence intervals. The tight 95% confidence intervals are indicative that the mucin specific 
inhibition of HIV-1 was a real effect and not a false positive. Differential mucin inhibition of 
HIV-1 was seen after purification by two density gradient ultracentrifugations. The two lowest 
IC50 values were seen in the purified mucins of the cardiac gland (IC50: 9.392µg/ml, see Table 
4.2) and purified body regions (IC50: 14.89µg/ml, see Table 4.2). This is interesting because 
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the cardiac gland area of the pig stomach is adjacent to the non-glandular pars oesophagea, an 
extension of the oesophagus into the pig stomach (see Figure 3.7), a region of keratinized 
squamous epithelium. Pigs spontaneously ulcerate in this region through stress (change of pens, 
transport to abattoir and human contact etc.) and with 100% reproducibility after the ligation 
of the bile-duct (Mall et al., 1997b). The region is protected by the flow of mucus from the 
cardiac gland area and so it would be expected that this region would produce significant 
amounts or a different kind of mucus (Mall et al., 1997b). These findings have made the pig a 
very suitable model for the study of gastric ulceration (Mall et al., 1997a), especially for the 
role of mucus in the context of the use of anti-ulcer preparations (Mall et al., 1991) and H. 
pylori and its role in gastric ulceration (Mall et al., 2004). 
In 1997, Karlsson et al performed high temperature gas chromatography mass spectrometry 
(GC-MS) and matrix-assisted laser-desorption mass spectrometry (MALDI-MS) to investigate 
oligosaccharides from different regions of pig gastric mucosa (Karlsson et al., 1997). 
Oligosaccharides present in mucins are mostly linked by a Ser(Thr)-GalNAc bond to the 
polypeptide chain (Allen, 1981a; Chantler, 2012). The most common sugars occurring in 
mucins are GalNAc, Gal, Fuc, GlcNAc and sialic acid (Chantler, 2012). Many mucins are 
sulphated at either Gal or GlcNAc. Mucin oligosaccharide structures are divided into four 
groups: Type 1 core (Galβ1-3GalNAc-), Type 2 core (Galβ1-3[GlcNAcβ1-6]GalNAc), Type 3 
core (GlcNAcβ1-3GalNAc1) and Type 4 core (GlcNAcβ1-3-[GlcNAcβ1-6]GalNAc) 
(Chantler, 2012). Chantler et al (2012) found significant differences between the regions, for 
instance, oligosaccharides containing Galβ1-3GalNAcα1- and Galβ1-3(GlcNAcβ1-
6)GalNAcα1- were widely distributed. The cardiac gland area and body region are the only 
sections that express GlcNAβ1-3GalNAα1- structures. Chantler et al (2012) noted that 
GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1- oligosaccharides were restricted to the cardia region. 
They also reported that GlcNAc addition in β1-linkage to both the C-3 and C-6 of protein bound 
GalNAc is limited to the cardia of the stomach. This substitution results in mucins from the 
cardiac gland region to undergo additional glycosylation. The most characteristic difference 
they found was that the oligosaccharides present in the body region were larger in size (7 to 18 
residues) than any other region of the gastric mucosa. This was the result of an increased 
number of N-acetyl-lactosamine units in linear arrangement. Karlsson et al (1997) noted that 
the core mucin structures (type 1 core, type 2 core, type 3 core and type 4 core) present in the 
pig stomach are the same as human gastric mucins (Hanisch et al., 1993). Karlsson et al (1997) 
rationalized that the presence of both shorter and longer oligosaccharides in gastric mucosa 
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offer modified structure and protection. Karlsson et al (1997) hypothesized that shorter, less 
complex oligosaccharides promote highly glycosylated domains to an extended conformation, 
whereas the longer glycans may offer protection by acting as interactive binding sites for 
bacterial surface proteins mucosa. This finding  may highlight the importance of preserving the 
polymeric structure when studying mucin specific inhibition of HIV. Our study showed that 
the differential mucin structures gave rise to varied regional IC50’s on the Pseudoviral assay. 
The more glycosylated cardiac gland region (purified cardiac mucin), showed the best 
inhibition (IC50: 9.392µg/ml, see Table 4.2). This data may highlight the importance of mucin 
glycosylation in viral inhibition. Purified mucin from the body region of the stomach (as 
previously mentioned, had the longest oligosaccharides) show the second lowest IC50’s 
(14.89µg/ml, see Table 4.2) compared to the unseparated purified PGM (10.50µg/ml). A 




Table 4.4 Shows the IC50 data and oligosaccharide types of pig gastric regions  








37.12 The mucus here is a combination of mucus from other regions 
of the stomach. The pars oesaphageal does not secrete mucus. It 





24.09 The mucus here is a combination of mucus from other regions 
of the stomach. The pars oesaphageal does not secrete mucus. It 
is made of keratinizing squamous epithelial cells (Orlando, 
1991). 
Crude Cardiac Gland 
Mucus (Muc5ac and 
Muc6) 
36.14 Galβ1-3GalNAcα1- (Type 1 core),  
Galb1-3(GlcNAcβ1-6)GalNAcα1- (Type 2 core),  
GlcNAcβ1-3GalNAcα1- (Type 3 core) 
GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1- (Type 4 core) 
Purified Cardiac Gland 
Mucin (Muc5ac and 
Muc6) 
9.392 Galβ1-3GalNAcα1- (Type 1 core),  
Galb1-3(GlcNAcβ1-6)GalNAcα1- (Type 2 core),  
GlcNAcβ1-3GalNAcα1- (Type 3 core) 
GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1- (Type 4 core) 
Crude Body Mucus 
(Muc5ac and Muc6) 
49.24 Galβ1-3GalNAcα1 (Type 1 core) 
Galβ1-3(GlcNAcβ1-6)GalNAcα1 (Type 2 core) 
GlcNAβ1-3GalNAα1 (Type 3 core) 
Purified Body Mucin 
(Muc5ac and Muc6) 
14.89 Galβ1-3GalNAcα1 (Type 1 core) 
Galβ1-3(GlcNAcβ1-6)GalNAcα1 (Type 2 core) 
GlcNAβ1-3GalNAα1 (Type 3 core) 
Crude Pyloric Antrum 
Mucus (Muc5ac and 
Muc6) 
63.67 Gal-3GalNAcol (Type 1 core) 
Gal-3(GlcNAc-6)GalNAcol (Type 2 core) 
Purified Pyloric 
Antrum Mucin 
(Muc5ac and Muc6) 
43.60 Gal-3GalNAcol (Type 1 core) 
Gal-3(GlcNAc-6)GalNAcol (Type 2 core) 
 
Our data show that PGM derivatives are effective in inhibiting HIV-1 in vitro and would be a 
good candidate for an anti-HIV-1 vaginal gel to be used prior to sexual intercourse, as an 
additional barrier against HIV transmission (Lai et al., 2009).  
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Lai et al (2009) showed that cervicovaginal mucus, obtained from donors with normal 
lactobacillus-dominated vaginal flora, efficiently traps HIV, causing it to diffuse more than 
1000-fold more slowly than it does in water. This is due to the acidification of the mucus by 
Lactobacilli, which produce lactic acid which acts by abolishing the negative surface charge 
on HIV without lysing the virus membrane, and facilitating its entrapment in the mucus (Lai et 
al., 2009). The surface charge of HIV at pH 7 lactic acid showed a negative charge but that 
negative charge was lost when the lactic acid solution was lowered to pH 4 where lactate ions 
are negatively charged themselves. Pig gastric mucus, like human gastric mucus, forms a 
mucus gel barrier on the mucosal surface of the stomach and protects it from the shear forces 
associated with digestion and the potency of hydrochloric acid and pepsin (Allen et al., 1983; 
Mall et al., 1997b; Rees et al., 1982). A vaginal anti-HIV-1 gel, acidic in nature (Lai et al., 




CHAPTER 5: THE EFFECT OF PIG SALIVARY MUCIN (PSM) DERIVATIVES ON HIV-1 IN VITRO 
 
5.1 Results 
5.1.1 The Purification of PSM 
5.1.1.1 Sepharose 4B Column Chromatography of Pig Saliva 
Pig saliva was collected in 0.2M NaCl:0.02% sodium azide (see Appendix section 1.2). 
Samples were pooled and centrifuged to eliminate contaminants. Thereafter, saliva in 0.2M 
NaCl:0.02% sodium azide was eluted on a Sepharose 4B column (eluting buffer was also 0.2M 
NaCl:0.02% sodium azide). Aliquots of pooled pig saliva samples shared a similar profile to 
each other after Sepharose 4B column chromatography. Figure 5.1 is a representative sample 
of protein and glycoprotein distribution after PSM was run on the Sepharose 4B column. 
 
 
Figure 5.1 Sepharose 4B separation profile of PSM in 0.2M NaCl:0.02% sodium azide. Pig saliva was 
diluted with 0.2M NaCl:0.02% sodium azide (4:1), centrifuged and eluted through a Sepharose 4B glass 
column under peristaltic pressure. Every second fraction was tested for proteins and glycoproteins. 
Protein content was determined using Bradford Reagent assay ( ); and glycoprotein content was 





























SEPHAROSE 4B CHROMATOGRAPHY OF PSM
PROTEIN ASSAY GLYCOPROTEIN ASSAY
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A distinct PAS positive peak eluted in the V0 of the column (Figure 5.1, fractions 10 – 16), 
suggesting the presence of large polymeric mucin in the purified sample. Another PAS positive 
peak can be seen in the Vi (Figure 5.1, fractions 22 – 30). The PAS positive Vi peak is indicative 
of a smaller mucin or other glycoproteins present in saliva. The V0 and Vi fractions were then 
dialysed against distilled water over three changes for a minimum of 6 hours each at 4oC and 
then freeze dried. For this study, we were interested in the mucins present in the V0. Thus, the 
V0 fractions were set up for further purification.  
5.1.1.2 Ultracentrifugation of PSM V0 
Aliquots of lyophilized V0 were dissolved in 4M GuHCl (see Appendix section 1.3). The 
density was adjusted and samples ultracentrifuged as stated in section 2.4. Figure 5.2 shows 
the protein, glycoprotein and density profiles of a representative sample.  
 
 
Figure 5.2 Ultracentrifugation profile of PSM V0. Lyophilized aliquots of PSM V0 were dissolved in 
4M GuHCl. Samples then had their densities adjusted to 1.39g/ml with caesium chloride and 4M 
GuHCl. They were then subjected to a 48-hour ultracentrifugation at 105 000g at 4oC. Protein content 
was determined using Bradford Reagent assay ( ); glycoprotein content was identified using a PAS 
assay ( ) and the densities ( ) were recorded on the secondary axis. The box on the X-axis represents 
the fractions collected for dialysis against distilled water over three changes of a minimum of 6 hours 














































ULTRACENTRIFUGATION OF PIG SALIVARY V0
PROTEIN ASSAY GLYCOPROTEIN ASSAY DENSITIES
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Samples that had high glycoprotein content and a density of 1.40 – 1.41g/ml were pooled. In 
Figure 5.2 fractions 3 – 6 were pooled. They were then dialysed against distilled water over 
three changes for a minimum of 6 hours each at 4oC and freeze dried. 
5.1.1.3 Sepharose 4B separation of PSM V0 Muc19 
Proteomic analysis carried out by Rousseau et al (2008) showed the presence of Muc19 and 
Muc5b in pig saliva. To separate Muc19 and Muc5b, new pig saliva samples collected in 0.2M 
NaCl:0.02% sodium azide were eluted through a Sepharose 4B column.  Unlike the Sepharose 
4B column in section 5.1.1, the fraction collector was set to collect 500µl per tube instead of 
the previous 1ml per tube. This was done to elicit broader V0 peaks to better separate Muc19 
and Muc5b. Figure 5.3 is a representative sample of protein and glycoprotein distribution after 
PSM was eluted through a Sepharose 4B column.  
 
 
Figure 5.3 Sepharose 4B separation of pig salivary Muc19 and Muc5b in salt azide. Pig saliva was 
diluted with 0.2M NaCl:0.02% sodium azide (4:1), centrifuged and eluted through a Sepharose 4B glass 
column under peristaltic pressure. Fractions were collected at 500µl per tube. Every second fraction 
was tested for proteins and glycoproteins. Protein content was determined using Bradford Reagent assay 
( ); and glycoprotein content was identified using a PAS assay ( ). The box on the X-axis represents 
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In Figure 5.3, fractions 20 to 42 were designated the V0 and fractions 54 to 74 were designated 
the Vi. Due to limiting amounts of Muc19 antibody, only the fractions corresponding to the V0 
peak was assessed under slot blot analysis. The V0 fractions were kept separate and set up for 
slot blot analysis (see section 2.10). Information on the Muc5b and Muc19 antibodies used for 
the slot blot can be seen in Appendix, Table 1. Figure 5.4 shows the results of slot blot analysis 
on the V0 fractions in Figure 5.3. They have been aligned with their fraction number to show 
the presence of Muc5b and Muc19.  
 
 
Figure 5.4 Slot blot analysis of Muc19 and Muc5b in PGM V0. PSM was run on a Sepharose 4B column 
collecting 500µl per tube. The V0 fractions then underwent slot blot analysis to determine the presence 
of Muc19 and Muc5b. Figure 5.4 is divided into three panels. The top panel shows the fraction number. 
The second panel from the top shows the expression of Muc19.  The bottom panel shows the presence 
of Muc5b. The antibodies used for this slot blot were anti-horse Muc19 (1:1000 dilution) and anti-
human MUC5B (1:2000 dilution). 
 
In Figure 5.4, fractions 20 and 38 – 42 stained positive for Muc19 in the absence of Muc5b. 
These fractions were pooled and then dialysed against 4M GuHCl over three changes for a 
minimum of 6 hours each at 4oC. The volume of 4M GuHCl was at least 20 times the volume 
of V0. 
5.1.1.4 Ultracentrifugation of PSM V0 Muc19 
In Figure 5.4, Muc19 positive fractions (fractions 20 and 38 – 42) were pooled and prepared 
for a density gradient ultracentrifugation. The density of the sample was adjusted to 1.41g/ml 
and subjected to a 48-hour ultracentrifugation at 105 000g at 4oC. Figure 5.5 shows the protein, 




Figure 5.5 Ultracentrifugation profile of pig salivary Muc19. Pig salivary mucus was passed through a 
Sepharose 4B column and the V0 fractions containing Muc19 only were pooled. They were then dialysed 
against 4M GuHCl over three changes for a minimum of 6 hours each at 4oC. Samples densities were 
adjusted to 1.41g/ml with caesium chloride and 4M GuHCl, before undergoing ultracentrifugation for 
48 hours at 105 000g at 4oC. Protein content was determined using Bradford Reagent assay ( ); 
glycoprotein content was identified using a PAS assay ( ) and densities ( ) were recorded on the 
secondary axis. The box on the X-axis represents the fractions collected for dialysis against distilled 
water and freeze dried. 
 
Fractions that had glycoprotein rich densities of 1.39g/ml to 1.41g/ml were pooled. In Figure 
5.5 fractions 6 – 8 were pooled. These samples were dialysed against 3 changes of distilled 
water for 6 hours each, then freeze dried for further investigation. 
5.1.1.5 SDS-PAGE 4 – 20% Gradient Gel Electrophoresis  
Aliquots of samples were run on an SDS-PAGE gradient gel (4 – 20%) before and after 
reduction with DTT and proteolysis with trypsin of PSM. Figures 5.6 and 5.7 are SDS-PAGE 
















































ULTRACENTRIFUGATION OF PIG SALIVARY Muc19




Figure 5.6 Protein stained 4 – 20% gradient SDS-PAGE gel of PSM derivatives. At different stages of 
pig gastric mucin purification and treatment, 1mg lyophilized aliquots were dissolved in 100µl 2%SDS, 
1% glycerol and 0.01% bromophenol blue for SDS-PAGE gel investigation. Lane 1, 10µl of Thermo 
Scientific PageRuler Prestained Protein Ladder; Lane 2, crude pig saliva; Lane 3, purified Sepharose 
4B V0 fraction density gradient ultracentrifugation (from section 5.1.2, Figure 5.2) (Muc5b and 
Muc19); Lane 4, Sepharose 4B Vi fraction (from section 5.1.1, Figure 5.1) (Muc7), Lane 5, purified 
PSM V0 Muc19 fraction density gradient ultracentrifugation (from section 5.1.4, Figure 5.5); Lane 6, 
DTT treatment of the Sepharose 4B V0 fraction (Muc5b and Muc19) and in Lane 7 was trypsin treated 
Sepharose 4B V0 fraction (Muc5b and Muc19).  
 
Gel electrophoresis showed that all samples had varying amounts of large material that 
remained in the stacking gel (Figure 5.6, lanes 2 – 7). Bands or regions of interest were 
highlighted as red boxes. More visible material was also present in the form of a smear at the 
beginning of the running gel, which is very likely subunit material of the larger mucin, an 
expected behaviour of mucins on gels (Mall et al., 1999; Mall et al., 1997b; Newton et al., 
1998; Pearson et al., 1981) (Figure 5.6, lanes 2 – 4 and 6). Untreated crude pig saliva (Figure 
5.6 lane 2) showed several protein bands visible at varying sizes (red boxes). Figure 5.6 lane 3 
shows the purification of Sepharose 4B V0 fraction by density gradient ultracentrifugation in 
CsCl (from section 5.1.2, Figure 5.2). Ultracentrifugation (Figure 5.6, lane 3) resulted in 
proteins moving down the gel (red boxes) that were previously immobilised at the top of the 
71 
 
running gel in Figure 5.6 lane 2. Protein bands were seen at 80, 22, 17 and 11kDa (red boxes 
in Figure 5.6, lane 3). The smaller proteins present in Figure 5.6 lane 2 were eluted in the Vi 
fraction (Figure 5.6 lane 4, red boxes). The Muc19 eluted material from the V0 of the Sepharose 
4B column (from section 5.1.4, Figure 5.5) (Figure 5.6, lane 5) and the trypsin treated V0 
carrying both Muc5b and Muc19 (lane 7) showed very little subunit material. In fact, treatment 
with trypsin (lane 7) showed a strong band in the region of 40 – 50kDa (red box). Figure 5.6, 
lane 6 shows the density gradient ultracentrifugation purified V0 fraction after DTT treatment. 
Here it can be seen that the bands previously present at the top of the stacking and running gel 
(Figure 5.6 lane 3) have moved down the gel. Most notably bands appeared at 190, 135, 80, 
58, 32, 22, 17 and 11kDa (Figure 5.6, lane 6, red boxes). Figure 5.6, lane 7 shows the effect 
trypsin had on the naked regions of the mucin. In this lane, there is an increase in the mucin 




5.1.1.6 PAS Stained SDS-PAGE 4 – 20% Gradient Gel Electrophoresis  
  
Figure 5.7 Glycoprotein stained 4 – 20% gradient SDS-PAGE gel of PSM. At different stages of pig 
saliva purification and treatment, 1mg aliquots were dissolved in 100ml Sample Application Buffer for 
SDS-PAGE gel investigation. Lane 1, crude pig saliva; Lane 2, Sepharose 4B V0 fraction purified after 
density gradient ultracentrifugation (from section 5.1.2, Figure 5.2) (Muc5b and Muc19); Lane 3, 
Sepharose 4B Vi fraction; Lane 4, ultracentrifugation purified Sepharose 4B separated Muc19 (from 
section 5.1.4, Figure 5.5); Lane 5, DTT treatment of the Sepharose 4B V0 fraction (Muc5b and Muc19) 
and Lane 6, trypsin treatment of the Sepharose 4B V0 fraction. 
 
Figure 5.7 illustrates the PAS stained distribution of PSM and its derivatives through an SDS-
PAGE (for method see Section 2.9.2).  The result of the staining showed prominent bands of 
mucin present in the top of the stacking gel and running gel (Figure 5.7, lanes 1, 2, 5 and 6). 
Figure 5.7 lane 1 shows crude mucus partially in the stacking gel and immobilised in the top 
of the running gel (see red boxes). Figure 5.7, Lane 2 shows the density gradient 
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ultracentrifugation of PSM Sepharose 4B V0 fraction (from section 5.1.1.2, Figure 5.2). Lane 
2 shows a band in the stacking gel (see first red box) and two distinct bands at the top of the 
running gel (see second red box) (similar to Lane 1). Figure 5.7, lane 3 shows the Vi of PSM 
eluted through a Sepharose 4B column. This lane shows faint mucin smearing banding pattern 
in the stacking gel and at the top of the running gel (see red box). Figure 5.7, lane 4 shows 
ultracentrifugation purified Sepharose 4B separated Muc19 (from section 5.1.1.4, Figure 5.5). 
There was a loss of mucin going through purification, and this is reflected by the faint staining 
but there is a very faint band that moved a little into the running gel (see red box). Figure 5.7, 
lane 5 shows DTT treatment of the Sepharose 4B V0 fraction (from section 5.1.1.2, Figure 5.2). 
DTT treatment resulted in the disappearance of bands previously seen in the stacking gel 
(Figure 5.7, lane 2, first red box) and in the start of the running gel (Figure 5.7, lane 2, first 
band in the second red box). DTT treatment also resulted in a thick band at the top of the 
stacking gel. Trypsin treatment (Figure 5.7, lane 6) allowed more subunit material into the 
stacking gel (see first red box) and into the top of the running gel (see second red box).  
5.1.1.7 Slot Blot Analysis of PSM 
Figure 5.4 shows the Muc5b and Muc19 slot blot of PSM but the MUC7 antibody available to 
us (see Appendix Table 1.) did not work for both the PSM V0 and Vi (data not shown). 
5.1.2 PSM derivatives Inhibits HIV-1 on a Pseudoviral Assay 
We measured the ability of pig salivary mucin isolates to inhibit HIV-1 entry into a model 
target cell line, TZM-bl (Montefiori, 2009). PSM derivatives were assessed on a pseudoviral 
assay. Data recorded from a luminometer was analysed on Microsoft Excel where percentage 
neutralizations were calculated based on negative and positive controls. This data was put into 
Graphpad Prism Version 6 to construct Log Dose Response Curves (Figure 5.8). From these 






Figure 5.8 Log dose response curve of PSM derivatives. A, crude pig saliva; B, PSM V0 eluted from 
Sepharose 4B column chromatography and subjected to density gradient ultracentrifugation (Muc5b 
and Muc19); C, PSM Vi eluted from Sepharose 4B column chromatography (Muc7); D, DTT treatment 
of PSM V0 (Muc5b and Muc19); E, trypsin treated PSM V0 (Muc5b and Muc19) and F, PSM V0 Muc19 
eluted from Sepharose 4B column chromatography. 
 
Reliability of the log dose response curves can be assessed visually by how close the points of 
the curve lie to the solid line, which corresponds to the best model of an inhibition curve. Points 
on the curve for PSM Vi (Figure 5.8 C) showed substantial deviation for the modelled inhibition 
curve and PSM Muc19 (Figure 5.8 F) also showed deviation to a lesser extent. Table 5.1 shows 
the calculated 95% confidence interval of the IC50 value based upon the level of deviation of 























Concentration of Mucins in µg/ml 
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Table 5.1 The calculated PSM IC50’s and 95% Confidence Intervals 
Pig Salivary Mucin Derivative IC50 (µg/ml) 95% Confidence Intervals 
(µg/ml) 
Crude PSM 83.67 50.17 to 139.6 
PSM V0 (Muc5b and Muc19) 23.61 13.89 to 40.13  
PSM Vi  498.9 277.0 to 898.6 
DTT treated PSM V0 (Muc5b and Muc19) 20.79 9.100 to 47.48 
Trypsin treated PSM V0 (Muc5b and Muc19) 34.44 16.35 to 72.54 
PSM Muc19 94.43 9.829 to 907.2 
 
All PSM derivatives showed HIV-1 inhibition in vitro. The PSM Muc19 IC50 (IC50: 
94.43µg/ml) was the only one to lie outside three times the upper and lower limits of its 95% 
Confidence Intervals. The IC50 for Crude PSM (IC50: 83.67µg/ml) improved almost 4-fold after 
elution through a 4B Sepharose column and undergoing one round of density gradient 
ultracentrifugation (PSM V0 IC50: 23.61 µg/ml). The PSM Vi showed the least inhibition (IC50: 
498.9µg/ml), more so than the crude (IC50: 83.67µg/ml). This may have been due to gel 
filtration removing Muc7 and contaminants from the crude PSM. DTT treatment of PSM V0 
did not change the IC50 by much (PSM V0 IC50: 23.61 µg/ml, DTT treated PSM V0 IC50: 20.79 
µg/ml). Trypsin treatment decreased inhibition of HIV-1 by almost half (IC50: 34.44µg/ml). 
Muc19 had an IC50 above that of crude PSM, but as stated the data was not as reliable as other 
data (IC50: 94.43µg/ml). 
5.1.3 Toxicity Assay for PSM 
Crude PSM, PSM V0 having undergone density gradient ultracentrifugation (Muc5b and 
Muc19), PSM Vi, DTT treated PGM V0 (Muc5b and Muc7), trypsin treated PGM V0 (Muc5b 
and Muc19) and PSM V0 Muc19 (having undergone density gradient ultracentrifugation), were 
tested for cell toxicity using an MTT assay (see section 2.13). It was necessary to run our 
samples on this toxicity assay to ensure the inhibition seen in the pseudoviral assay was not the 





Table 5.2 The Results of PSM Derivatives on an MTT Assay 






Crude PSM Curve did 
not 
converge 62.50 64.36  
PSM V0 (Muc5b and Muc19) 3 446   
PSM Vi (Muc7) 943.9   
PSM V0 treated with DTT (Muc5b and Muc19) 1 247   
PSM V0 treated with Trypsin (Muc5b and 
Muc19) 
127.2   





LD50 values were calculated for most samples. Dose response curves did not converge for crude 
PSM and PSM V0 Muc19, in these instances the percentage viability of mucin close to the 
calculated IC50 was reported. The highest LD50 values were seen in PSM V0 (LD50: 3 446µg/ml) 
and DTT treated PSM V0 (LD50: 1 247µg/ml). Crude PSM did not show good cell viability (at 
62.50µg/ml there was 64.36% cell viability). PSM Muc19 showed a higher than 100% cell 
viability at 83.33µg/ml, this may have been due to the constituents of the samples that promote 
cell division over and above the cell control or interference by cellular enzyme activity 
(Pozzolini et al., 2003).  
5.2 Discussion 
5.2.1 Purification and Treatment of PSM derivatives 
This part of our project investigated the potential of using PSM as an alternative to human 
salivary mucin. Previous researchers have shown that there are similarities in tissue distribution 
and structure between pig and human salivary MUC5B (Eckhardt et al., 1997). O-glycan side 
chains make up ~60 – 70% of PSM mucins’ mass. It is believed that these O-glycan side chains 
are responsible for PSM mucins extended structure, resistance to proteases and play an 
important role in the protective property of PSM mucins (Jentoft, 1990; Shorgen et al., 1989). 
These extended structures are possible due to intra- and interchain disulphide bonds between 
half-cysteine residues present in the D-domains (D1, D2 and D3) of PSM von Willebrand factor 
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domain. Unlike other mucins, the D1-, D2- and D3-domains of PSM are N-glycosylated when 
expressed in COS-7 cells (Perez-Vilar et al., 1996; Sadler, 1998).  
Pig saliva was not collected in guanidine but 0.2M NaCl: 0.02% sodium azide, as a cost saving 
measure. There were saliva samples collected from 20 pigs and large mucin subunits could still 
be extracted from 0.2M NaCl.  This buffer may have allowed mucins to undergo endogenous 
proteolysis but this extraction still yields 2MDa subunits (Carlstedt & Sheehan, 1984). Our 
laboratory has previously eluted human saliva through gel filtration (Sepharose 4B) with 0.2M 
NaCl: 0.02% sodium azide (Peacocke et al., 2012). A Sepharose 4B column was chosen for 
PSM as our laboratory had previously separated human salivary mucins by using the same 
Sepharose 4B gel filtration (Habte et al., 2010; Habte et al., 2006; Peacocke, 2011; Peacocke 
et al., 2012). Figure 5.1 shows the Sepharose 4B profile of PSM eluted with the same buffer 
i.e. 0.2M NaCl: 0.02% sodium azide. The Sepharose gel filtration profile of PSM is similar to 
human saliva showing two mucin rich peaks, one present in the V0 and the other in the Vi 
(Habte et al., 2006; Peacocke et al., 2012). The mucin rich peak in the V0 was smaller than the 
Vi and contained less protein much like that of human salivary mucins eluted through a 
Sepharose 4B column (Peacocke et al., 2012). 
Figure 5.6 shows the protein staining pattern of PSM derivatives under SDS-PAGE (4 – 20%) 
gradient gel electrophoresis. Crude pig saliva (Figure 5.6 lane 2) showed many bands especially 
at the lower end of the gel (last red box). Crude PSM (Figure 5.6 lane 2) showed more protein 
bands than crude PGM (Figure 3.4, lane 2). After gel filtration (on a Sepharose 4B column) 
and ultracentrifugation, crude pig saliva the V0 fraction (Figure 5.6, lane 3) showed no bands 
below 190kDa. This staining pattern was similar to PGM V0 (Figure 3.4, lane 4) apart from 
PSM V0 (Figure 5.6, lane 3) having a more intense stain in the upper running gel indicating the 
presence of high molecular weight proteins. The Vi fraction (from section 5.1.1, Figure 5.1) 
contained the bands below 190kDa (Figure 5.6, lane 4) that were also present in the crude saliva 
(Figure 5.6, lane 2). The banding patterns displayed by PSM V0 (purified by ultracentrifugation 
from section 5.1.2, Figure 5.2) and Vi (Figure 5.6 lanes 3 and 4 respectively) share similar 
features to human saliva eluted through a Sepharose CL-4B column after two density gradient 
ultracentrifugations (Habte et al., 2006). The main difference is the presence of more protein 
bands in the PSM V0 and Vi (see red boxes). It is important to note that the PSM V0 underwent 
just one round of density gradient ultracentrifugation in contrast to the two ultracentrifugations 
that human saliva had undergone in that study (Habte et al., 2006). The PSM Vi did not undergo 
a density gradient ultracentrifugation so any contaminating proteins in the Vi had not been 
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removed and these contaminating proteins are visible in Figure 5.6 lane 4. Previous work done 
on human saliva by Habte et al (2006) also showed multiple bands in the Vi. Habte et al (2006) 
collected human saliva in 6M GuHCl with protease inhibitors (10mM EDTA, 5mM NEM and 
0.05% CHAPS at pH6.5) and eluted it on a Sepharose CL-4B gel column with 4M GuHCl. The 
comparison of our PSM Vi and human saliva Vi from Habte et al (2006) is shown in Figure 
5.9. 
 
Figure 5.9 Comparison of PSM Vi and human saliva Vi. A, PSM collected in 0.2M NaCl:0.02% sodium 
azide was eluted through a Sepharose 4B column with the same buffer, then run on a 4 – 20% gradient 
SDS-PAGE gel and stained for proteins; Lane 1, 10µl of Thermo Scientific PageRuler Prestained 
Protein Ladder and Lane 2, PSM Vi from the Sepharose 4B column. B, Human saliva collected in 6M 
GuHCl with protease inhibitors (10mM EDTA, 5mM NEM and 0.05% CHAPS at pH6.5) was eluted 
on a Sepharose CL-4B column with a buffer made up of 4M GuHCl plus protease inhibitors (10mM 
EDTA, 5mM NEM and 0.05% CHAPS at pH6.5) and run on a 10% SDS-PAGE gel then stained for 
proteins; Lane 1, Molecular weight marker; Lane 2, human saliva Vi (Habte et al., 2008). 
Human saliva Vi (Figure 5.9, B, Lane 2) showed multiple bands, much like PSM Vi (Figure 
5.9, A, Lane 2). PSM Vi (Figure 5.9, A, Lane 2) showed higher molecular weight protein bands 
than human saliva Vi (Figure 5.9, B, Lane 2). Human saliva Vi (Figure 5.9, B, Lane 2) did not 
show the protein blob seen at ~46kDa in PSM Vi (Figure 5.9, A, Lane 2). PGM Vi (Figure 3.4, 
lane 5) showed far less protein bands but a more intense smearing effect than PSM Vi (Figure 
5.6, lane 4). Figure 5.6, lane 5 shows Muc19 present in the Sepharose 4B V0 fraction (from 
section 5.1.4, Figure 5.5). Muc19 is the largest gel forming mucin (Chen et al., 2004) but from 
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where our Muc19 samples were eluted off the Sepharose 4B column we may be testing the 
smallest gene product. The presence of Muc19 has been verified in pig saliva but not in human 
saliva (Rousseau et al., 2008). This lane (Figure 5.6, lane 5) shows very little protein staining 
with bands at the start of the running gel, a band just below 58kDa and a band at 17kDa (see 
red boxes). Low protein staining is expected as very few fractions of the V0 were taken for 
Muc19 enrichment. DTT treatment of PSM V0 fraction (Figure 5.6, lane 6) allowed protein 
bands to travel further down the lane. Bands in this lane were seen at 245, 190, 135, <80, 58, 
46, 32, 22 and 11kDa (see red boxes). The protein band seen below 80kDa (third red box from 
the top, Figure 5.6, lane 6) may be the 70kDa low molecular weight “link” protein described 
by Pearson et al (1981). The presence of the other bands may be due to degradation. DTT 
treated PSM V0 (Figure 5.6, lane 6) showed more protein bands than DTT treated PGM V0 
(Figure 3.4, lane 6). Trypsin treatment of V0 fraction (Figure 5.6, lane 7) created a protein smear 
from 80kDa to 11kDa. This contrasted with trypsin treated PGM V0 that showed a protein 
smear throughout the lane (Figure 3.4, lane 7). 
Figure 5.7 shows the PAS staining pattern of PSM derivatives under SDS-PAGE (4 – 20%) 
gradient gel electrophoresis. In Figure 5.6, the smear effect, characteristic of mucins, can be 
seen in lanes 2 – 4, 6 and 7, but when the corresponding derivatives are PAS stained (Figure 
5.7, lanes 1, 2, 4 – 6) the smear effect is limited to the top of the running gel and in the stacking 
gel. One possible explanation is that the amount of mucins present is below the limit of 
detection for PAS, another reason could be the presence of mucin-like proteins in pig saliva 
similar to those found in bovine saliva (Bhargava et al., 1990). Figure 5.7, lanes 1, 2 and 6 (lane 
1, crude pig saliva; lane 2, Sepharose 4B V0 fraction purified after density gradient 
ultracentrifugation (from section 5.1.2, Figure 5.2) and lane 6, trypsin treatment of the 
Sepharose 4B V0 fraction show two bands at the top of the running gel. Habte et al (2006) 
found the same banding pattern present in the V0 of human saliva eluted through a Sepharose 
CL-4B column. Kirkham et al (2002) performed Western blot analysis on the V0 of human 
sputa eluted through a Sepharose CL-2B column and found both bands at the top of the running 






Figure 5.10 Comparison of PAS stained PSM V0 from this study versus human salivary V0 from 
Habte et al (2006) and Kirkham et al (2002). A, PAS stained bands from the top of the 4 – 20% SDS-
PAGE running gel from PSM V0 Figure 5.7 lane 2; B, PAS stained human salivary V0 eluted from a 
Sepharose CL-4B column and run on a 10% SDS-PAGE gel (Habte et al., 2006); C, human saliva V0 
after ultracentrifugation and elution on a  Sepharose CL-2B column then reduced, alkylated and run 
on a 1% w/v agarose gel and transferred to a nitrocellulose membrane for PAS staining (Kirkham et 
al., 2002).  
Kirkham et al (2002) proposed that the presence of these two bands is due to the two 
glycoforms of MUC5B. They suggested MUC5B exists as a high-charge and low-charge 
glycoform, where the top band was a low-charge MUC5B glycoform that underwent less 
migration under the influence of an electric current and the lower band was the high-charge 
MUC5B glycoform that migrated further due to charge (Kirkham et al., 2002). Another 
contributing factor to the two bands is the presence of Muc19 in pig saliva (Rousseau et al., 
2008). Mucins lay in the stacking gel or moved minimally into the running gel, regardless of 
the treatment. Purifying the PSM Sepharose 4B V0 fraction (from section 5.1.2, Figure 5.2) 
with a density gradient ultracentrifugation showed a darker band in the stacking gel and two 
bands at the top of running gel (Figure 5.7, lane 2). This contrasted with PGM V0 (Figure 3.5 
lane 3, second red box) where a small amount of mucin that had moved into the running gel 
with no bands present but had a smear effect. Bands in the PSM V0 (purified through gradient 
density ultracentrifugation) (Figure 5.7, lane 2) showed darker PAS staining than human saliva 
eluted through a Sepharose CL-4B column after two density gradient ultracentrifugations 
(Habte et al., 2006). This may be indicative of more mucin present in pig saliva after 
purification steps. The Vi fraction of PSM Sepharose 4B gel filtration (Figure 5.7, lane 3) 
showed very faint smearing of mucins in the stacking gel and a faint band just entering the 
running gel. The PAS staining of PSM Vi fraction was fainter than the Vi fraction of human 
saliva eluted through a Sepharose CL-4B column after two density gradient ultracentrifugations 
(Habte et al., 2006). Human saliva Vi did show patient variability but there was the presence 
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of two bands, much like our PSM Vi (Habte et al., 2006). A comparison of these results can be 
seen in Figure 5.11.  
 
Figure 5.11 Comparison of PSM Vi and human salivary Vi. A, PAS stained bands from the top of the 4 
– 20% SDS-PAGE gel from PSM Vi Figure 5.7 lane 3; B, PAS stained human salivary Vi eluted from 
a Sepharose CL-4B column and run on a 10% SDS-PAGE gel (Habte et al., 2006). 
In Figure 5.11, lane A PSM Vi shows two faint bands, the first in the stacking gel and the 
second in the running gel. Lane B (Figure 5.11) the two bands lie at the top of the running gel. 
This may be due to two differentially charged glycoforms of Muc7 present in PSM Vi and 
MUC7 in human salivary Vi. Mucins present in the PGM Vi moved further into the running gel 
than PSM Vi indicating the mucins present in PGM Vi may have been smaller in size. Muc19 
(from section 5.1.4, Figure 5.5) showed faint staining (Figure 5.7, lane 4), with a partially 
visible band in the top of the running gel (see red box). The location of the band coincides with 
the lower of the two bands present in Figure 5.7, lanes 1, 2, 5, 6 (lane 1, crude pig saliva; lane 
2, Sepharose 4B V0 fraction purified after density gradient ultracentrifugation (from section 
5.1.2, Figure 5.2); lane 5, DTT treatment of the Sepharose 4B V0 fraction and lane 6, trypsin 
treatment of the Sepharose 4B V0 fraction) which indicates that Muc19 may lie in the same 
region as the high-charge Muc5b glycoform. DTT treatment of the PSM V0 fraction (Figure 
5.7, lane 5) resulted in less banding in the stacking gel and one distinct band in the running gel. 
It is possible the DTT treatment lowered the charge of one of the Muc5b glycoforms resulting 
in the immobilized band present at the top of the well in Figure 5.7, lane 5. This difference in 
migration between the two bands is similar to the DTT treatment of human saliva V0 (Figure 
5.10 lane C (Kirkham et al., 2002)). DTT treated PGM V0 (Figure 3.5, lane 5) resulted in just 
one band in the top of the running gel (see red box) and unlike DTT treated PSM V0 (Figure 
5.7, lane 5) there was no band in the stacking gel only a smear of glycoproteins. Trypsin 
treatment of the PSM V0 fraction (Figure 5.7, lane 6) showed movement of mucins from the 
top of the wells into the stacking gel and two thick bands at the top of the running gel. In 






no bands but intense smearing at the bottom of the stacking gel and the top of the running gel. 
This may indicate that PSM V0 (Figure 5.7, lane 6) contained more trypsin sensitive 
glycoproteins (PSM Muc5b and Muc19) than PGM V0 (Muc5ac and Muc6). 
Slot blot analysis on PSM derivatives was carried out with antibodies raised to human MUC5B 
and MUC7 (Appendix Table 1). Muc19 antibodies were raised against horse Muc19 (Appendix 
Table 1). Figure 5.4 confirms the presence of Muc5b and Muc19 in the V0 fraction. These 
findings are in line with previous research done by Rousseau et al (2008). They performed 
proteomic analysis of pig and human saliva and found that Muc19 is present in pig but not 
human. They could not confirm the presence of Muc5b in pig saliva as there was too little pig 
Muc5b genome sequence data to perform analysis on (Rousseau et al., 2008). The presence of 
Muc5b in our PSM V0 fraction (Figure 5.4) was similar to Western blot work done in our 
laboratory on human saliva MUC5B present in the V0 of Sepharose 2B and Sepharose CL-4B 
columns (Habte et al., 2010; Peacocke, 2011; Peacocke et al., 2012). Antibodies raised to pig 
Muc7 were not available for the duration of this study so the presence of Muc7 was based on 
previous work on Sepharose gel filtration Vi fractions of human saliva, in our lab and elsewhere 
(Bobek et al., 1996; Habte et al., 2010; Peacocke, 2011; Peacocke et al., 2012; Thornton et al., 
1999). Habte et al (2010) and Peacocke et al (2012) had purified human saliva by subjecting 
them to density gradient ultracentrifugation. They then eluted the purified products through a 
Sepharose CL-4B column followed by SDS-PAGE and Western blot analysis on the void and 
included volumes. MUC7 was shown to be present in human saliva Vi fraction (Bobek et al., 
1996; Habte et al., 2010; Peacocke, 2011; Peacocke et al., 2012; Thornton et al., 1999). 
Multiple methods (within our budget and with the available equipment) were used to try and 
separate Muc5b and Muc19 from the PSM V0, but our attempts were unsuccessful (data not 
shown). 
5.2.2 PSM derivatives as an Anti-Viral Agent 
Our results showed that PSM derivatives (crude PSM, PSM V0, PSM Vi, DTT treated PSM V0, 
trypsin treated PSM V0 and PSM Muc19) all inhibited HIV-1 in vitro. In 1994, Bergey et al 
(1994) investigated the interaction between salivary mucins and HIV-1. This was the first study 
to demonstrate mucin induced inhibition of HIV-1 by showing the inhibitory activity of human 
submandibular-sublingual (HSMSL) gland secretions on viral particles using electron 
micrographs. After subjecting HSMSL saliva to Sephadex G-200 chromatography, they 
incubated the mucin rich components with HIV-1 (~100 particles) then filtered the mixture 
through a low protein binding cellulose acetate 0.22 micrometre filter. The filtrate was added 
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to HeLa CD4+ cell monolayers for 90 mins of adsorption, thereafter monolayers were fixed 
with methanol and incubated with anti-HIV antibody (AIDS Research Reference Program, 
catalogue #192). Plaques were counted on an inverted microscope following the addition of 
amioethyl carbazol. They found that the mucin-rich fractions reduced the number of infectious 
units by 75% (Bergey et al., 1994). They then immobilized salivary components onto latex 
beads and monitored their interaction with HIV particles (including recombinant gp120) with 
low molecular weight mucin (MUC7). Their electron microscopic data suggested inhibition 
was due to aggregation of virus particles by the mucin-rich fractions. 
Recently, our laboratory also performed experiments investigating how human saliva MUC5B 
and MUC7 affect HIV-1 infectivity. In 2012 Peacocke et al (2012) collected human saliva from 
HIV negative and positive volunteers and eluted them on a Sepharose CL-4B column. After 
purifying MUC5B and MUC7 mucins from each cohort, they were individually incubated with 
HIV-1 subtype C virus. The individual mucins were added to virus and incubated with CD4+ 
human T cell line (CEM SS) at three different time points. Thereafter the supernatant was 
collected after 4 days. The supernatant was tested on a qualitative p24 assay to assess viral 
replication. Peacocke et al (2012) showed that both the high and low molecular weight mucin 
fractions (MUC5B and MUC7) inhibited HIV-1 infection. These findings contrasted with the 
results of  Bergey et al (1994), by showing MUC5B had better pseudovirus HIV-1 inhibition 
than MUC7 (Peacocke, 2011; Peacocke et al., 2012). This study confirmed the importance of 
salivary mucins in inhibiting HIV-1 in vitro.  
Our study showed that, much like Peacocke et al (2012), both the high and low molecular 
weight mucin fractions (MUC5B and MUC7) inhibited HIV-1 infection. From our data, we 
have shown that all PSM derivatives (crude PSM, PSM V0, PSM Vi, DTT treated PSM V0, 
trypsin treated PSM and PSM Muc19) inhibited an HIV-1 subtype C pseudovirus in vitro. The 
lowest inhibition from our PSM derivatives was seen in the low molecular weight mucin rich 
fraction of PSM eluted through a Sepharose 4B column (PSM Vi IC50: 498.9µg/ml, see Table 
5.1). The PSM derivatives that showed the best HIV-1 inhibition were large molecular weight 
mucin rich fractions of PSM eluted through a Sepharose 4B column and purified by density 
gradient ultracentrifugation (PSM V0 IC50: 23.61µg/ml, see Table 5.1) and PSM V0 with 
disulphide bond cleavage (DTT treated PSM V0 IC50: 20.79µg/ml, see Table 5.1). Both PSM 
V0 and DTT treated PSM V0 have a good 95% confidence interval indicating that this inhibitory 
effect is reliable. In contrast to the good inhibition shown by DTT treated PSM V0 (IC50: 
20.79µg/ml, see Table 5.1), DTT treated PGM V0 (IC50: 110.1µg/ml, see Table 4.1) showed 
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low inhibition which may be due to the collection buffer. PSM was extracted in 0.2M 
NaCl:0.02% sodium azide which unlike the PGM extraction buffer viz. GuHCl with protease 
inhibitors, may have rendered PSM susceptible to protease activity. It is possible DTT 
treatment reduced PSM mucins that were already smaller due to endogenous protease activity, 
whereas GuHCl and protease inhibitors kept the structural integrity of PGM before DTT 
treatment. The effect of DTT treatment of PSM collected in GuHCl with protease inhibitors 
and DTT treated PGM collected in 0.2M NaCl:0.02% sodium azide needs further investigation. 
This data also indicates PSM V0 with a mixture of Muc5b and Muc19 subunits inhibit HIV-1 
best. This part of our study shows that PSM V0 and DTT treated PSM V0 are the best candidates 
to be components of an anti-HIV-1 gel. When these results are compared to PGM pseudoviral 
data, we can see that PGM (IC50: 10.50µg/ml, see Table 4.1) and PGM V0 (IC50: 1.668µg/ml, 
see Table 4.1) showed better inhibition than our PSM data, making purified PGM the better 
candidate for an anti-HIV-1 gel.  
5.2.3 Toxicity Assay of PSM Derivatives 
PSM V0 (LD50: 3 446µg/ml, see Table 5.2), PSM Vi (LD50: 943.9µg/ml, see Table 5.2), DTT 
treated PSM V0 (LD50: 1 247µg/ml, see Table 5.2) and trypsin treated PSM V0 (LD50: 
127.2µg/ml, see Table 5.2) all gave high LD50 values. This indicates that their respective IC50 
values were a true reflection of anti-HIV-1 activity and not a consequence of the mucin being 
toxic to TZM-bl target cells. LD50 values for crude PSM   and PSM V0 Muc19 could not be 
constructed but the former showed poor percentage cell viability (62.50µg/ml crude PSM 
showed 64.36%, see Table 5.2) and in contrast the latter showed good percentage cell viability 
(at 83.30µg/ml PSM V0 Muc19 showed 180.2%, see Table 5.2).  
Our results show that pig salivary mucins can be used for in vitro anti-HIV-1 studies with good 
inhibition and toxicity data that proves the reliability for our purified PSM derivatives. If an 
anti-HIV-1 gel were to be constructed from a PSM derivative it would be PSM V0 (Muc5b and 
Muc19) as this derivative had good sample yield and showed promising inhibition with a tight 
95% confidence interval (increasing the chances that we see a true inhibitory effect from PSM 
V0 on pseudoviral HIV-1).  
These findings are encouraging because collecting human saliva can be problematic and 
inconvenient. People are reluctant to donate samples and in most cases, even when they do, the 
amounts donated are negligible. Pigs produce large amounts of saliva whilst feeding and a 
minimal number of animals are required to meet our needs for purification of mucins and HIV 
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assays.  There is a possible suggestion here that a mucin does not have to be large and polymeric 
to inhibit HIV-1. It could be that a mucin fragment with the required number of 
oligosaccharides or perhaps even the type of sugar side-chain of a specific sequence and 
composition, could inhibit HIV-1 by aggregation. Further studies are required to accurately 
determine what role size plays on HIV inhibition.  
As far as we know there has not been any work done on the specific interaction between mucins 
and HIV-1. Our research (Habte et al., 2010; Habte et al., 2008; Habte et al., 2007; Habte et 
al., 2006; Lieleg et al., 2012; Mthembu et al., 2014; Peacocke, 2011; Peacocke et al., 2012), 




CHAPTER 6: THE EFFECT OF PIG CERVICO-VAGINAL MUCINS (PCM) ON HIV-1 IN VITRO 
 
6.1 Results 
6.1.1 First Ultracentrifugation of Pig Cervico-vaginal Mucus  
Aliquots taken from pooled pig gastric mucus samples shared similar profiles to each other 
after the first density gradient ultracentrifugation process. Figure 6.1 shows the protein, 
glycoprotein and density profiles of a representative sample.  
 
 
Figure 6.1 First ultracentrifugation profile of pig cervico-vaginal mucus in caesium chloride. Pig 
cervico-vaginal mucus was slowly stirred overnight in 6M guanidine hydrochloride with 10mM 
Na2HPO4, 10mM EDTA, 1mM PMSF and 5mM NEM. Samples then had their densities adjusted to 
1.39g/ml with caesium chloride and 4M GuHCl. They were then subjected to a 48-hour 
ultracentrifugation at 105 000g at 4 ̊C. Protein content was determined using Bradford Reagent assay (
); glycoprotein content was identified using a PAS assay ( ) and the densities ( ) were recorded 
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Fractions that had glycoprotein rich densities of 1.39g/ml to 1.41g/ml were pooled. In Figure 
6.1 fractions 5 – 7 were pooled. These samples were then prepared for a second round of density 
gradient ultracentrifugation.  
6.1.2 Second Ultracentrifugation of Pig Cervico-vaginal Mucus 
The densities of the pooled mucin fractions were adjusted to 1.41g/ml by the addition of 
caesium chloride and 4M GuHCl. Samples were ultracentrifuged under the same conditions as 
the first ultracentrifugation process. Protein and glycoprotein content as well as densities were 
all recorded in the same way as the first density gradient ultracentrifugation. The second density 
gradient ultracentrifugation profiles of pig cervico-vaginal mucus all shared a similar pattern 
to each other. Figure 6.2 shows the pattern of a representative sample.  
 
 
Figure 6.2 Profile of second ultracentrifugation of pig cervico-vaginal mucus. Glycoprotein rich 
fractions from the first ultracentrifugation were pooled and had their densities adjusted to 1.41g/ml with 
caesium chloride and 4M GuHCl. The fractions then underwent ultracentrifugation for 48 hours at 
105 000g at 4oC. Protein content was determined using Bradford Reagent assay ( ); glycoprotein 
content was identified using a PAS assay ( ) and the densities ( ) were recorded on the secondary 
axis. The box on the X-axis represents the fractions collected, pooled, dialysed against distilled water 
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Samples that had high glycoprotein content and a density of 1.40 – 1.41g/ml were pooled. In 
Figure 6.2 fractions 5 – 7 were pooled. They were then dialysed against distilled water over 
three changes for a minimum of 6 hours each at 4oC and then freeze dried. 
6.1.3 Size Exclusion Sepharose 2B Column Chromatography of PCM 
Aliquots of lyophilized PCM were run on a Sepharose 2B column to separate mucins based on 
size. Protein and glycoprotein profiles stayed consistent throughout the many chromatography 
runs. Figure 6.3 is a representative sample of protein and glycoprotein distribution after PCM 
was run on the Sepharose 2B column. 
 
 
Figure 6.3 Profile of Sepharose 2B separation of PCM in 0.2M NaCl:0.02% sodium azide. Purified 
lyophilized PCM was dissolved in 10ml 0.2M NaCl:0.02% sodium azide. It was then eluted through a 
Sepharose 2B glass column under peristaltic pressure. Every second fraction was tested for proteins and 
glycoproteins. Protein content was determined using Bradford Reagent assay ( ); and glycoprotein 
content was identified using a PAS assay ( ). The box on the X-axis represents fractions that were 
pooled. Fractions 26 – 38 were pooled and designated V0. Fractions 46 – 74 were pooled and designated 
Vi.  
 
There was a clear PAS positive peak from fractions 26 – 38. These fractions were pooled and 
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some protein in the V0, this may have been the result of the protein stain detecting mucin 
interference. The second PAS positive peak (Vi) (fractions 46 – 74) extended into the included 
volume of the column and would represent degraded or subunit mucin, as opposed to polymer 
(Mall et al., 1999; Mall et al., 1988; Pearson et al., 1981). The V0 and Vi fractions were then 
dialysed against distilled water over three changes of a minimum of 6 hours each at 4⁰C and 
then freeze dried. 
6.1.4 SDS-PAGE Gradient Gel Electrophoresis 
Aliquots of crude untreated PCM were run on an SDS-PAGE gradient gel (4 – 20%) following 
reduction with DTT or proteolysis with trypsin treatments of PCM. Figure 6.4 shows the results 
of the samples run on the SDS-PAGE under protein staining (see section 2.9.2) and Figure 6.5 
shows the gel under PAS glycoprotein staining (see section 2.9.3). 
 
  
Figure 6.4 Protein stained 4 – 20% gradient SDS-PAGE gel of PCM derivatives. 1mg lyophilized 
aliquots, of crude and differentially treated samples were dissolved in 100µl 2% SDS, 1% glycerol and 
0.01% bromophenol blue for SDS-PAGE gel investigation. Lane 1, 10µl of Thermo Scientific 
PageRuler Prestained Protein Ladder; Lane 2, crude pig cervico-vaginal mucus; Lane 3, purified PCM 
after purification in two density gradient ultracentrifugations; Lane 4, the PCM Sepharose 2B V0 
fraction; Lane 5, the PCM Sepharose 2B Vi fraction; Lane 6, DTT treatment of the PCM Sepharose 2B 




In Figure 6.4, the crude pig cervico-vaginal mucus (lane 2) showed bands at the top of the well, 
the top of the running gel, just below 58kDa and a thick band from 22 – 11kDa (see red box). 
There were visibly less proteins after two density gradient ultracentrifugations (Figure 6.4, lane 
3). The bands were still present at the previously mentioned sizes for crude mucin, but the 
bands were smaller (see red boxes). Figure 6.4, lane 4 shows the eluted V0 fraction from a 
Sepharose 2B column after two density gradient ultracentrifugations. The lane was very lightly 
stained as there was very little sample left to run on an SDS-PAGE gel. The reason for this was 
that the pseudoviral and MTT assays were a high priority leaving very little sample for gel 
electrophoresis. PCM Vi (Figure 6.4, lane 5) had an abundance of protein around the 46 – 
58kDa range (see red box). DTT treatment of PCM V0 (Figure 6.4, lane 6) showed the same 
profile as PCM Vi (Figure 6.4, lane 5). Trypsin treatment of PCM V0 (Figure 6.4, lane 7) 
allowed the movement of glycoproteins farther down the gel. Bands present in lane 7 were seen 





Figure 6.5 Glycoprotein stained 4 – 20% gradient SDS-PAGE gel of PCM derivatives. One milligram 
lyophilized aliquots, of crude and differentially treated samples were dissolved in 100l 2% SDS, 1% 
glycerol and 0.01% bromophenol blue for SDS-PAGE gel investigation. Lane 1, crude pig cervico-
vaginal mucus; Lane 2, purified PCM after two density gradient ultracentrifugations; Lane 3, the PCM 
Sepharose 2B V0 fraction; Lane 4, the PCM Sepharose 2B Vi fraction; Lane 5, DTT treatment of the 
PCM Sepharose 2B V0 fraction and Lane 6, trypsin treatment of PCM Sepharose 2B V0 fraction. 
 
Figure 6.5 illustrates the PAS stained distribution of PCM and its derivatives through an SDS-
PAGE (for method see Section 2.9.2). As previously mentioned the bulk of the PCM samples 
went to the pseudoviral assay and MTT assay, this accounts for the faint staining in Figure 6.5, 
lanes 3 – 6. It is possible the mucin in these gels are present lower than the detectable limit for 
the assay. Lane 1 shows the crude PCM mucin distribution. There is smearing in the stacking 
gel and at the top of the running gel (see red box). After two density gradient 
ultracentrifugations (Figure 6.5, lane 2), PCM showed a darker smear effect in the same regions 
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(see red box) as seen in crude PCM (Figure 6.5, lane 1). Lanes 3 – 6 shows faint smearing in 
the stacking gel and with a very faint band at the top of the wells (see red boxes). 
6.1.5 Slot Blot Analysis of PCM 
Antibodies used for this study (see Appendix Table 1 for antibody type and dilutions) were 
mostly raised against human mucins. None of the antibodies gave a positive signal to PCM 
derivatives on slot blot analysis (data not shown). At the time of the study there weren’t 
suppliers who stocked or shipped antibodies raised to PCM that were within our budget.  
6.1.6 PCM Derivatives Inhibits HIV-1 on a Pseudoviral Assay 
We measured the ability of PCM derivatives to inhibit HIV-1 entry into a model target cell 
line, TZM-bl (Montefiori, 2009). Aliquots of PCM were taken from every stage of purification 
and chemical treatment and run on a pseudoviral assay. Data was recorded from a luminometer 
onto Microsoft Excel where percentage neutralizations were calculated based on negative and 
positive controls. This data was put into Graphpad Prism Version 6 to construct Log Dose 
Response Curves (see Figure 6.6). From these curves the IC50 was calculated. 
         
 
 
Figure 6.6 Log dose response curve of PCM. A shows the dose response curve for crude PCM; B shows 
purified PCM after two rounds of ultracentrifugation; C shows PCM V0 after Sepharose 2B column 


















Concentration of Mucins in µg/ml 
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DTT treatment of PCM V0 had on HIV-1 inhibition and F shows the effect Trypsin treatment of PCM 
V0 had on HIV-1 inhibition. 
 
Reliability of the log dose response curves can be assessed visually by how close the points of 
the curve lie to the solid line, which corresponds to the best model of an inhibition curve. The 
most reliable curves came from PCM V0 (Figure 6.6 C) and DTT treatment of PCM V0 (Figure 
6.6 E). Points on the curve for PCM Vi (Figure 6.6 D) showed substantial deviation for the 
modelled inhibition curve. Table 6.1 shows the calculated 95% confidence interval of the IC50 
value based upon the level of deviation of the points from the modelled inhibition curve. 
Table 6.1 The summary of PCM IC50 values and 95% confidence intervals    
PCM Derivative IC50 (µg/ml) 95% Confidence Intervals 
(µg/ml) 
Crude PCM 128.4 31.95 to 515.8 
Purified PCM 10.32 2.520 to 42.23 
PCM V0 8.974 5.055 to 15.93 
PCM Vi 72.12 16.55 to 314.3 
DTT treated PCM V0 18.92 7.014 to 51.01 
Trypsin treated PCM V0 12.90 8.036 to 20.71 
 
Our data shows that all PCM derivatives (crude PCM, PCM having undergone two 
ultracentrifugations, the large (V0) and smaller molecular weight (Vi) PCM fractions eluted 
from a Sepharose 2B column, PCM V0 with DTT reduction and PCM with trypsin digested 
naked regions) tested on the pseudoviral assay inhibited HIV-1 in vitro. The most reliable data 
(in terms of 95% confidence intervals) came from the PCM V0 (5.055 to 15.93µg/ml), DTT 
treated PCM V0 (7.014 to 51.01µg/ml), trypsin treated PCM V0 (8.036 to 20.71µg/ml). Trypsin 
treated PCM V0 showed a dose response curve in he opposite direction as the others and this 
needs to be investigated further. The least reliable data came from the crude PCM (31.95 to 
515.8µg/ml). The purified PCM was almost within 4 orders of the upper and lower 95% 
Confidence intervals (2.520 to 42.23µg/ml). The lowest IC50 values were shown by PCM V0 
(8.974µg/ml) and purified PCM (10.32µg/ml). The highest IC50 value was exhibited by crude 
PCM (128.4µg/ml). Cleaving of disulphide bonds (with DTT) changed PCM V0’s inhibition 
potential over two-fold (18.92µg/ml).  
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6.1.7 Toxicity Assay for PCM 
PCM derivatives (crude PCM, purified PCM, PCM V0, PCM Vi, DTT treated PCM V0 and 
trypsin treated PCM V0) were run on an MTT assay (see section 2.13) to authenticate the HIV-
1 inhibition seen in section 6.1.5. If the PCM derivatives were toxic and subsequently killed 
target cells it would have resulted in luminescence reduction giving false inhibition data. Table 
6.2 shows the results of this MTT assay. 
 
Table 6.2 Results of PCM Derivatives on MTT Assay 




Crude PCM Curve did 
not converge 168.13 66.93 
Purified PCM 4 060   
PCM V0 186.2   
PCM Vi 1 303   
DTT treated PCM V0  1 071   
Trypsin treated PCM V0  396.8   
 
All PCM derivatives, excluding crude PCM, showed high LD50 values which indicates that a 
high concentration of those PCM derivatives are needed to kill 50% of the target cells. The 
highest LD50 was seen in purified PCM (4 060µg/ml) and the lowest LD50 was shown by PCM 
V0 (186.2µg/ml). An LD50 for crude PCM could not be calculated so a cell viability was quoted 
that was at a concentration close to crude PCM IC50 (IC50: 128.4µg/ml, percentage cell 
viability: 66.93% at 168.13µg/ml). There were poor percentage cell viability values for crude 
PCM, which lowers the integrity of its inhibition data.  
6.2 Discussion 
6.2.1 Purification and Treatment of PCM  
Cervico-vaginal mucus regulates sperm transport to the upper reproductive tract and 
fertilization (Carlstedt et al., 1983b; Carlstedt et al., 1982). Cervico-vaginal mucus also 
prevents desiccation by enhancing lubrication, impedes cervical enzymatic degradation and 
protects against pathogenic infection (Gipson et al., 1995; Idris et al., 1999; Venegas et al., 
1995). Cervical mucus of farm animals may contain endometrial, follicular, oviductal and 
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peritoneal fluids; leukocytes, proteins, trace elements, enzymes as well as cellular debris from 
the cervical, vaginal and uterine epithelia (Hafez et al., 2013).  The cervical mucus of farm 
animals is a hydrogel composed of water, low- and high-viscosity components (Hafez & Hafez, 
2013). Cervical mucus have low molecular weight components such as amino acids, and free 
simple sugars (mannose, maltose and glucose) (Hafez & Hafez, 2013). The female human 
reproductive tract contains 6 mucins, namely MUC1, MUC2, MUC4, MUC5AC, MUC5B and 
MUC6 (Gipson et al., 1997a). To our knowledge there have been no studies on the mucins 
present in pig cervico-vaginal mucus.  
Our laboratory has previously performed experiments on crude and purified human pregnancy 
plugs (Habte et al., 2008). Habte et al (2008) purified pregnancy plug mucins by two caesium 
chloride density gradient ultracentrifugations and characterized the products by Western blot 
analysis. Figure 6.1 showed the first caesium chloride density gradient ultracentrifugation 
profile of PCM as more protein was present in the first three fractions. The PCM profile was 
different from the first human pregnancy plug ultracentrifugation. The second PCM 
ultracentrifugation followed the same pattern as the second human pregnancy plug 
ultracentrifugation in that there was a distinct mucin rich peak and low protein content (Habte 
et al., 2008).  
After two caesium chloride density gradient ultracentrifugations, aliquots of cervico-vaginal 
mucin were eluted through a Sepharose 2B column. Previous researchers have used Sepharose 
2B gel filtration for human cervical pregnancy mucus so Sepharose 2B was assessed to be 
adequate to separate high and low molecular weight PCM mucins (Carlstedt et al., 1983b). The 
glycoprotein and protein profile of the Sepharose 2B chromatography is shown in Figure 6.3. 
The V0 has a distinct mucin rich peak and the high protein stain in the Vi may again (as seen 
previously in Figure 3.3) be explained by mucin interference pattern of the protein stain 
detecting mucins rather than the presence of lingering protein contamination in the sample 
(Mall et al., 1988).  
Figure 6.4 shows the protein staining pattern of PCM derivatives under SDS-PAGE (4 – 20%) 
gradient gel electrophoresis. Crude pig cervico-vaginal mucus (Figure 6.4, lane 2) showed 
bands at the top of the gel, at the start of the running gel, just below 58kDa and at the bottom 
of the gel (see red boxes). After two density gradient ultracentrifugations (Figure 6.4, lane 3), 
there were lighter bands in the same positions as Figure 6.4, lane 2 (see red boxes). After the 
ultracentrifugations (Figure 6.4, lane 3) PCM showed more bands and a darker protein smear 
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than purified PGM (Figure 3.4, lane 3) Figure 6.4, lane 4 shows the eluted V0 fraction from a 
Sepharose 2B column. The faint banding is due to very little sample being present in the lane 
as the bulk of PCM V0 was used for the neutralization assay and MTT assay. PCM V0 was also 
subjected to repeat analysis on neutralization and MTT assays, this contributed to sample 
depletion. The smaller mucins and proteins eluted in the Vi (Figure 6.4, lane 5) shared the same 
banding pattern as DTT treated PCM V0 (Figure 6.4, lane 6). This indicates that larger mucins 
may have undergone degradation before being eluted in the Vi (Figure 6.4, lane 5) and when 
the V0 underwent disulphide bond breakage (Figure 6.4, lane 6) the same pattern was observed. 
The red boxes in Figure 6.4 lanes 5 and 6 show protein bands (between 46 – 58kDa) typically 
seen by the presence of albumin. In human crude cervical mucus, albumin is present at ~68kDa; 
the α-chain of IgA present just below 68kDa and the γ-chain of IgG is present at ~56kDa (Van 
Kooij et al., 1983). A similar protein blob was seen in PSM Vi at ~46kDa (Figure 5.6, lane 4). 
The proteins present in red boxes of Figure 6.4 lanes 5 and 6 were not identified as this lay 
outside the scope of our study. Trypsin treatment of the naked regions of PCM V0 (Figure 6.4, 
lane 7) resulted in the appearance of protein bands from 11 – 80kDa (see red box) and the 
absence of mucins at the top of the running gel (previously seen in Figure 6.4 lanes 1, 2, 5 and 
6). This may suggest that there were more naked regions and PCM V0 had little glycosylation 
to protect the mucin from the proteolytic action of trypsin. Trypsin treatment of PCM V0 
(Figure 6.4, lane 7) resulted in a fainter protein smear than trypsin treated PGM (Figure 3.4, 
lane 7) and PSM (Figure 5.6, lane 7). The glycoprotein stain of PCM derivatives showed mucin 
smears in the stacking gel and at the start of the running gel (Figure 6.5, lanes 1 – 6). This was 
a pattern seen in PGM (Figure 3.5, lanes 1 – 6) and PSM (Figure 5.7, lanes 1 – 6) PAS stains, 
but PCM derivatives (Figure 6.5, lanes 1 – 6) showed no bands like those exhibited by PSM 
(Figure 5.7, lanes 1 – 2, 4 – 6). Our slot blots were unsuccessful as the antibodies available to 
us were raised against human mucins. Pig antibodies were unavailable due to logistic issues as 
suppliers who did have pig mucin antibodies did not ship to South Africa.  
6.2.2 Pseudoviral Assay of PCM Derivatives 
We tested the anti-HIV-1 potential of PCM derivatives on a pseudoviral assay and all 
derivatives showed inhibition. The affect cervico-vaginal mucus had on HIV-1 was previously 
studied by Lai et al (2009). In 2009, Lai et al (2009) performed experiments on cell free HIV 
diffusion through normal human cervico-vaginal mucus (CVM). They then mixed an HIV 
virus-like particle (VLP) incorporated with a green fluorescent protein (GFP) fused Vpr 
(Campbell et al., 2007) with undiluted CVM and tracked the virions with high-resolution 
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multiple-particle tracking (Lai et al., 2007; Suh et al., 2005). Their results showed that not only 
did healthy CVM slow HIV diffusion over a 1000-fold when compared to water, but HIV 
diffusion was better at low pH rather than neutral (Lai et al., 2009). 
Habte et al (2008) previously tested the anti-HIV-1 Subtype D activity of crude and purified 
human pregnancy plug mucins by incubating them (0.9mg of each) with HIV-1 for an hour and 
then incubated on a human T lymphoblastoid cell line (CEM SS cells). HIV-1 infection was 
measured by the p24 antigen assay. Our study tested PCM derivatives on replication defective 
HIV-1 Subtype C. Crude PCM had the highest IC50 (128.4µg/ml, see Table 6.1) followed by 
the low molecular weight fraction eluted off the Sepharose 2B column (PCM Vi IC50: 
72.12µg/ml, see Table 6.1). Purifying PCM with two density ultracentrifugations enhanced 
HIV-1 inhibition almost 13-fold from crude PCM (IC50: 10.32µg/ml, see Table 6.1). Isolating 
the larger mucin fraction eluted off a Sepharose 2B column (PCM V0: 8.974µg/ml, see Table 
6.1) gave the lowest IC50 which was marginally better than purified PCM (purified PCM IC50: 
10.32µg/ml, see Table 6.1). Removing disulphide bonds from the PCM V0 lowered inhibition 
by over 50% (PCM V0: 8.974µg/ml; DTT treated PCM V0: 18.92µg/ml, see Table 6.1) 
indicating the importance of PCM V0 keeping a longer structure to ensure maximum inhibition. 
A similar effect was seen in trypsin treated PCM V0 (12.90µg/ml, see Table 6.1) i.e. the shorter 
PCM structure lowered HIV-1 inhibition but Figure 6.6, F shows the gradient of the dose 
response curve to be in the opposite direction of the other curves. If this is not the result of 
experimental error the it would suggest trypsin treated PCM V0 increased infection at higher 
concentration. This requires further investigation. Habte et al (2008) reported 97.5% inhibition 
by 0.9mg purified human pregnancy plug mucins on HIV-1 Subtype D infection whereas we 
showed 1.04mg of purified PCM inhibited HIV-1 Subtype C by 97.78% (data not shown). The 
larger mucin components had the better IC50 values but removing the disulphide bonds and 
naked proteins had little effect on the IC50. The 95% confidence intervals for purified PCM 
(2.520 to 42.23µg/ml, see Table 6.1), PCM V0 (5.055 to 15.93µg/ml, see Table 6.1), DTT 
(7.014 to 51.01µg/ml, see Table 6.1) PCM V0 were narrow and this can be interpreted as true 
inhibitory effect of HIV-1. Purified PCM (IC50: 10.32µg/ml, see Table 6.1) and PCM V0 (IC50: 
8.974µg/ml, see Table 6.1) showed lower IC50 values than the best inhibitors from PSM 
derivatives (PSM V0 IC50: 23.61µg/ml; DTT treated PSM V0 IC50: 20.79µg/ml, see Table 5.1) 
and were comparable to purified PGM (IC50: 10.50µg/ml, see Table 4.1) but higher than PGM 




6.2.3 Toxicity Assay of PCM Derivatives 
To assess the validity of our inhibition data, PCM derivatives were run on an MTT assay to 
determine if the PCM derivatives were toxic to the TZM-bl target cells. All PCM derivatives 
apart from crude PCM, had high LD50 values. The highest LD50 was shown by purified PCM 
(4 060µg/ml, see Table 6.2) and crude PCM showed poor percentage cell viability values 
(crude PCM at 168.13µg/ml showed 66.93% cell viability (see Table 6.2)). The toxicity data 
from this part of the study shows that the inhibition data from all PCM derivatives (apart from 
crude PCM) can be trusted. 
The results from this chapter indicate that PCM derivatives can be used for HIV-1 research and 
have the potential to inhibit HIV-1 in vitro. If a PCM derivative were to be used for an anti-
HIV-1 gel, the most likely candidates (based on IC50 and LD50 values) would be purified PCM 
and PCM V0. From these two derivatives (purified PCM and PCM V0) purified PCM was 
chosen to progress to the anti-HIV-1 gel part of our study as the sample yield was higher, and 
that was crucial as gels were created at a concentration of 30mg of mucin per 1ml of buffer.
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CHAPTER 7: THE EFFECT OF HORSE SALIVARY MUCIN (HSM) ON HIV-1 IN VITRO 
 
7.1 Results 
7.1.1 Sepharose 4B Column Chromatography of Horse Saliva 
Horse saliva was collected in 6M guanidine hydrochloride with protease inhibitors (viz. 10mM 
Na2HPO4, 10mM EDTA, 1mM PMSF and 5mM NEM) (see Appendix section 1.1) as the 
sample had to be stored by Ms Heather Epstein (who runs a farm) and lived far away. Samples 
were pooled and centrifuged to eliminate contaminants. Thereafter, the supernatant was 
dialysed against distilled water over three changes for a minimum of 6 hours each at 4oC and 
then freeze dried. Aliquots of lyophilized crude saliva were dissolved in 0.2M NaCl:0.02% 
sodium azide and eluted on a Sepharose 4B column (eluting buffer was also 0.2M NaCl:0.02% 
sodium azide). Horse saliva samples shared a similar profile with each other after Sepharose 
4B column chromatography. Figure 7.1 is a representative sample of protein and glycoprotein 
distribution after HSM was run on the Sepharose 4B column. 
 
 
Figure 7.1 Sepharose 4B separation profile of HSM in 0.2M NaCl:0.02% sodium azide. Lyophilized 
crude horse saliva was dissolved in 0.2M NaCl:0.02% sodium azide (4:1) and eluted through a 
Sepharose 4B glass column under peristaltic pressure. Every second fraction was tested for proteins and 
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content was identified using a PAS assay ( ). The box on the X-axis represents fractions that were 
pooled.  
 
The samples had two distinct peaks denoting the presence of two sizes of mucins present in the 
sample. The first PAS positive peak eluted in the V0 of the column (fractions 32 – 44), 
suggesting the presence of large polymeric mucins in the purified sample. These fractions were 
where the void volume usually eluted. The second PAS positive peak was observed in the Vi 
(fractions 50 – 54). The PAS positive Vi peak is indicative of some smaller mucins present in 
saliva. The V0 and Vi fractions were then dialysed against distilled water over three changes 
for a minimum of 6 hours each at 4oC and then freeze dried. For this study, we were interested 
in the large mucins present in the V0. Thus, the V0 fractions were set up for further purification. 
7.1.2 Ultracentrifugation of HSM V0 
Aliquots of V0 were dialysed against 3 changes of 4M GuHCl (see Appendix section 1.3) at 6 
hour intervals. The volume of 4M GuHCl was at least 20 times the volume of V0. The density 
was adjusted and samples ultracentrifuged as stated in section 2.4. Figure 7.2 shows the protein, 
glycoprotein and density profiles of a representative sample.  
 
 
Figure 7.2 Ultracentrifugation profile of HSM. PSM V0 was dialysed against 4M GuHCl. Samples then 
had their densities adjusted to 1.39g/ml with caesium chloride and 4M GuHCl. They were then 
subjected to a 48-hour ultracentrifugation at 105 000g at 4oC. Protein content was determined using 
Bradford Reagent assay ( ); glycoprotein content was identified using a PAS assay ( ) and the 
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collected for dialysis against distilled water over three changes of a minimum of 6 hours each at 4oC 
and freeze dried. 
 
Fractions that had high glycoprotein content and a density of 1.40 – 1.41g/ml were pooled. In 
Figure 7.2 fraction 5 and 6 were pooled. They were then dialysed against distilled water over 
three changes for a minimum of 6 hours each at 4oC and then freeze dried. There was a high 
protein content throughout all the fractions. 
7.1.3 Slot Blot of HSM V0 
The presence of Muc19 in horse saliva was confirmed by proteomic analysis carried out by 
Rousseau et al (2008). Aliquots of the Sepharose 4B column V0 from Figure 7.1 (fractions 32 
– 44) were set up for Muc5b and Muc19 slot blot analysis (see section 2.12). Due to limiting 
amounts of anti-horse Muc19 antibody, only the fractions corresponding to the V0 peak was 
assessed under slot blot analysis. Information on the Muc5b and Muc19 antibodies used for the 
dot blot can be seen in Appendix Table 1. Figure 7.3 shows the results of slot blot analysis on 
the V0 fractions.  
 
 
Figure 7.3 Slot blot analysis of Muc19 and Muc5b in HSM V0. HSM was run on a Sepharose 4B column 
under peristaltic pressure (see Figure 7.1). The V0 fractions then underwent slot blot analysis to 
determine the presence of Muc19 and Muc5b. Figure 8.3 is divided into three panels. The top panel 
shows the fraction number. The second panel from the top shows the expression of Muc19.  The bottom 
panel shows the presence of Muc5b. 
 
Figure 7.3 shows fractions 32 to 44 analysed by Slot blot. Fractions containing Muc19 only 
were 32 – 34 and 42 – 44 were pooled for a total Muc5b-Muc19+ representation. They were 
then dialysed against distilled water over three changes for a minimum of 6 hours each at 4oC 




7.1.4 Ultracentrifugation of HSM V0 Muc19 
Aliquots of freeze dried HSM Muc19 mucin were dissolved in 4M GuHCl. The density of the 
sample was adjusted to 1.41g/ml and subjected to a 48-hour ultracentrifugation at 105 000g at 
4oC. Figure 7.4 shows the protein, glycoprotein and density profiles of a representative sample. 
 
 
Figure 7.4 Ultracentrifugation profile of horse salivary Muc19. Pig salivary mucus was passed through 
a Sepharose 4B column and the V0 was pooled and dialysed against distilled water over three changes 
for a minimum of 6 hours each at 4oC. Freeze dried HSM Muc19 was dissolved in 4M GuHCl. Samples 
then had their densities adjusted to 1.39g/ml with caesium chloride and 4M GuHCl, before undergoing 
ultracentrifugation for 48 hours at 105 000g at 4oC. Protein content was determined using Bradford 
Reagent assay ( ); glycoprotein content was identified using a PAS assay ( ) and densities ( ) were 
recorded on the secondary axis. The box on the X-axis represents the fractions collected and dialysed 
against distilled water and freeze dried. 
 
Fractions that had glycoprotein rich densities of 1.39g/ml to 1.41g/ml were pooled. In Figure 
7.4 fractions 4 – 6 were pooled. These samples were dialysed against 3 changes of distilled 
water for 6 hours each, then freeze dried for further investigation. 
7.1.5 HSM Derivatives Inhibits HIV-1 on a Pseudoviral Assay 
We measured the ability of HSM derivatives to inhibit HIV-1 entry into a model target cell 
line, TZM-bl on a pseudoviral assay (Montefiori, 2009). Data recorded from a luminometer 
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negative and positive controls. This data was put into Graphpad Prism Version 6 to construct 
Log Dose Response Curves (Figure 7.5). From these curves IC50 values were calculated. 
 
 
Figure 7.5 Dose response curves of HSM derivatives. A, crude horse saliva; B, HSM V0 eluted from 
Sepharose 4B column chromatography and subjected to density gradient ultracentrifugation (Muc5b 
and Muc19); C, HSM Vi eluted from Sepharose 4B column chromatography (Muc7) and D, HSM V0 
Muc19 eluted from Sepharose 4B column chromatography. 
. 
Crude HSM (Figure 7.5 A) showed substantial deviation from the modelled inhibition curve. 
HSM V0, HSM Vi and HSM Muc19 showed points close to the solid line which corresponds 
to the best model of an inhibition curve. Table 7.1 shows the calculated 95% confidence 
interval of the IC50 value based upon the level of deviation of the points from the modelled 
inhibition curve. 
Table 7.1 Showing the calculated HSM IC50’s and 95% Confidence Intervals 
Horse Salivary Mucin Derivative IC50 (µg/ml) 95% Confidence Intervals (µg/ml) 
Crude HSM 51.32 6.060 to 434.7 
HSM V0 (Muc5b and Muc19) 76.35 40.27 to 144.8 
HSM Vi  841.8 516.4 to 1372 




All HSM derivatives showed HIV-1 inhibition in vitro. The most reliable data came from the 
HSM V0 (95% Confidence intervals: 40.27 to 144.8µg/ml) and Vi (95% Confidence intervals: 
516.4 to 1372µg/ml). The least reliable data was seen in crude HSM (95% Confidence 
intervals: 6.060 to 434.7µg/ml) and HSM Muc19 (95% Confidence intervals: 35.03 to 
496.8µg/ml). Crude HSM showed the best inhibition (IC50: 51.32µg/ml) but it’s wide 95% 
confidence intervals indicated that the true inhibitory effect of crude HSM could not be seen in 
this experiment. HSM V0 showed the second-best inhibition (IC50: 76.35µg/ml) but showed 
tighter 95% confidence intervals (40.27 to 144.8µg/ml) indicating that the inhibition shown by 
HSM V0 was reliable. The IC50 of the HSM Vi, presumably Muc7, (IC50: 841.8µg/ml) showed 
the least inhibitive potential, in fact the IC50 was over 16 times that of crude HSM IC50 (crude 
HSM IC50: 51.32µg/ml). The IC50 of HSM Muc19 (IC50: 131.9µg/ml) was almost twice the 
IC50 of HSM V0 (HSM V0 IC50: 76.35µg/ml) and almost three times that of the crude (crude 
HSM IC50: 51.32µg/ml). 
7.1.6 Toxicity Assay of HSM Derivatives 
Crude HSM, HSM V0 having undergone density gradient ultracentrifugation (Muc5b and 
Muc19), HSM Vi (Muc7) and HSM V0 Muc19 (having undergone density gradient 
ultracentrifugation) were tested for cell toxicity using an MTT assay (see section 2.13). Table 
7.2 shows the results of this MTT assay. 
Table 7.2. Results of HSM Derivatives on MTT Assay 
Horse Salivary Mucin 
Derivative 




Crude HSM Curve did not 
converge 
71.88 98.85 
HSM V0 737   
HSM Vi ~986.1   
HSM Muc19 59.79   
 
LD50 values were calculated for HSM V0, HSM Vi, and HSM Muc19 but not for crude HSM. 
For crude horse saliva, the percentage cell viability quoted was at the nearest concentration to 
the crude HSM IC50 value (crude HSM IC50: 51.32µg/ml). Crude HSM showed good 
percentage cell viability (at 71.88µg/ml there was a 98.85% cell viability). The mucin-rich low 
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molecular weight fraction eluted from a Sepharose 4B column showed the highest LD50 value 
(HSM Vi LD50: ~986.1µg/ml) followed by the void volume eluted from the Sepharose 4B 
column (HSM V0 LD50: 737µg/ml). The lowest LD50 value was shown by HSM Muc19 (HSM 
Muc19 LD50: 59.79µg/ml). 
7.2 Discussion 
7.2.1 Purification and Treatment of HSM 
This part of our study looks at the possibility of using HSM derivatives as an alternative to 
human mucin. HSM was chosen as an alternative to human saliva due to the presence of large 
polymeric Muc19 in horse saliva (Rousseau et al., 2008). Horse saliva is comprised of over 
99% water (Alexander, 1966). It contains more chloride and calcium and less bicarbonate and 
sodium than ruminants. This gives horse saliva the characteristics of carnivora and omnivora 
(Alexander et al., 1970; Stick et al., 1981). Unlike carnivora and omnivora, horse saliva 
contains almost no digestive enzymes (e.g. amylase is detected at 0.44 enzyme units per ml) 
suggesting horse saliva does not play an important role in digestion but rather in lubrication 
(Varloud, 2006). Horse saliva contains less than 10 colony forming units of total bacteria per 
ml (Varloud, 2006). Adult horses can secrete from 35 – 40L a day (primarily from the parotid 
salivary gland), with a pH of 8.6 – 9.1 (Meyer et al., 1985; Moeller et al., 2008; Stick et al., 
1981). The rate of salivary secretion increases when the horse is stimulated by food intake and 
mastication (Meyer et al., 1985; Meyer et al., 1986). Horse saliva collected for this study was 
collected during mastication to ensure maximum sample yield.  
Rousseau et al (2008) performed proteomic analysis on horse saliva to determine the presence 
of large polymeric mucins. Rousseau et al (2008) collected horse saliva in 8M GuHCl (in the 
absence of protease inhibitors), adjusted densities to 1.41g/ml by the addition of caesium 
chloride and 4M GuHCl and ultracentrifuged samples at 40 000rpm for at least 68 hours (at 
15oC). Centrifuging at 15oC may have caused degradation to mucin structure. The density 





Figure 7.6 Purification of horse mucins from Rousseau et al (2008). Horse saliva collected in 8M GuHCl 
had their density adjusted to 1.4g/ml with caesium chloride and 4M GuHCl. They were then subjected 
to an ultracentrifugation for at least 68 hours at 40 000rpm at 15oC. Glycoprotein content was identified 
using a PAS assay ( ) and the densities ( ) were recorded on the secondary axis. Fractions 10 – 16 
were pooled and collected for proteomic analysis. 
Glycoprotein rich samples were then pooled, reduced, carboxymethylated, digested with 
trypsin, dialysed against water and freeze dried (Rousseau et al., 2008). When we compare our 
ultracentrifugation profile (Figure 7.2) with the profile of Rousseau et al (2008) there is a major 
difference. The profile of Rousseau et al (2008) HSM ultracentrifugation shows a distinct PAS 
positive peak from fractions 10 – 16, whereas our ultracentrifugation profile (Figure 7.2) did 
not show a distinct peak.  The difference may be explained by the methods chosen. Our method 
differed in that we ultracentrifuged the HSM V0 fraction, and where we divided our samples 
into 9 fractions, Rousseau et al (2008) fractioned their samples into 20. Mucins were then 
identified using tandem mass spectrometry on a quadropole-time-of-flight micromass 
spectrometer. Rousseau et al (2008) showed that horse saliva contains a mixture of two 
polymeric mucins namely, Muc5b and Muc19.  
Our laboratory has previously eluted human saliva through gel filtration (Sepharose 2B) with 
0.2M NaCl: 0.02% sodium azide (Peacocke et al., 2012). Figure 7.1 shows the Sepharose 4B 
profile of HSM eluted with the same buffer i.e. 0.2 M NaCl: 0.02% sodium azide. The protein 
and glycoprotein profile of HSM eluted Sepharose 4B column showed similarities to human 
salivary mucin eluted on the same column (Peacocke et al., 2012) with respect to the presence 
of two distinguishable mucin-rich peaks (designated V0 and Vi respectively). Figure 7.1 shows 
two glycoprotein rich peaks denoting two sizes of mucins present. The proteins were small 
enough to be eluted just after the Vi. The separation between the HSM V0 and Vi was a lot 
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closer than the Sepharose 4B separation of PSM V0 and Vi (Figure 5.3). Aliquots of the 
Sepharose 4B V0 from Figure 7.1 was analysed on a slot blot. This method to identify fractions 
with Muc19 only contrasted with section 5.1.1.3 for PSM V0 Muc19. This was due to limited 
availability of horse saliva. Each fraction was then subjected to slot blot analysis using human 
antibodies raised to Muc5b and horse antibodies raised to Muc19 (Figure 7.3, see Appendix 
for dilutions). The few fractions that did contain Muc19 were collected and dialysed against 3 
changes of distilled water for 6 hours each, then freeze dried for further investigation. When 
we compare the Muc19 slot blot analysis of HSM (Figure 7.3) and PSM (Figure 5.4) we can 
see that there is stronger MUC19 expression in PSM V0 (Figure 5.4). 
SDS-PAGE gel electrophoresis could not be performed on HSM derivatives as samples were 
used entirely for the replicate rounds of pseudoviral and MTT assays. Palm et al (2016) ran 
crude pooled saliva (centrifuged at 470g for 5 mins to remove debris) from 15 healthy horses 
on a 6% SDS-PAGE gel and stained with Coomassie brilliant blue (CBB). CBB binds to 
proteins by heteropolar and hydrophobic interactions with basic amino acids (Georgiou et al., 
2008). CBB staining of crude horse saliva showed a smearing effect typical of mucins with 
protein bands present at ~440kDa (Palm et al., 2016). Western blot revealed the presence of 
IgA and to a lesser extent IgG (Palm et al., 2016). Sousa-Pereira et al (2015) ran crude saliva 
(centrifuged at 12 000g for 10 mins at 4oC to remove debris) on an 8 – 16% gradient 
polyacrylamide gel and stained with a modified CBB to enhance protein detection (Candiano 
et al., 2004).  They found multiple protein bands from <5 – 250kDa and identified 103 protein 
families through liquid chromatography–mass spectrometry (Sousa‐Pereira et al., 2015). 
Among the protein families found was Latherin (which aids mastication), Cas (zinc 
metalloenzymes that convert carbon dioxide to bicarbonate), Casein (protein family of 
phosphoproteins) and CRISP3 (a protein with antimicrobial properties) (Haendler et al., 1999; 
McDonald et al., 2009; Sousa‐Pereira et al., 2015; Tashian, 1989). 
7.2.2 HSM Inhibits HIV-1 in vitro 
All HSM derivatives (crude HSM, HSM V0, HSM Vi and Muc19) showed HIV inhibition. 
Figure 7.5 shows the inhibition curves of HSM on HIV-1 inhibition in vitro and Table 7.1 
shows the IC50 values based upon the level of deviation of the points from the modelled 
inhibition curve. Crude HSM showed the best inhibition (IC50: 51.32µg/ml, see Table 7.1) but 
the 95% confidence intervals (6.060 to 434.7µg/ml, see Table 7.1) were too wide for this result 
to be reliable. The next best inhibition came from the large molecular weight fraction eluted 
from a Sepharose 4B column (HSM V0 IC50: 76.35µg/ml, see Table 7.1). This data was more 
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reliable as there were tighter confidence intervals (HSM V0 95% confidence interval: 40.27 to 
144.8µg/ml, see Table 7.1) indicating the this was a true effect of inhibition. The low molecular 
weight fraction eluted from the Sepharose 4B column showed inhibition but had the highest 
IC50 value of the HSM derivatives (HSM Vi IC50: 841.8µg/ml, see Table 7.1). Peacocke et al 
(2012) showed both the high and low molecular weight fraction (MUC5B and MUC7 
respectively) eluted from a Sepharose 4B column inhibited pseudoviral HIV-1 subtype C 
Du422.1 infection in vitro with MUC5B showing marginally better inhibition (Peacocke, 
2011). While HSM V0 did show the better inhibition in our studies the key difference in our 
samples is that HSM V0 contains a mixture of Muc5b and Muc19 (Rousseau et al., 2008) and 
when separated, HSM Muc19 on its own showed an almost 100% reduction in HIV-1 inhibition 
(HSM Muc19 IC50: 131.9µg/ml, see Table 7.1). This data suggests that the combination of 
HSM Muc5b and Muc19 is more efficient but further experiments are required to assess the 
action of HSM Muc5b on HIV-1 as separation of Muc5b and Muc19 in this study proved 
problematic (data not shown). When we compare the best and most reliable HIV-1 inhibitor 
from the HSM derivatives i.e. HSM V0 (IC50: 76.35µg/ml, see Table 7.1) we can see that it’s 
IC50 value is over 45 times higher than PGM V0 (IC50: 1.668µg/ml, see Table 4.1), over three 
times higher than DTT treated PSM V0 (IC50: 20.79µg/ml, see Table 5.1) and over eight times 
higher than PCM V0 (IC50: 8.974µg/ml, see Table 6.1). This shows that our HSM derivatives 
have the lowest inhibitive potential from the mucin sources in our study. 
7.2.3 Toxicity of HSM Derivatives 
To assess the validity of our inhibition data, HSM derivatives were run on an MTT assay to 
determine if the HSM derivatives were toxic to the TZM-bl target cells. LD50 values were 
calculated for all but the crude HSM samples. For crude HSM cell viability was quoted that 
was at a concentration close to crude HSM IC50 (IC50: 51.32µg/ml (see Table 7.1), percentage 
cell viability: 98.85% at 71.88µg/ml (see Table 7.2)). Crude HSM showed good percentage 
cell viability so the corresponding IC50 was deemed reliable (crude HSM IC50: 51.32µg/ml, see 
Table 7.1). The LD50 value for HSM V0 (HSM V0 LD50: 737µg/ml, see Table 7.2) was over 9 
times the corresponding IC50 value (HSM V0 IC50: 76.35µg/ml, see Table 7.1), indicating that 
HSM V0 inhibition data could be trusted. HSM Vi showed a high LD50 (HSM Vi LD50: 
~986.1µg/ml, see Table 7.2) but when compared to its corresponding IC50 (HSM Vi IC50: 
841.8µg/ml, see Table 7.1) value it could be seen that HSM Vi inhibitory effect may not be 
reliable. The LD50 value for HSM Muc19 (HSM Muc19 LD50: 59.79µg/ml, see Table 7.2) was 
under 50% of the corresponding IC50 (HSM Muc19 IC50: 131.9µg/ml, see Table 7.1) which is 
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a clear indication that the HSM Muc19 inhibitory data could not be trusted, as the mucin was 
toxic and killed the target cells before pseudoviral HIV-1 could infect target cells and promote 
luciferase expression. 
While horse saliva has big mucins (i.e. Muc19 and Muc5b), it does not inhibit HIV-1 as 
effectively as its pig counterpart or PGM. After our first findings of HSM V0 not being better 
than PSM V0, it was decided that their components would not undergo DTT or trypsin 
treatment. The effect DTT and trypsin would have on HSM and its effect on HIV-1 is a subject 
for further studies. The high IC50 values seen in HSM derivatives (when compared to PGM, 
PSM and PCM data), as well as saliva’s low viscosity compared to PGM and PCM, excluded 
horse saliva from mucin-derived gel analysis.  One explanation for HSM having high IC50 
values and lower cell survival may be due to the preparation, as HSM only underwent one 
round of density ultracentrifugation. This may have not been enough to fully eliminate 
contaminating and/or harmful proteins. Further studies are required to assess the effect of better 
purification of HSM and its effect on HIV in vitro.
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CHAPTER 8: THE ANALYSIS OF MUCIN DERIVED GELS ON HIV-1 IN VITRO 
 
Our study has shown the anti-HIV-1 potential of PGM, PSM, PCM and HSM in vitro. The 
next step was to construct a gel from the most abundant and effective sources (i.e. purified 
PGM and purified PCM). We then measured the ability of pig gastric and cervico-vaginal 
mucin-derived gels to inhibit HIV-1 entry into a model target cell line, TZM-bl (Montefiori, 
2009). 
8.1 Results 
8.1.1 Investigation of Gel Solutions on Pseudoviral Assay  
To create the gels, mucins were combined with solutions based on research done by Allen et 
al (1976) and Owen et al (1999). Four solutions were constructed in distilled water. These 
solutions were gel solution 1 (0.02M potassium acetate), gel solution 2 (0.2M potassium 
chloride), gel solution 3 (0.002% (w/v) sodium azide) and gel solution 4 which was a vaginal 
fluid simulant (0.351% sodium chloride, 0.14% potassium hydroxide, 0.0222% calcium 
hydroxide, 0.0018% bovine serum albumin, 0.2% lactic acid, 0.1% acetic acid, 0.016% 
glycerol, 0.04% urea and 0.5% glucose). All gels were adjusted to neutral pH to successfully 
use them on in vitro assays. The gel solutions were first tested on a pseudoviral assay and MTT 
assay in the absence of mucins to assess the solutions’ inhibitory potential and toxicity 
respectively, before the addition of mucins. Figure 8.1 shows the log dose response curves of 






             
 
Figure 8.1 Log dose response curves of gel solutions. A, gel solution 1: 0.02M potassium acetate; B, 
gel solution 2: 0.2M potassium chloride; C, gel solution 3: 0.002% (w/v) sodium azide, and D, gel 
solution 4: 0.351% sodium chloride, 0.14% potassium hydroxide, 0.0222% calcium hydroxide, 
0.0018% bovine serum albumin, 0.2% lactic acid, 0.1% acetic acid, 0.016% glycerol, 0.04% urea and 
0.5% glucose. 
 
Figure 8.1 shows the effect gel solutions had on HIV-1 inhibition before the addition of mucins 
to rule out that the inhibitory effects recorded were not due to the solution. Reliability of the 
dose response curves can be assessed visually by how close the points of the curve lie to the 
solid line, which corresponds to the best model of an inhibition curve. Gel solution 1 (Figure 
8.1 A) and gel solution 4 (Figure 8.1 D) showed substantial deviation for the modelled 
inhibition curve. Gel solution 4 also had a negative slope, which is the opposite of what we 
expect to see from our dose response curves. One interpretation of this is that with increasing 
concentration there was increased infection over and above the positive control (HIV-1 and 
TZM-bl cells alone). This may need to be confirmed in further investigations. Gel solution 2 


















Microlitre of Gel Buffer per millilitre of 10% DMEM 
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the calculated 95% confidence interval of the IC50 values based upon the level of deviation of 
the points from the modelled inhibition curve and the LD50 values from the MTT assay. 
Table 8.1 Results of Gel Solutions on Pseudoviral Assay and MTT Assay 
Component Pseudoviral Assay MTT Assay 
 IC50 (µg/ml) 95% Confidence Intervals (µg/ml) LD50 (µg/ml) 
Gel Solution 1 No Inhibition  0.01128 
Gel Solution 2 1.207 1.161 to 1.256 0.08 
Gel Solution 3 No Inhibition  0.01 
Gel Solution 4 4.544 0.3454 to 59.79 302.3 
 
Gel solutions 1 and 3 showed no inhibition on the pseudoviral assay and showed low LD50 
values (gel solution 1 LD50: 0.01128µg/ml; gel solution 3 LD50: 0.01µg/ml). This indicates that 
gel solutions 1 and 3 in the absence of mucins have a toxic effect on the TZM-bl cell line. Gel 
solution 2 had a low IC50 (IC50: 1.207µg/ml) and tight 95% confidence intervals (95% 
confidence intervals: 1.161 to 1.256 µg/ml) but showed toxicity as it showed a very low LD50 
(0.08µg/ml). Gel solution 4 showed a low IC50 (IC50: 4.544µg/ml) but exhibited wide 95% 
confidence intervals (0.3454 to 59.79µg/ml). Gel solution 4 did show a high LD50 
(302.3µg/ml). Figure 8.2 shows the log dose repose curves of these assays.   
8.1.2 Investigation of Mucin-Derived Gels on Pseudoviral Assay  
The next step was to combine mucins with the gel solutions and run them on pseudoviral and 
MTT assays. Mucins were dissolved with gel solutions (see Appendix Table 2.) at a ratio of 





           
 
Figure 8.2 Log dose response curve of mucin-derived gels. A, PGM in gel solution 1: 0.02M potassium 
acetate; B, PGM in gel solution 2: 0.2M potassium chloride; C, PGM in gel solution 3: 0.002% (w/v) 
sodium azide; D, PGM in gel solution 4: 0.351% sodium chloride, 0.14% potassium hydroxide, 
0.0222% calcium hydroxide, 0.0018% bovine serum albumin, 0.2% lactic acid, 0.1% acetic acid, 
0.016% glycerol, 0.04% urea and 0.5% glucose and E, PCM in gel solution 4: 0.351% sodium chloride, 
0.14% potassium hydroxide, 0.0222% calcium hydroxide, 0.0018% bovine serum albumin, 0.2% lactic 
acid, 0.1% acetic acid, 0.016% glycerol, 0.04% urea and 0.5% glucose. 
All points for mucin derived gels lay close to the solid line that corresponds to the best model 
of an inhibition curve. This indicated that the data for all mucin-derived gels were reliable. 
Table 8.2 shows the calculated 95% confidence intervals of the IC50 values based upon the 
level of deviation of the points from the modelled inhibition curve as well as calculated LD50 


























Table 8.2 Showing the Pseudoviral Assay IC50’s and MTT Assay Percentage Cell Viabilities of Mucin 
Derived Gels 

















PGM in Gel Solution 2 5.701 0.3401 to 95.57 134 845   
PGM in Gel Solution 3 71.10 54.01 to 93.59 ~17 204   
PGM in Gel Solution 4 20.23 9.566 to 42.76 525.4   
PCM in Gel Solution 4 248.9 234.9 to 263.8 2 088   
 
Inhibition was shown in all pig mucin-derived gels on the pseudoviral assay. PCM was 
combined with gel solution 4 only due to limited PCM sample yield. PGM in gel solution 2 
showed the best inhibition (IC50: 5.701µg/ml) but had a wide 95% confidence interval (0.3401 
to 95.57µg/ml) indicating that we cannot assess the true inhibitory effect of PGM in gel solution 
2. PGM in gel solution 4 showed the second-best inhibition (IC50: 20.23µg/ml) and a tight 95% 
confidence interval (9.566 to 42.76µg/ml). PGM in gel solution 4 had a high LD50 (525.4µg/ml) 
and this indicated the inhibition data as being reliable. PCM in gel solution 4 showed the 
highest IC50 (IC50: 248.9µg/ml) from all the mucin gels and had a high LD50 (2 088µg/ml).  
8.1.3 Probing of the Mucus Gel Mesh to Determine Structural Arrangement and Tracking of 
Fluorescently Labelled HIV 
Following the results of section 8.1.1 PGM in gel solution 4 was assessed to be the best 
inhibitor of HIV-1 in vitro and thus progressed to further investigation. Initial studies have been 
performed by the Lai laboratory on PGM in gel solution 4 and it showed the virus was retarded 
at pH 4 rather than at pH 7. Real trapping/immobilization of the pseudovirus was not seen with 
either condition. The PEG-coated beads were slowed substantially, perhaps to a comparable 
extent as similar sized but typically muco-sticky carboxylated latex beads. These experiments 
are currently being repeated and further assessed. As these experiments are time consuming 




8.2.1 The Inhibition of HIV-1 by Mucin-Derived Gels 
The final part of my study investigates the effect of mucin-derived gels on HIV-1 in vitro. To 
our knowledge this is the first time that pig mucins have been used in the context of an anti-
HIV-1 gel in vitro. The difficulty of working with gels on the pseudoviral assay is the gel 
blocking media and cell interactions. This problem was alleviated through serial dilution.  
In 1976, Allen et al published a paper describing how glycoproteins form a gel in vivo while 
being semi-permeable to proteolytic enzymes. They performed viscosity studies at varying 
concentrations on PGM in three solutions namely,  0.2M potassium chloride 0.02% sodium 
azide; 0.02M potassium acetate buffer, pH 5.5 (Allen et al., 1976). From the PGM in solution 
data Allen et al (1976) determined PGM’s effective hydrodynamic volume, and showed PGM 
concentration above 20 – 25mg/ml resulted in gel formation and the average glycoprotein 
concentration found in stomachs is ~30 – 40mg/ml.  
Using the results of Allen et al (1976) we constructed our first set of gels from the most 
abundant available source, namely purified PGM. PGM was diluted at 30mg/ml with the same 
solutions (gel solution 1: 0.02M potassium acetate; gel solution 2: 0.2M potassium chloride; 
gel solution 3: 0.02% sodium azide). In the absence of pig mucins, gel solutions 1 and 3 showed 
no inhibition, where gel solution 2 did inhibit HIV-1 (gel solution 2 IC50: 1.207µg/ml, see Table 
8.1) but it had a very low LD50 (0.08µg/ml, see Table 8.1) which indicates that the low 
inhibition may have been due to the solution being toxic to the target cells, allowing less cells 
to produce luciferase.  
Addition of pig mucins brought about inhibition in the presence of all solutions. PGM in gel 
solution 2 gave the lowest IC50 (gel solution 2 IC50: 5.701µg/ml, see Table 8.2) and despite 
having a high LD50 (gel solution 2 LD50: 134 845µg/ml, see Table 8.2) gel solution 2 had a 
very wide 95% confidence interval indicating that in this study the true inhibitory effect cannot 
be determined. The next lowest IC50 was shown by PGM in gel solution 1 (PGM in gel solution 
1 IC50: 56.19µg/ml, see Table 8.2) and then PGM in gel solution 3 (PGM in gel solution 3 IC50: 
71.10µg/ml, see Table 8.2) with tight 95% confidence intervals (PGM in gel solution 1 95% 
confidence interval:  31.00 to 101.9µg/ml; PGM in gel solution 3 95% confidence interval: 
54.01 to 93.59µg/ml, see Table 8.2). PGM in gel solution 1 showed good percentage cell 
viability (at 140.63µg/ml there was 84.62% cell viability, see Table 8.2) and PGM in gel 
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solution 3 had a high LD50 indicating that both the gels were not toxic to the TZM-bl cell lines 
and that our IC50 data can be trusted.  
Previous research into the anti-viral effect of PGM involved testing commercial PGM mixed 
with a basal lamina gel matrix (Lieleg et al., 2012). Lieleg et al (2012) used a 1% 
(weight/volume) mucin in gel solution and tested it against HPV (on a HeLa cell line), 
Influenza H1N1 strain (on a MDCK cell line) and MCV (on an A549 cell line).  They reported 
their data in terms of percentage infected cells, and for HPV: ~5.6% infection; Influenza H1N1: 
~1.2% and finally for MCV: ~3.2%. Percentage infected cells data were not shown for our 
samples in this thesis due to the large volume of data calculated, but percentage infected cells 
and percentage neutralization data were used to calculate the IC50 values. Our data showed 
comparative results for two PGM in gel solutions (PGM in gel solution 2: 3.23% infected cells 
and PGM in gel solution 3: 6.47% infected cells (data not shown)) and PGM in gel solution 1 
showed over two-fold percentage infected cells (PGM in gel solution 1: 13.25% (data not 
shown)). It is important to note one large difference between the studies, is the solution added. 
Lieleg et al (2012) used a basal lamina matrigel that is a subtype of extracellular matrix, 
whereas this part of our study used biochemical gels to see if neutralization was possible. 
Despite using biochemical i.e. non-physiological solutions, we showed good inhibition and 
proved that our mucins were ready for the next stage of gel research. 
The successful results of this study thus far prompted us to find a solution to be added to our 
pig mucins that mimicked the cervico-vaginal mucus make up. The solution chosen was 
developed by Owen and Katz (1999) to imitate the fluid produced in the human vagina. They 
reviewed literature on human vaginal secretions, considering interactions with therapeutic, 
prophylactic and contraceptive products, including pH. Owen and Katz (1999) formulated that 
in 1L of vaginal fluid simulant (pH 4.2) there were: 3.51g NaCl, 1.4g KOH, 0.222g Ca(OH)2, 
0.018g bovine serum albumin, 2g lactic acid, 1g acetic acid, 0.16g glycerol, 0.4g of urea and 
5g glucose. 
The simulated vaginal fluid (gel solution 4) on its own showed inhibition of HIV-1 in the 
neutralization assay (gel solution IC50: 4.544µg/ml, see Table 8.1) and despite having a high 
LD50 (gel solution 4 LD50: 302.3µg/ml, see Table 8.1) it had a wide 95% confidence interval 
(0.3454 to 59.79µg/ml, see Table 8.1). This indicated that the true HIV-1 inhibitory effect of 
gel solution 4 was unreliable. After the addition of PGM to gel solution 4, the IC50 (20.23µg/ml, 
see Table 8.2) was higher than gel solution 4 alone but had a narrower 95% confidence interval 
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(9.566 to 42.76µg/ml, see Table 8.2) showing more reliability of inhibition data. PGM in gel 
solution 4 also had a high LD50 (525.4µg/ml, see Table 8.2) indicating that the inhibition data 
was not influenced by toxicity. PCM addition to Gel Solution 4 gave a higher than 12-fold IC50 
(248.9µg/ml, see Table 8.2), very tight 95% confidence interval (PCM in gel solution 4 95% 
confidence interval: 234.9 to 263.8µg/ml, see Table 8.2) and a high LD50 value (PCM in gel 
solution 4 LD50: 2 088µg/ml, see Table 8.2). PGM in gel solution 4 displayed a higher IC50 
(20.23µg/ml, see Table 8.2) than PGM alone (1.668µg/ml, see Table 4.1). This lowering of 
inhibition may be due to the gel solution components masking or diluting the full inhibitory 
potential of PGM.  
When the mucins in gel solution 4 data was compared to the Lieleg et al (2012) study, our 1% 
mucin derived gels displayed percentage infections like HPV penetration of PGM in matrigel 
(~5.6%). At 1% PGM in Gel Solution 4, there is 6.33% (data not shown) infection and the 
corresponding PCM in Gel Solution 4 allowed 5.96% infection (data not shown). Future studies 
may be to combine our PGM and PCM with matrigel as a direct comparison to Lieleg et al 
(2012) on our neutralization assay. 
When comparing our PGM derivatives and anti-HIV-1 mucin-derived gels to candidate 
microbicides, we see varying results. Microbicide gel studies are mostly tested on animal 
models and animal studies were outside the scope of this project but may be covered in future 
projects. The subsequent studies mentioned all tested compounds diluted with media (PBS or 
DMEM) against HIV-1 in in vitro assays like the pseudoviral assay used in this study unless 
otherwise stated.  
Tao et al (2007) assessed the ability of sodium rutin sulphate, a sulphated rutin enhanced from 
the natural flavonol glycoside rutin, to inhibit HIV-1 subtype B. They measured inhibition on 
a TZM-bl cell luciferase gene reporter assay like our assay and a p24 ELISA assay. They found 
that sodium rutin sulphate had an IC50 of 11.99µg/ml (Tao et al., 2007). This IC50 value is 
almost half of our PGM in gel solution 4 (IC50: 20.23µg/ml, see Table 8.2) and 20 times lower 
than PCM in gel solution 4 (IC50: 248.9µg/ml, see Table 8.2). PGM V0 (IC50: 1.668µg/ml, see 
Table 4.1) and PCM V0 (IC50: 8.974µg/ml, see Table 6.1) showed marginally better inhibition 
than sodium rutin sulphate (IC50: 11.99µg/ml). O’Keefe et al (2009) assessed the ability of 
plant produced Griffithsin to inhibit HIV-1 Subtype C Du156.12 on TZM-bl cells in a 
pseudovirus-based neutralization assay like the one used in our study. Griffithsin showed a 
very low IC50 value (IC50: <0.003µg/ml), and inhibited HIV-1better than all our PGM 
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derivatives and mucin-derived gels (O'Keefe et al., 2009). One advantage PGM derivatives or 
mucin-derived gels have over plant produced Griffithsin is that mucins form part of the innate 
immune system and may enhance vaginal protection against HIV-1. Alcami et al (2014) tested 
5-Hydroxytyrosol, a natural compound that has been shown to possess biochemical activity, 
against HIV integrase and gp41 (Lee-Huang et al., 2007a, 2007b). They used a luciferase 
reporter gene assay (like the one we used to assess inhibition) with pseudoviral HIV-1 subtypes 
A, C, D, E and F on pre-activated peripheral blood mononuclear cells. They showed that 5-
Hydroxytyrosol had IC50 values from 4.62 to 9.25µg/ml across all HIV-1 subtypes (Alcami et 
al., 2014). Our PGM (IC50: 20.23µg/ml, see Table 8.2) and PCM (IC50: 248.9µg/ml, see Table 
8.2) derived gels had higher IC50 values, while our PCM V0 IC50 (IC50: 8.974µg/ml, see Table 
6.1) lay within the range of the 5-Hydroxytyrosol IC50 values but our PGM V0 on its own, 
showed better inhibition with a lower IC50 (IC50: 1.668µg/ml (see Table 4.1); 5-Hydroxytyrosol 
IC50: 4.62 to 9.25µg/ml). Pasetto et al (2014) used a novel way to test the anti-HIV-1 
microbicide activity of the plant flavonoid, Myricetin (not as a gel) on a dual chamber model. 
In previous studies, researchers have shown Myricetin to possess antibacterial, anti-viral, anti-
inflammatory and antioxidant properties (Basso et al., 2005; Comalada et al., 2005; Di Stasi et 
al., 2002; Havsteen, 1983; Kandaswami et al., 1994; Mehla et al., 2011; Yu et al., 2007). The 
Dual Chamber Model consisted of a HeLa cell lined apical chamber and a TZM-bl lined basal 
chamber. The two chambers were separated by a permeable membrane. Both chambers were 
immersed in cell media and the apical chamber was laid with Myricetin and HIV-1BaL subtype 
B for 24 hours. Thereafter, the basal TZM-bl cells were tested on a Luciferase assay (Pasetto 
et al., 2014). They found Myricetin had an IC50 of 6.21µg/ml which was lower than our mucin 
derived gels but over 3.5 times higher than our large mucin fraction of PGM eluted off a 
Sepharose 2B column (PGM V0 IC50: 1.668µg/ml, see Table 4.1). Styczynski et al (2015) 
assessed the HIV-1 inhibitory potential of copper (II) phthalocyanine sulphate on a TZM-bl 
luciferase gene reporter assay. They chose a copper compound as copper has previously been 
shown to have antibacterial, anti-viral and anti-fungal properties (Borkow et al., 2004, 2005; 
Coyle et al., 2004). They measured the inhibitory potential of copper (II) phthalocyanine 
sulphate against pseudoviral HIV-1 subtype B (Styczynski et al., 2015). They found copper (II) 
phthalocyanine sulphate to have an IC50 of 65µg/ml which is over three times higher than our 
PGM in gel solution 4 (20.23µg/ml, see Table 8.2), over seven times higher than our PCM V0 
(IC50: 8.974µg/ml, see Table 6.1) and over almost forty times higher than PGM V0 
(1.668µg/ml, see Table 4.1). A summary of these comparisons can be seen in Table 8.3. 
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Table 8.3 Comparison of IC50 Data from Our Mucin-Derived Gels and Best Inhibitors Versus Other 
Microbicidal Candidates 
Study Anti-HIV-1 Candidate Virus and Cell Line Tested On IC50 (µg/ml) 
Our Study PGM V0 (Muc5ac and 
Muc6) 
HIV-1 Subtype C Du422.1 on 
TZM-bl cells 
1.668 
PCM V0  HIV-1 Subtype C Du422.1 on 
TZM-bl cells 
8.974 
PGM in gel solution 4 HIV-1 Subtype C Du422.1 on 
TZM-bl cells 
20.23 
PCM in gel solution 4 HIV-1 Subtype C Du422.1 on 
TZM-bl cells 
248.9 
Tao et al (2007) Sodium rutin sulphate HIV-1BAL Subtype B on TZM-
bl cells 
11.99 
O’Keefe et al (2009) Plant produced 
Griffithsin 
HIV-1 Subtype C Du156.12 on 
TZM-bl cells 
<0.003 
Alcami et al (2014) 5-Hydroxytyrosol HIV-1 Subtypes A, C, D, E, F 
on pre-activated peripheral 
blood mononuclear cells 
4.62 – 9.25 
Pasetto et al (2014) Myricetin HIV- 1BAL Subtype B on TZM-
bl cells 
6.21 








8.2.2 Structural Arrangement and HIV Particle Tracking of PGM in Simulated Vaginal Fluid 
 The next stage of our study was to determine the structural arrangement and track fluorescently 
labelled HIV particles through our PGM in gel solution 4. Aliquots of lyophilized PGM were 
shipped to our collaborator in North Carolina (Associate Professor Sam Lai, University of 
North Carolina Eshelman School of Pharmacy, Division of Molecular Pharmaceutics) to 
construct and add simulated vaginal fluid to our PGM and run on his assay. 
Our results showed that virus particles were slowed at lower pH (pH 4). Migration of PEG-
coated beads was retarded and the pore size experiments showed comparable magnitude of the 
carboxylated latex beads. This suggests that our PGM in Gel Solution 4 doesn’t form a rigid 
matrix, but rather a soft gel most likely due to mucin entanglement effects. These results 
suggest our reconstituted mucins don’t exhibit the same mucin-mucin end links or cross links 
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compared to native mucins. The assay did demonstrate that our reconstituted mucins provide 
some level of barrier properties. 
Pig gastric mucus has previously undergone particle tracking to determine the microrheology 
of the mucus (Georgiades et al., 2014). Researchers collected PGM in non-chaotrophic 
conditions and purified them by CsCl density gradient ultracentrifugation. While they tested 
for Muc5ac, they did not mention testing for the presence of Muc6 so it is possible that the 
results are not for just Muc5ac alone, but in combination with Muc6. Using carboxyl-activated 
polystyrene microspheres, microrheology experiments revealed that PGM self-assembles, 
forming a viscoelastic solution at high mucin concentration (Georgiades et al., 2014). It was 
also noted that not only did gelation occur in PGM at low pH but there was a hundred-fold 
increase in the elastic shear modulus (Georgiades et al., 2014). Forming a gel at low pH is 
important to the protection of gastric epithelia from auto-digestion (Hong et al., 2005). This 
corresponds with our PGM in gel solution 4 data which shows better retardation at a lower gel 
forming pH (pH 4). 
From our data, it can be seen our best HIV-1 inhibiting mucin derivatives (PGM V0 and PCM 
V0), as well as PGM in gel solution 4 are comparable to other microbicidal candidates and in 
some cases, better (see table 8.3). If the PGM in Gel Solution 4 were to progress to an anti-
HIV-1 vaginal gel, the ability to only retard HIV movement (in vitro) at pH 4 may be 
advantageous with respect to the human cervico-vaginal environment. In 2009, Lai et al 
performed experiments on normal human cervico-vaginal mucus (CVM) that contained healthy 
lactobacillus-dominated vaginal flora, had inhibited HIV infection a 100-fold better than HIV 
diffusion through water (Lai et al., 2009). They hypothesized that the normal CVM lactobacilli 
continuously produced lactic acid thus lowering the pH to 4, and removed the overall negative 
charge present on the surface of HIV without membrane lysis. During sexual intercourse, 
semen temporarily neutralizes CVM (to pH 6 – 7) and this neutral pH allows HIV to maintain 
its native surface charge and diffusion is only slowed down 15-fold. They hypothesized, if a 
mechanism could be developed that maintained an acidic pH for CVM and hence a high lactic 
acid content during sexual intercourse, it would provide effective protection for the vagina and 
penis by trapping HIV before infection can occur (Lai et al., 2009). While our PGM in Gel 
Solution 4 has been shown to inhibit HIV at pH 4 and contains lactic acid, further experiments 
are needed to see if our gel can neutralize HIV infected semen, testing in vivo non-human 
primate models as well as to determine the effect on vaginal flora. The best way to test the gel 
at full concentration would be in an animal model but this lies outside the scope of this study 
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and may be assessed in future studies. Further studies would also seek to understand the 
mechanism of mucin specific HIV-1 inhibition by stepwise de-glycosylation to assess the role 
of glycan groups, as well as, changing the charge of different mucin glycoforms, to see if 
inhibition changes. Thus far, our data shows that the large molecular weight fraction of PGM 
eluted from a Sepharose 2B column is our best inhibitor and purified PGM in gel solution 4 is 









CHAPTER 9: CONCLUSION 
 
Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) still 
presents a global problem with 1.2 million deaths worldwide reported in 2014. Two million 
new infections were also reported globally. Sub-Saharan Africa is hardest hit by this epidemic 
and South Africa not only had the highest number of people living with HIV, but also an 
increase in unsafe sexual practices like no condom use. One possible way to curb the spread of 
new infections (via the vaginal route of infection), even in the absence of condoms, would be 
through a microbicide. A vaginal microbicide is a topical gel that, in theory, could be applied 
to the vagina protecting women from sexual transmission of HIV. Thus far, there has been no 
success in constructing effective and safe microbicides. Previous anti-HIV gels have disrupted 
cellular and microbial membranes and altered the pore size of genital mucus coating. The need 
for a safe and effective HIV-1 preventative gel could not be greater.  
This study aimed to prove that mucins derived from animal sources were as effective at 
inhibiting HIV-1 as human mucins from saliva, breast-milk and cervical plug mucins. This is 
particularly important for the future direction of this research because we envisage requiring 
large amounts of material for the development of a vaginal gel that would further fortify 
epithelial linings subjected to shear and possible tear during sexual activity, increasing the risk 
of transmission. Human material, although available, requires negotiation and when donated, 
is usually in small amounts that may need to be pooled to obtain sufficient yield of mucin. 
Animal material is easily available from local abattoirs and nearby farms.  
Our laboratory performs work on mucins, the glycoproteins that gives mucus its gel properties. 
Previously our laboratory showed mucins from human breast milk (MUC1 and MUC4), 
cervical mucus plugs and saliva inhibit HIV-1 in vitro. After the success of these projects there 
was a need to source a more abundant supply of mucins to continue HIV research, and this 
study assesses two animal models, namely, pig (sourced from gastric, saliva and cervico-
vaginal) and horse (saliva). Mucus from these sources were purified by a combination of 
density gradient ultracentrifugation and size exclusion column chromatography. Samples were 
then treated with either DTT or trypsin and then all derivatives were tested on an in vitro 
pseudoviral HIV-1 subtype C neutralization assay and results were used to calculate the half 
maximal inhibitory concentration also known as IC50.  
Almost all the mucin derivatives from both sources inhibited HIV-1 in vitro, where the 
Sepharose 2B void volumes of PGM (PGM V0 IC50: 1.668µg/ml) and PCM (PCM V0 IC50: 
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8.974µg/ml) gave the best IC50’s. Purified pig gastric and cervico-vaginal mucins then 
progressed to the anti-HIV-1 gel phase of this study, where mucins were combined with either 
0.02M potassium acetate (gel solution 1); 0.2M potassium chloride (gel solution 2); 0.02% 
(w/v) sodium azide (gel solution 3) or a simulated vaginal fluid (gel solution 4). The most 
reliable and effective inhibition was seen in PGM coupled with gel solution 4, it also gave good 
cell viability in a toxicity assay. This combination of PGM in gel solution 4 was sent to 
collaborators at the University of North Carolina to be run on a virion particle tracking assay 
and the results showed successful inhibition at low pH and nanoparticles also revealed the soft 
structure of our gel is due to mucin entanglement effects. It has been previously shown that at 
low pH PGM gelation occurs as well as a hundred-fold increase in the elastic shear modulus 
(Georgiades et al., 2014). Forming a gel at low pH is important to the protection of gastric 
epithelia from auto-digestion (Hong et al., 2005). 
This study had the objective of finding an anti-HIV-1 mucin source that could be made into a 
gel that was abundant and effective in vitro and those endpoints were met, but further studies 
are needed to assess safety and efficacy in a non-human primate model as well as monitoring 
how the gel affects the vaginal flora. There is also a need to see how the gel reacts to HIV 
positive semen as pH is also an issue and it would be important to neutralize the pH raising 
ability of semen. The long-term goal of this study is to have our PGM-based anti-HIV-1 gel 
progress to a safe and effective microbicide. Microbicide gels have recently been adding anti-






All buffers that required a specific pH were adjusted with either HCl or NaOH and measured 
on a Basic Crison 20 pH meter (Alella, Spain). 
1.1 Collection Buffer 1 
1) 10mM Na2HPO4 
2) 6M GuHCl 
3) 10mM EDTA 
4) 1mM PMSF (dissolved in 1ml of pure ethanol) 
5) 5mM NEM 
The above reagents were dissolved in 500ml distilled water, then pH adjusted to 6.5 with 1M 
HCl and 1M NaOH. This was then made up to 1L with distilled water. 
1.2 Collection Buffer 2/Column Chromatography Elution Buffer 
1) 11.69g NaCl 
2) 0.2g NaN3 
The above reagents were dissolved in 1L distilled water. 
1.3 Ultracentrifugation Buffer 
1) 10mM Na2HPO4 
2) 4M GuHCl 
3) 10mM EDTA 
4) 1mM PMSF (dissolved in ± 2ml of pure ethanol) 
5) 5mM NEM 
The above reagents were dissolved in 500ml distilled water, then pH adjusted to pH6.5 with 
1M HCl and 1M NaOH. This was then made up to 1L with distilled water. 
1.4 5% DMEM 
1) 2.5ml heat inactivated FBS 
2) 1% NEAA 
3) 0.25ml of 200x PenStrep 
4) 0.5ml of 100x L-glutamine 
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5) 25mM HEPES 
6) 4500mg/L glucose 
These reagents were made up in 50ml centrifuge tubes. 
1.5 10% DMEM 
1) 5ml heat inactivated FBS 
2) 1% NEAA 
3) 0.25ml of 200x PenStrep 
4) 0.5ml of 100x L-glutamine 
5) 25mM HEPES  
6) 4500mg/L glucose 
These reagents were made up in 50ml centrifuge tubes. 
1.6. Gradient (4 – 20%) Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) Gel Buffers:  
1.6.1. 30% Bis/Acrylamide 
1) 30g Acrylamide 
2) 0.8g Bis 
The above reagents were made up to 100ml, with distilled water. 
1.6.2. Running gel buffer 
1) 0.75M Tris 
2) 0.2% SDS 
The above reagents were made up to 100ml, with distilled water. The pH was adjusted to pH8.8 
with 1M HCl and 1M NaOH. 
1.6.3. Spacer gel Buffer 
1) 0.25M Tris 
2) 0.2% SDS 
The above reagents were made up to 100ml, with distilled water. The pH was adjusted to pH6.8 
with 1M HCl and 1M NaOH. 
1.6.4. Tank Buffer 
1) 0.025M Tris 
2) 0.19M Glycine 
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3) 0.1% SDS 
The above reagents were made up to 5L, with distilled water. The pH was adjusted to pH8.8 
with 1M HCl and 1M NaOH. 
1.6.5. Sample Application Buffer 
1) 2% SDS 
2) 10ml Glycerol 
3) 0.01% Bromophenol Blue 
The above reagents were made up to 100ml, with distilled water. 
 
2. Ammonium Persulphate (AMPS) 
1) 80mg/ml AMPS 
2) Made up in distilled water just before gel application. 
 
3. Gradient (4 – 20%) SDS-PAGE Gels 
3.1. 4% running gel 
1) 30% Bis/Acrylamide 
2) 1.5ml Tris-Buffer, pH8.8 + 0.1% SDS 
3) 3.7ml distilled water 
4) 30µl AMPS 
5) 5µl TEMED 
3.2. 20% running gel 
1) 30% Bis/Acrylamide 
2) 1.5ml Tris-Buffer, pH8.8 + 0.1% SDS 
3) 0.5ml distilled water 
4) 30µl AMPS 
5) 5µl TEMED 
3.3. 3% stacking gel 
1) 30% Bis/Acrylamide 
2) 2.80ml spacer gel buffer 
3) 73µl AMPS 
4) 5µl TEMED 
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4. Periodic acid Schiff (PAS) gel staining 
4.1. Schiff’s reagent 
1) 1g pararosaniline hydrochloride dissolved in 200ml boiling distilled water, with 
constant stirring. 
2) Solution cooled to 50°C on bench and 20ml 1M HCl added. 
3) Cooled to 25°C and added 1g potassium metabisulphite and left in the dark for 12-24 
hours. 
4) Added 2g activated charcoal, mixed for 1 minute and filtered. 
5) Stored at 4°C in the dark. 
4.2. 50% ethanol 
1) 50ml ethanol 
2) 50ml distilled water 
4.3. 0.1% periodic acid and 3% acetic acid 
1) 1ml 50% solution of periodic acid 
2) 99ml 3% acetic acid 
4.4. 0.1% SDS 
1) 0.1g SDS 
2) 100ml distilled water 
 
5. Periodic acid Schiff (PAS) assay for in vitro glycoprotein detection 
5.1. Schiff’s reagent 
1) 10g pararosaniline chloride dissolved in 1L boiling distilled water, with constant 
stirring 
2) Solution cooled to 50°C on bench and 200 ml 1M HCl added. 
3) 3g activated charcoal added, mixed for 5 – 60 mins and filtered to remove charcoal 
4) Step 3 was repeated and then stored at room temperature in a dark bottle. 
5.2. Periodic acid solution 
1) 7% acetic acid 




5.3. Decolourised Schiff’s reagent 
1) 100mg sodium metabisulphite 
2) 6ml Schiff’s reagent 
3) Incubated at 37oC until colourless 
4) Prepared fresh for every assay 
 
6. BIO-RAD assay for in vitro protein detection 
1) One part BIO-RAD dye reagent added to 4 parts distilled water. 
 
7. Saline-Sodium Citrate (SSC) 
1) A stock solution of 20x SSC was prepared by making up 176g sodium chloride and 
88.2g tri-sodium citrate in 1L of distilled water and adjusting to pH7.  
2) To make a 4x SSC solution, a 1 in 4 dilution of 20x SSC solution was made with 
distilled water. 
Table 1. Western Blot Primary and Secondary Antibody Dilutions 

























MUC5AC Rabbit Human 1:5000 Goat Rabbit 1:5000 
MUC5B Rabbit Human 1:2000 Goat Rabbit 1:5000 
MUC6 Rabbit Human 1:1000 Goat Rabbit 1:5000 
MUC7 Mouse Human 1:2000 Goat Mouse 1:5000 







Table 2. Showing components of each Mucin-derived gel 
Gel Solution 
No. 
Components Based on research by 
1 0.02M K acetate (Allen et al., 1976) 
2 0.2M KCl (Allen et al., 1976) 
3 0.02% (w/v) Na Azide (Allen et al., 1976) 
4 Composition 
(in distilled water) 
Grams 
per Litre 
sodium chloride 3.51 
potassium hydroxide 1.40 




lactic acid 2.00 







(Marques et al., 2011) 
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